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Vaughan Jean Maurel September 2016 
BENEFICIATION OF SELECTED PESTICIDES AND AN ANTIHYPERLIPIDEMIC AGENT 
VIA  CYCLODEXTRIN COMPLEXATION AND CO-CRYSTALLISATION 
The applications of many bioactive molecules are limited by their undesirable physicochemical 
properties, such as poor aqueous solubility and low thermal stability. The agrochemicals methyl-
2,5-dichlorobenzoate (fungicide, DCB) and fenthion (insecticide), as well as the medicinal 
compound acipimox (lipid-lowering agent) were selected for study in this context.  
The cyclodextrin (CD) complexes γ-CD/DCB, 2,6-dimethylated-β-CD/DCB, β-CD/fenthion, 
permethylated -CD/fenthion and permethylated β-CD/fenthion, were synthesised. 1H-NMR 
spectroscopy, thermogravimetric analysis (TGA), differential scanning calorimetry (DSC) and hot 
stage microscopy (HSM) were used to assess their stoichiometries and thermal behaviours. The 
complexes 2,6-dimethylated-β-CD/DCB, permethylated -CD/fenthion and permethylated 
β-CD/fenthion have 1:1 host-guest stoichiometries, while those for γ-CD/DCB and β-CD/fenthion 
are 3:4 and 2:1 respectively. Single crystal X-ray structures were elucidated to investigate the 
modes of DCB inclusion and crystal packing. All of the solid complexes displayed higher thermal 
stabilities than those of the untreated pesticides. Furthermore, the volatility of the insecticide 
fenthion (a liquid at 25 C) was significantly reduced by its transformation to a solid on CD-
complex formation.  
The solution-state behaviour of fenthion was qualitatively evaluated using UV-visible 
spectrophotometry and induced circular dichroism. Phase solubility profiles at 25 C were of type 
Bs for solubilisation of DCB by β-CD and (2-hydroxypropyl)-β-CD, and for solubilisation of 
fenthion by β-CD, the respective 1:1 association constants being 737 ± 108 M-1, 412 ± 53 M-1 and 
789 ± 170 M-1. For solubilisation of fenthion by (2-hydroxypropyl)-β-CD and randomly-
methylated β-CD, AN- and AP-type behaviours were recorded respectively, with association 
constants 1863 ± 26 M-1 and 3582 ± 106 M-1 respectively.  
Eight multi-component crystalline systems (co-crystals and salts) of acipimox were isolated via 
its reaction with co-formers 4-aminobenzamide, 4-aminopyridine, benzamide, isonicotinamide, 
tranexamic acid and urea. NMR spectroscopy revealed 1:1 stoichiometries for all products. Their 
designation as salts or co-crystals was based on unequivocal evidence gleaned from single crystal 
X-ray structural studies, these assignments being confirmed by infrared spectroscopy. The 
melting points and decomposition temperatures of the products containing the coformers 4-
aminobenzamide, 4-aminopyridine, isonicotinamide and tranexamic acid were significantly 
higher than those of untreated acipimox. Equilibrium aqueous solubilities of the multi-
component systems ranged from 0.31 to 2.77 times those of untreated acipimox.   
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COMPOUND CODE NAMES 
Listed below are the code names assigned to the products in this thesis: 
 
GCDDCB γ-cyclodextrin/2,5-dichlorobenzoic acid methyl ester 






ACPAPYR-W Acipimox/4-aminopyridine dihydrate 
ACPBEN Acipimox/benzamide hemihydrate 
ACPISO Acipimox/isonicotinamide 
ACPTRA Acipimox/tranexamic acid 
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Chapter 1 – Introduction 
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CHAPTER 1 –  INTRODUCTION 
  




The first use of the term “supramolecular chemistry” was to describe the “chemistry of molecular 
assemblies and of the intermolecular bond” by Jean-Marie Lehn in 1978.1 It has also been 
expressed as “chemistry beyond the molecule”, “the chemistry of the non-covalent bond” and 
“non-molecular chemistry”.2 Under such definitions, the vast applications of supramolecular 
chemistry include, but are not limited to, host-guest systems, molecular devices and machines, 
self-assembly systems and nanochemistry.2 This project is focused on two of the sub-categories, 
namely cyclodextrin inclusion complexes and multi-component crystalline systems (salts and 
co-crystals). 
CYCLODEXTRIN INCLUSION COMPLEXES 
Cyclodextrins are macrocyclic structures comprising glucopyranose subunits linked through 
α-1,4-glycosidic bonds.3–5 The native cyclodextrins are composed of six, seven or eight of these 
subunits and are known as α-cyclodextrin, β-cyclodextrin and γ-cyclodextrin, respectively 
(Figure 1.1a. and Figure 1.1b.). The glucopyranose subunits adopt a 4C1 chair conformation. This 
results in a truncated cone structure (Figure 1.1c.) whereby the interior cavity is lined by C3-H 
and C5-H atoms and the lone pairs of the O4 atoms (see Figure 1.1d. for labelling), giving rise to a 
hydrophobic interior cavity. The hydrophilic -OH groups are located on the primary and 
secondary rims of the cyclodextrin molecules, which results in the exterior of the molecule having 
hydrophilic nature.3–5 The importance of this separation of the hydrophobic and hydrophilic 
areas of the cyclodextrin is that it allows the formation of inclusion complexes with hydrophobic 
molecules or moieties.3–8 Another feature arising from the 4C1 conformation of the glucopyranose 
subunits is the formation of the hydrogen bonding along the secondary rim between the O2-H 
and O3-H hydroxyl groups on neighbouring residues. These hydroxyl residues act as either 
acceptors or donors in the hydrogen bond resulting in both O2-H···O3′ and O2···H-O3′ hydrogen 
bonds. These have been described as ‘flip-flop hydrogen bonds’.4,9,10 The presence of these 
hydrogen bonds stabilises the cyclodextrin and slightly limits its solubility. In α-cyclodextrin 
hydrate structures this hydrogen bonding is only partially complete at the secondary rim. The 
hydrogen bonding of the secondary rim is complete in β-cyclodextrin, causing it to have the 
lowest solubility of the three. The largest, γ-cyclodextrin, is a more flexible structure and 
therefore is the most soluble.3 The properties of the native cyclodextrins are presented in 
Table 1.1. 




Figure 1.1: a. Chemical structures of the cyclodextrins α-, β- and γ-cyclodextrin, b. the cyclodextrins 
α-, β- and γ-cyclodextrin showing the macrocyclic structure, c. toroidal shape of a cyclodextrin 
molecule illustrating the primary and secondary rim and d. labelling scheme of a glucopyranose 
subunit 
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Table 1.1: Properties of native cyclodextrins3,5  
Property α-cyclodextrin β-cyclodextrin γ-cyclodextrin 
Number of units 6 7 8 
Molar mass (g mol-1) 972 1135 1297 
Aqueous solubility (mg ml-1)‡ 127 18.8 256 
Cavity diameter (Å) 4.7-5.3 6.0-6.5 7.5-8.3 
Torus height (Å) 7.9 ± 0.1 7.9 ± 0.1 7.9 ± 0.1 
Cavity volume (Å3) 174 262 427 
‡ measured at 25 ℃ 
CHEMICALLY MODIFIED CYCLODEXTRINS 
The derivatised cyclodextrins are synthesised by functionalisation of the primary and secondary 
hydroxyl groups of the native cyclodextrins. The derivatisation with methyl groups can greatly 
alter the physical properties of the parent cyclodextrin. A noteworthy change in property is the 
negative temperature coefficient of their aqueous solubility, resulting in higher solubility at lower 
temperatures. Saenger et al.11,12 have suggested that the formation of a channel type clathrate 
hydrate enclosing the methylated cyclodextrins is responsible for this phenomenon. The 
researchers believe that upon heating an aqueous solution of the methylated cyclodextrins the 
clathrate water molecules regain mobility allowing the cyclodextrins to aggregate.11,12 The 
methylation of the hydroxyl groups also deepens the cavity, extending the hydrophobic region. In 
this study, three crystalline and two amorphous derivatised cyclodextrins were used. 
The crystalline cyclodextrins employed in this study are hexakis(2,3,6-tri-O-methyl)-α-
cyclodextrin (TRIMEA), heptakis(2,3,6-tri-O-methyl)-β-cyclodextrin (TRIMEB) and heptakis(2,6-
di-O-methyl)-β-cyclodextrin (DIMEB). TRIMEA and TRIMEB are permethylated with the O2, O3 
and O6 atoms methylated on all of their glucopyranose residues. The lack of hydroxyl groups 
disrupts the O2-H···O3′ hydrogen bonding present in the parent cyclodextrins. This destabilises 
the cyclodextrin allowing greater conformational flexibility. In at least one case the loss of the 
hydrogen bonding network leads to an inversion of a single methyl glucose residue to the 1C4 
chair conformation, seen in the TRIMEB monohydrate structure.13 The selectively methylated 
cyclodextrin used in this study, DIMEB, is methylated at the O2 and O6 positions. This allows the 
structure to maintain the O2···H-O3′ hydrogen bonding network, which stabilises the 
cyclodextrin. Therefore, DIMEB has a similar conformation and geometry to its parent 
cyclodextrin, albeit with an extended cavity. A schematic representation of these derivatised 
cyclodextrins is shown in Figure 1.2. 
 




Figure 1.2: Schematic representation of the methylated cyclodextrins 
The two amorphous derivatised cyclodextrins used in this study are randomly methylated-β-
cyclodextrin (RAMEB) and 2-hydroxypropyl-β-cyclodextrin (HPBCD). The methylated 
amorphous cyclodextrin, RAMEB, is often employed as a substitute for DIMEB due to the expense 
of producing the selectively methylated cyclodextrin. RAMEB is produced on an industrial scale 
and has been used in the pharmaceutical, cosmetic and agrochemical industries. The use of 
HPBCD (generally applied as a solubilising agent) has also been evident across these industries. 
HPBCD is nontoxic and increases bioactive molecule delivery through biological membranes. The 
extremely high aqueous solubility of HPBCD complexes has been used to create intravenously 
deliverable drug formulations of poorly soluble drug compounds.14,15 
CYCLODEXTRIN INCLUSION 
Cyclodextrin inclusion complexes form reversibly through non-covalent interactions between a 
guest and the host molecule (Equation 1.1). Each inclusion complex has a binding constant (also 
termed: equilibrium constant, association constant, formation constant), K. The binding constant 
is a measure of the strength of interaction between the host and guest, given by Equation 1.2. 
Equation 1.1 








It is understood that several factors drive the host guest complexation reaction. These include 
hydrophobic interactions, hydrogen bonding, electrostatic interactions, release of high energy 
water molecules from the interior of the cyclodextrin cavity, released strain energy of the 
cyclodextrin and van der Waals interactions.16,17  




To be pharmaceutically relevant the binding constant of the complex must be less than 10 000 M-1 
so as to not interfere with the pharmacokinetics of the drug upon administration. Fortunately, 
most cyclodextrin complexes of pharmaceuticals have binding constants between 50 M-1 and 
2000 M-1, with values greater than 5000 M-1 rarely observed.14 Binding constants are often used 
as a basic measure for evaluation of a host-guest complexation process and it is therefore 
imperative to determine this value. 
The binding constant can be derived from the results of various experimental methods. UV-Vis 
spectroscopy can be employed for a guest molecule with a chromophoric moiety. Changes in the 
molar absorptivity or λmax versus host concentration can be used to calculate the binding constant 
of the complex. A similar procedure is employed for induced circular dichroism. The formation of 
an inclusion complex can result in changes in the chemical shifts of the host and/or guest protons 
in the 1H-NMR spectrum. By measuring these changes and plotting the values against the molar 
ratio of the host molecules one can evaluate the binding constant and stoichiometry of the 
complex. Isothermal titration calorimetry allows direct measurement of thermal parameters of 
complexation from which the binding constants can be calculated.   
One of the most readily available methods for binding constant determination is phase solubility 
analysis, developed by Higuchi and Connors.18,19 To use this method an excess of the guest 
compound is added to several cyclodextrin solutions of varying host concentration. This mixture 
is then agitated until saturation equilibrium is reached. The apparent guest solubility is then 
determined using an appropriate method (such as UV-Vis spectroscopy or High Performance 
Liquid Chromatography). The phase solubility profile is then plotted as the apparent 
concentration of the guest molecule against the increasing concentration of the host. From the 
profile the complexation behaviour is established and the binding constant can be evaluated. This 
experimental method will be expanded upon in relevant sections of the research presented. 
GEOMETRIC PARAMETERS DESCRIBING CYCLODEXTRINS 
Several geometric parameters are employed to describe the conformations of cyclodextrin 
molecules.20,21 Once evaluated these are compared with the values obtained for other inclusion 
complexes and the free host molecules (typically hydrated) to gain a greater understanding of the 
effect of guest inclusion on the host geometry. 
The polygon defined by the O4 atoms is a central feature used to describe the geometric 
parameters. The distance from the O4 atoms to the centroid generated by the polygon (l), the 
O4···O4′ distance between neighbouring glucose residues (D) and the O4···O4′···O4″ angle (ϕ) are 
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measured using the polygon defined by the O4 atoms and are measures of distortion of the 
polygon. These geometric parameters can be seen in Figure 1.3. The O4···O4′···O4″···O4‴ torsion 
angle (d) and the deviation from the least-squares plane through the O4 atoms (α), Figure 1.4a., 
give a measure of planarity of the cyclodextrin polygon. The final parameter defined by the O4 
polygon is the tilt angle τ2 (Figure 1.4b.). This is the angle of intersection of the least-squares plane 
through the O4 atoms and that through the O4, C4, C1 and O4′ atoms of a glucose ring. The 
O2···O3′ distance (D3) gives a measure of the intramolecular hydrogen bonds described above. 
The final geometric parameter is the torsion angle ω (O5-C5-C6-O6, labels shown in Figure 1.3) 
whose value indicates the extent to which the C6-O6 bond is directed toward or away from the 
cyclodextrin cavity. 
 
Figure 1.3: Figure of the β-cyclodextrin geometric parameters l, D, ϕ and d as representative of the 
native cyclodextrins. Hydrogen atoms have been omitted for clarity 
 
Figure 1.4: a. β-cyclodextrin molecule illustrating a. the O4 least-squares mean plane and b. the tilt 
angle τ2 between the O4 least-squares mean plane (blue) and the least-squares plane through 
O4-C4C1-O4′ atoms of a glucose residue (green). Hydrogen atoms have been omitted for clarity 
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In the case of an idealised cyclodextrin molecule the least-squares mean plane would pass 
through all the O4 atoms. The torsion angles d and the deviations of the atoms from the mean 
O4-plane would be zero and the parameters l, D and ϕ would be equal for each residue. 
A positive value of the torsion angle ω indicates that the group is directed towards the cavity, 
while a negative value indicates that the group is directed away from the cavity. The tilt angle, τ2, 
gives a measure of the inclination of the glucose substituents. The values are generally positive, 
indicating an inclination of the primary rim of the glucose subunit towards the cavity. The glucose 
residues of the native cyclodextrins generally all have positive τ2 values. 
PACKING ARRANGEMENTS OF CYCLODEXTRIN COMPLEXES 
Cyclodextrin inclusion complexes tend to form monomeric or dimeric structures. These 
structures pack into two general categories, cage-type and channel-type. In channel-type 
structures, the cyclodextrin molecules are stacked such that their cavities align to create infinite 
channels which include the guest molecules. The cyclodextrins within a column are arranged in a 
head-to-head or head-to-tail manner. The columns are stabilised by hydrogen bonding between 
the primary and secondary rims of subsequent molecules in head-to-tail arrangements. In head-
to-head arrangements, the primary rim hydrogen bonds to the primary rim of the sequential 
cyclodextrin and similarly at the secondary rim.5 
The cage-type structures occur when the primary and secondary rims of the cyclodextrin 
molecules are blocked off by neighbouring cyclodextrin molecules. There are two such motifs, the 
herringbone- and brickwork-type packing arrangements. Illustrations of these arrangements are 
shown in Figure 1.5.  




Figure 1.5: Illustrations of cyclodextrin packing arrangements showing common monomeric and 
dimeric packing motifs 
Two cyclodextrin inclusion complexes can be said to be isostructural if the unit cells of the 
structures have similar dimensions, and the host molecules have similar atomic co-ordinates. The 
relatively rigid glucose backbone of the host molecules is responsible for the packing 
arrangement of the inclusion complexes.22 Isostructural cyclodextrin complexes can have a 
varying guest molecule and water molecule positions, but very similar host arrangements. Caira22 
and Lubhelwana23 have characterised several isostructural series of the native and methylated 
cyclodextrin inclusion complexes. Once a new complex is identified as a member of a particular 
isostructural series, one can immediately gain a greater understanding of the arrangement of the 
host molecules within the structure. The dominance of the host molecules on the packing 
arrangement has the consequence that within an isostructural series, the powder X-ray 
diffraction (PXRD) patterns of the members have the same principal features, regardless of the 
guest molecule. One can therefore employ this quick, non-destructive technique to obtain 
important structural information for an inclusion complex. A further application of the 
isostructurality of cyclodextrin inclusion complexes is isomorphous replacement (or 
isostructural replacement). One can use the atomic coordinates of the rigid backbone of the host 
molecule of a refined crystal structure as a trial model of an unknown complex, if they are 
members of the same isostructural series. This method is expanded upon in the relevant sections 
of the thesis. 
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APPLICATIONS OF CYCLODEXTRINS TO BIOACTIVE MOLECULES 
Many reviews on the topic of the applications of cyclodextrins are available.7,19,24–28 Their uses 
include, but are not limited to, aqueous solubility enhancement of bioactive compounds, enzyme 
mimics, food packaging, modified textiles, taste masking, protection against oxidative 
degradation, cholesterol sequestration, chemical and thermal stability modification and 
enantioselective chromatographic separations. In this study cyclodextrins will be applied to 
pesticides, and thus some examples of such systems are presented below. 
A study was performed by Szente29 on five volatile organophosphorus pesticides (malathion, 
dichlorvos, fenitrothion, chlorpyriphos and sulprofos) with β-cyclodextrin. The β-cyclodextrin 
inclusion complexes showed slower pesticide vapour release relative to the untreated 
compounds. The complexes were subjected to evolved gas detection analysis to investigate loss 
of the pesticide from the formulation. The thermal stability of the products was also investigated. 
This was done by storing the formulations at 40℃ at a relative humidity of 75 % and samples 
were taken at 1, 2, 3 and 6 weeks and the pesticide content was then evaluated. The 
β-cyclodextrin/malathion and β-cyclodextrin/chlorpyriphos complexes were shown to greatly 
reduce the rate of loss of the pesticides when compared to formulation of the pesticides adsorbed 
on starch. The loss of malathion from the starch formulation was 78 % from 60 ℃ to 100 ℃. Over 
the same temperature range, only 6 % of this pesticide was lost from the cyclodextrin complex 
formulation. Similar improvements were seen for chlorpyriphos. The stability test performed on 
dichlorvos, fenitrothion and malathion β-cyclodextrin complexes showed losses of less than 10 % 
over the same six-week period. Szente concluded that the use of β-cyclodextrin in these 
formulations may be considered a starting point to preparing pesticide formulations with 
extended shelf life. 
Cyclodextrins have been employed to improve the solubility and dissolution of pesticides to allow 
the reduced use of the pesticides while increasing the efficacy. Manolikar and Sawant30 reported 
the formation of β-cyclodextrin inclusion complexes with the herbicide isoproturon with 
improved solubility and dissolution rates over the untreated active compound. Initial phase 
solubility studies allowed the researchers to determine the 1:1 equilibrium constant of 
1890.33 M-1. Dissolution rate studies were then performed on the 1:1 and 1:2 (guest:host) 
complexes prepared by kneading, co-evaporation and co-precipitation. They found that the 
co-evaporation product of the 1:1 complex showed the greatest improvement in its dissolution 
rate over uncomplexed isoproturon. Only 17 % of the untreated herbicide was found to have 
dissolved after 2 hours, while the kneaded and co-evaporated products showed that the 
percentage isoproturon dissolved was 50 % and 55 % respectively over the same time. In the 1:2 
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complexes, the co-precipitation product gave the greatest improvement in dissolution rate, with 
76 % of the herbicide dissolved over two hours. They surmised that the improvement in 
dissolution rates would allow a more rational approach to application of isoproturon with 
improved efficacy. A similar study was performed by Villaverde et al.31 on an inclusion complex 
of the herbicide norflurazon with β-cyclodextrin. The phase solubility analysis of this system 
showed AL-type behaviour, increasing the apparent solubility of the pesticide 5-fold (at 12 mM 
β-cyclodextrin) and the K1:1 equilibrium constant was calculated to be 360 M-1. The complexes 
prepared by kneading, spray drying and co-evaporation all showed improved dissolution rates 
with 100 % of norflurazon dissolving in 5 minutes, compared to only 15 % of untreated 
norflurazon in 30 minutes. Villarverde et al. concluded that the use of β-cyclodextrin/norflurazon 
inclusion complexes could improve the leaching behaviour of the herbicide in soil, improving its 
application.  
Cyclodextrins occasionally form insoluble complexes with certain guest molecules. This process 
can be exploited to use these hosts to remove pollutants from water. An example of this is the use 
of γ-cyclodextrin as a complexation agent to remove the pesticide chlordecone from 
contaminated water.32 The pesticide chlordecone was used to control banana weevil populations 
in the French West Indies for many years. It has since shown to be noxious to humans and it has 
severely contaminated the soil, rivers and crops of the islands. It has been linked to an increase 
in central nervous system toxicity in the population surrounding the production sites. 
Chlordecone is known to have strong persistence and exposure is expected to last several 
hundred years. Thus far, only one study on the removal of chlordecone from contaminated sites 
has been performed and it was found that activated charcoal may be used; however, more 
efficient alternatives would be beneficial. The use of cyclodextrins was therefore investigated. 
After testing several cyclodextrins, the researchers found that γ-cyclodextrin would be the most 
suitable agent as chlordecone forms a stable, water-insoluble complex with this host. Simple 
filtration would provide a bulk method for the removal of the pesticide. The researchers tested 
the direct extraction of the complex using activated charcoal by preparing a 1 dm3 sample of 
contaminated water. A stoichiometric amount of γ-cyclodextrin was added and the complex 
allowed to precipitate. This mixture was then filtered through activated charcoal. With this 
method the researchers showed that as little as 15 mg of activated charcoal would suffice to 
remove 98 % chlordecone from the 1 dm3 solution once complexation with γ-cyclodextrin was 
complete. Under similar conditions, without the use of cyclodextrin, activated charcoal removed 
only 32 % of the pesticide. The researchers also tested the use of a cyclodextrin-modified-
activated charcoal substance. The cyclodextrin-modified substance showed a 10-15 % 
improvement in chlordecone removal over pure activated charcoal. These results show that 
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cyclodextrins could be used for environmental rehabilitation with the removal of harmful 
substances from pesticide contaminated water. 
While this project will focus on the application of cyclodextrins to pesticides, the most active area 
of research on cyclodextrin inclusion complexes is their application to pharmaceutically active 
compounds and as such a few examples will be presented here. Many products containing 
cyclodextrin formulations of active pharmaceutical ingredients (APIs) are available on the 
market, for example cisapride/HPBCD (propulsid), nicotine/β-cyclodextrin (Nicorette), 
chloramphenicol/RAMEB (Clorocil).24 A study by Gibaud et al.33 was performed in an attempt to 
improve the solubility and dissolution rate of melarsoprol. This drug is used in the treatment of 
African trypanosomiasis (sleeping sickness) and recent studies showed that it is very effective in 
treating several types of refractory leukaemia. However, melarsoprol is a poorly water-soluble 
drug and is administered intravenously as a propylene glycol solution. In its current formulation 
the application of this drug can result in complications for the patient, such as pain, burns and 
necrosis at the site of administration. Therefore, the researchers investigated the use of HPBCD 
and RAMEB as potential solubilisers of the drug. They found that both HPBCD and RAMEB bind 
strongly to the guest with remarkably high equilibrium constants of 56077 ± 4205 M-1 and 
54168 ± 5305 M-1 determined from mole-ratio titration plots. The solubility enhancement factors 
(apparent solubility of the API at 250 mM cyclodextrin/intrinsic solubility of API) were found to 
be similar, at 7.2⨯103 for both cyclodextrins. This was promising for an aqueous intravenous 
formulation using HPBCD. The methylated cyclodextrin RAMEB, however, is not suitable for 
intravenous administration, so its potential as an oral formulation was investigated by testing its 
dissolution rate relative to the untreated API. The researchers found that the dissolution rate of 
the RAMEB/melarsoprol complex was vastly higher than that of pure melarsoprol: after 60 
minutes the complex was completely dissolved compared to only 60.1 ± 6.1 % of the API. In vitro 
studies performed on the cyclodextrin inclusion complexes showed no loss in cytotoxic effects 
relative to the untreated melarsoprol. 
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SALTS AND CO-CRYSTALS 
In a special issue of Crystal Growth & Design the editors noted in their introduction34 the revival 
of the area of co-crystal research. Multi-component crystalline systems offer a huge diversity in 
structure, composition and properties that are of great interest to solid-state chemists and the 
pharmaceutical industry. 
The exact definition of a co-crystal has been the subject of much recent debate amongst 
researchers.35–37 In 2012 a large group of researchers published a response to United Food and 
Drug Administration (FDA) draft guidelines from December 2011 pertaining to the classification 
of pharmaceutical co-crystals.38 The FDA defined co-crystals as: “solids that are crystalline 
materials composed of two or more molecules in the same crystal lattice.” The researchers argue 
that this definition is restrictive and ambiguous. The definition would limit co-crystals to 
molecular components, which is not borne out in the literature or patents. The ambiguity of the 
molecules in the “crystal lattice” arises as all molecular crystals must have two or more molecules 
in its crystal structure by definition. The authors proposed two alternative definitions of 
co-crystals. The first, broader definition, is “co-crystals are solids that are crystalline single phase 
materials composed of two or more different molecular and/or ionic compounds generally in a 
stoichiometric ratio”. The second distinguishes solvates with the definition “co-crystals are solids 
that are crystalline single phase materials composed of two or more different molecular and/or 
ionic compounds generally in a stoichiometric ratio which are neither solvates nor simple salts”. 
In August 2016 the FDA released revised draft guidelines for the appropriate classification of 
co-crystals, including a listing of data required for submission of a new co-crystal product for 
assessment and the regulatory implications of the classification.39 These draft guidelines40 are 
intended to clarify the FDA’s current thinking on the appropriate classification of pharmaceutical 
co-crystals. In this draft document they retain the definition of co-crystals as “crystalline 
materials composed of two or more molecules within the same crystal lattice”. However, the FDA 
makes the further distinction that the co-former interacting with the active pharmaceutical 
ingredient (API) is neutral and that the interaction is non-ionic. Co-crystals are separate from 
hydrates and solvates, which are classified under the polymorph umbrella term as 
“pseudopolymorphs”. 
Therefore, for the purposes of this study multi-component crystalline systems will be considered 
as crystalline substances of two or more molecular components. The differentiation between salts 
and co-crystals will be done on the basis of a proton transfer.41–43 The distinction between the 
neutral and ionised components is necessary because the state of ionisation can influence 
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physicochemical properties, such as stability and solubility.44 As the recent FDA guidelines 
indicate, this differentiation between salts and co-crystals has regulatory implications. 
Investigations into co-crystallisation of active pharmaceutical ingredients (APIs) are usually 
performed with compounds (‘co-formers’ or partner molecules) on the FDA’s Generally 
Recognised As Safe (GRAS) list.45 The compounds on this list have been shown to be safe under 
the conditions of intended use by a panel of qualified experts. These substances are often 
employed in the synthesis of pharmaceutically acceptable co-crystals. 
PROPERTIES 
The relationship between the structure and physicochemical properties of multi-component 
crystalline systems is multi-factorial. The presence of two or more components in the crystal can 
cause unexpected changes to the physicochemical properties of the final product. 
Two of the most important properties of salts and co-crystals are their melting point and their 
aqueous solubility. A survey44 of 50 multi-component crystalline systems showed that prediction 
of their properties based on the starting materials is difficult. The survey showed that of the 50 
systems analysed, 51 % had a melting point between those of the API and co-former, 39 % had 
melting points lower than both components, 6 % had melting points higher than both 
components and 4 % had the same melting point as one of the components. For a given API a 
correlation is often observed where the melting point of the multi-component crystal system is 
related to that of the co-former. That is to say, the general trend observed is that with increasing 
co-former melting point one observes an increase in the melting point of the multi-component 
crystalline system.44,46,47 
One of the main reasons for investigating co-crystals and salts is to modify the solubility of an API, 
either by attempting to raise or decrease the solubility. The mechanism by which co-crystals 
solubilise the API has been termed “spring-and-parachute” effect.48–50 The proposed mechanism 
for this process is based on the initial dissociation of the co-crystal in solution. The more soluble 
co-former dissolves in solution leaving loosely aggregated API clusters resembling an amorphous 
phase. These clusters can exhibit similar spikes in concentration as amorphous forms of the drug; 
this is the “spring” effect. The “parachute effect” is achieved by the time scale required for the API 
to convert to a stable crystalline form. If several crystalline forms exist, the process will first 
convert to a more stable polymorph and finally to the apparently most stable crystalline 
polymorph, following Ostwald’s Law of Stages.49,50 If the drug converts directly to the stable 
crystalline form, only the “spring” effect is observed.  
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The relationship between solubility and the melting point of a crystalline substance is complex. A 
general trend of increasing melting temperatures correlating to decreasing solubility has been 
observed in many cases. However, this relationship is complicated and has been shown to be non-
linear or logarithmic in some cases.51 Black et al.52 concluded that no correlation existed between 
melting point and solubility in their study of 25 salts. The difficulty in prediction of the 
relationship between these properties is attributed to the complicated nature of interactions in 
multi-component systems compared to crystals containing only a single chemical component. 
ADVANTAGES OF SALT/CO-CRYSTAL FORMATION 
Salts and co-crystals can impart several advantages over the pure pharmaceutical product. A 
review published in 2013 by Elder et al.51 gave a detailed outline on the use of salts and co-crystals 
to improve various aspects of pharmaceutical products. Salts and co-crystals are often used to 
alter the dissolution rate or solubility of an API. These multi-component crystalline systems can 
enhance the apparent solubility of the API by several orders of magnitude.51,53 Another advantage 
is the existence of a vast library of pharmaceutically acceptable co-formers that can be employed 
in salt and co-crystal formation. Co-crystals do not require the presence of acid or basic 
functionalities, enabling the derivatisation of non-ionisable compounds. A further advantage of 
salts and co-crystals is crystallinity (by definition co-crystals are crystalline). Crystalline products 
can often lead to increased stability over amorphous products in terms of thermal, hydrolytic and 
photolytic stability. Polymorphic control is of interest to pharmaceutical scientists and co-crystals 
exhibit a measure of predictability of polymorphs (although this advantage does not apply for 
salts).54,55 In the chemical industry purification by crystallisation of a salt or co-crystal is 
frequently employed. The advantages presented here highlight the importance of pursuing this 
line of research.  
DISADVANTAGES OF SALT/CO-CRYSTAL FORMATION 
While the advantages over an API are numerous for salts and co-crystals, several disadvantages 
are known. In their review Elder et al.51 outlined several of these. Addressing the dissolution rate 
and solubility through salt or co-crystal formation has in some cases reduced the apparent 
solubility of the API, where this was not intended.53,56,57 As mentioned in the advantages above, 
predictability of polymorphism is an issue in salt formation. While polymorphs themselves may 
provide physicochemical improvements to an API their presence adds the developmental issue 
of characterisation and thermodynamic stability investigations.58 This issue is less common with 
co-crystals, but co-crystal polymorphs are known.54,55 As co-crystals are non-ionic they tend to 
have lower melting points than salts. In general, APIs with lower melting points can cause 
Chapter 1 – Introduction 
 
 16 
undesirable outcomes in large scale processing, such as plastic deformation which leads to caking 
and impacts on compressibility during the production of tablets. 
APPLICATIONS OF SALTS/CO-CRYSTALS CONTAINING BIOACTIVE MOLECULES  
Salts and co-crystals containing pharmaceuticals are generally employed with an aim to improve 
particular undesirable physicochemical properties. However, co-crystals are also used in 
preparation and physicochemical property control of other materials such as luminescent organic 
solid-state materials59 and explosives.60 A few examples of the applications of multi-component 
crystalline systems in pharmacy are presented below. 
In 2011 Cheney et al.61 performed a study on the nonsteroidal anti-inflammatory drug meloxicam. 
Due to the low solubility of the drug under acidic conditions it takes an extended period of time 
to reach therapeutic levels. If meloxicam were to be implemented for use in acute pain relief, the 
time to reach therapeutic levels would need to be reduced. Co-crystallisation was investigated as 
a method to achieve this goal. After screening several co-formers, the co-crystal comprising 
meloxicam and aspirin was selected and investigated as a potential solution to the slow onset of 
action problem. During an animal pharmacokinetics study the researchers showed that the 
co-crystal exhibited an oral bioavailability of 69 % relative to only 16 % for the untreated API. 
Furthermore, the required therapeutic concentration was achieved in 10 minutes, while the time 
to reach maximal concentration was unchanged. This study shows the potential for improving the 
administration of some pharmaceuticals without modifying the mode of action of the drug. 
Ribavirin is a broad-spectrum antiviral with high aqueous solubility. It is used in combination 
therapy for Hepatitis C and requires large regular doses. The high aqueous solubility and large 
dosages result in large fluctuations in concentration of the active drug in the blood plasma of 
patients, with undesirable side effects. Chen et al.62 identified co-crystals as a potential method to 
control the rate of ribavirin release. Three hydrated co-crystals with co-formers 
3,5-dihydroxybenzoic acid, gallic acid and barbituric acid were synthesised, characterised and 
their dissolution investigated. The researchers found that while the untreated ribavirin reached 
80 % concentration after 8 minutes, the co-crystals containing 3,5-dihydroxybenzoic acid, gallic 
acid and barbituric acid attained the same concentration as the API after 64 minutes, 30 minutes 
and 16 minutes respectively. Chen et al. thus showed that the release of an API can be controlled 
with careful selection of a co-former. 
A growing application of co-crystallisation is purification of a product during manufacture. Billot 
et al.63 employed co-crystallisation as a purification method to large scale synthesis of SAR1 (a 
SRC kinase inhibitor selected for treatment of myeloid leukaemia). The crude product of the 
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synthesis was initially a solution in chlorobenzene in which SAR1 represented only 60 % of the 
dry concentrate. Chromatography and impurity adsorption followed by repeated crystallisations 
yielded SAR1 of only 90 % purity (below the required standards) with unacceptable residual 
solvent content. Co-crystallisation was therefore investigated. After screening several co-formers 
and using phase diagrams it was determined that benzoic acid would be the most suitable 
co-former. SAR1 and benzoic acid have symmetrical phase diagrams, with similar solubilities in 
chlorobenzene. The co-crystal was prepared from chlorobenzene to test the feasibility of this 
process. To cleave the co-crystal, isopropanol was selected as the solvent as the API is insoluble, 
and benzoic acid is soluble, in isopropanol. In the phase diagram of SAR1 and benzoic acid in 
isopropanol there is no domain for the co-crystal. After an initial proof of concept study, the 
method was successfully applied to a small laboratory sample of the crude API showing a purity 
increase from 60 % to 99 %. The experiment was then scaled up and the additional modification 
that the benzoic acid be added as a solution in isopropanol to the crude sample was implemented. 
The effect of the ratio of benzoic acid to SAR1 on sample purity was also tested and found to be 
negligible at molar ratios between 1 and 2. During the scaling up experiment the kinetics of 
co-crystal formation necessitated 1.8 equivalents of benzoic acid and a temperature of 40 ℃. The 
extra benzoic acid allows for the potential side reactions with unknown impurities. Cleaving of 
the co-crystal was achieved through slurrying in isopropanol. The final scaling up to the pilot 
plant was implemented, returning 10 kg batches of purified SAR1. The final method employed 
co-crystallisation of the API with benzoic acid. The product was filtered and washed with 
chlorobenzene. The dried co-crystal was then cleaved by repeated slurrying with isopropanol to 
ensure completion. This process had an overall yield of 54 % with 99 % purity which was within 
the International Conference on Harmonization specifications. Billot et al. thus managed to 
implement large scale purification using an efficient co-crystallisation strategy. 
INTELLECTUAL PROPERTY 
Researchers involved in novel pharmaceutical research rely on patents for protection of their 
intellectual property. Patents protect the revenue from any products produced from this 
intellectual property for 20 years from the date of first application. This provides the organisation 
or researcher awarded the patent market protection and an income stream from which the costs 
of product development can be recovered. Patents encourage research for the benefit of society 
by providing an incentive to the inventor before providing the invention to the public. 
To be eligible for patent protection an application must fulfil three criteria: novelty, utility and 
non-obviousness. At the time of applying for a patent, the product must not have been published, 
or otherwise publicly divulged, this is the requirement for novelty. Utility of a product relies on 
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the new product being an improvement or having a useful application. The final criterion is non-
obviousness; this is the most subjective, as the product must not be obvious or self-evident to a 
“person having ordinary skill in the art”.64 
Salts and co-crystals fulfil all the requirements for patent applications. Assuming research on the 
product has, up to the date of patent application, not been published it is considered novel. The 
vast number of suitable co-formers gives an advantage to the novelty of these products. Utility is 
generally considered applicable as salts and co-crystals modify the physicochemical properties 
of the active ingredient, both a useful improvement and new composition of matter. Furthermore, 
co-crystals and salts have the same therapeutic effects as the untreated API. The requirement that 
the product be non-obvious is resolved by the lack of predictability in the formation of new 
crystalline systems and changes in the physicochemical properties resulting from co-
crystallisation. Examples are outlined in the preceding sections of the introduction. However, it 
is worth reiterating that the formation of a salt or co-crystal can improve the dissolution rate and 
solubility over untreated APIs. This improvement in dissolution rate and solubility is a possible 
indication of improved bioavailability, clearly fulfilling the utility requirement. Slow release 
formulations allow fewer dosages with improved effect. Other useful improvements relate to 
physical stability, among others outlined in the Advantages of Salt/Co-crystal Formation section 
above. Crystalline structures are often unpredictable; while crystal engineering allows one to 
possibly predict the individual interactions between two components of a co-crystal or salt, 
prediction of the overall crystal structure remains elusive. Even if one could predict the crystal 
structure of a multi-component system, including solvates and polymorphic forms, the prediction 
of properties is generally impractical. With the current technology and theories, the synthesis of 
new multi-component crystalline systems is still largely trial-and-error based, and thus non-
obvious. 
CO-CRYSTAL DESIGN 
The successful synthesis of salts and co-crystals still relies on trial-and-error screening 
experiments. Supramolecular synthons (examples in Figure 1.6), chosen on the basis of crystal 
engineering, can allow one to narrow the list of all possible co-formers by eliminating unlikely 
compounds. This however, is no guarantee of success. Many, if not most co-crystals and molecular 
salts still arise purely from screening experiments. 
In silico screening using the Cambridge Structural Database (CSD)65 by searching for potential 
hydrogen bonding interactions to investigate in co-crystal formation is often employed. Once 
suitable supramolecular synthons are identified (examples in Figure 1.6) co-formers with the 
desired functional groups are selected for experimental screening. 




Figure 1.6: Examples of hydrogen bonding synthons often employed in crystal engineering66  
One parameter used to predict the occurrence of a proton transfer when synthesising multi-
component crystalline systems is the difference between the pKa values (ΔpKa) of the starting 
materials. This difference is defined as ΔpKa = pKa(base) - pKa(acid). It is generally accepted that 
a proton transfer will occur if the ΔpKa value is greater than 3. If this difference is less than zero 
it is likely that a co-crystal will form. Between these limits it is difficult to predict the formation 
of either a salt or a co-crystal.42 While the ΔpKa value is a good indicator for the prediction of a 
proton transfer the final position of the proton must always be established by X-ray or neutron 
diffraction or spectroscopic methods. When screening for solid forms of an API it can be useful to 
remove the constraints of ΔpKa values.42 This can lead to an increased hit rate of multi-component 
crystalline systems with possibly improved physicochemical properties over the untreated API. 
  




Three bioactive molecules are presented for study: two pesticides and one antihyperlipidemic 
(i.e. lipid-lowering) agent. The two pesticides are 2,5-dichlorobenzoic acid methyl ester 
(henceforth DCB) and fenthion, and the antihyperlipidemic agent is acipimox. Their chemical 
structures and selected properties are presented in Table 1.2. 
Table 1.2: Chemical structures and physical properties of the bioactive molecules selected for study 






























‡ No temperature for determination of the solubility of acipimox was reported 
2,5-DICHLOROBENZOIC ACID METHYL ESTER 
The compound 2,5-dichlorobenzoic acid methyl ester (DCB) is a plant growth regulator and 
fungicide. It is generally applied as a waxy formulation for grafting of grapevines to encourage 
callus formation68,71,72 and it has recently been reapproved for use in the European Union until 
2019. It is sold under the trade name Rebwachs WF, containing 0.35 g/kg DCB and 1g/kg 
8-hydroxyquinoline. As this product is generally used indoors, the environmental residual impact 
has not been investigated in detail. DCB is neurotoxic to rats (acute LD50 = 1030 mg kg-1) and has 
been classified as “harmful” (classification Xn) and “harmful if swallowed” (risk phrase R22) by 
the European Food Safety Authority.68 It has also shown potential as a plant growth regulator, but 
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the efficacy is limited by its poor aqueous solubility.71 If such an application were to be 
implemented, the long term environmental impact would require further study; however, early 
indications are that the environmental damage would be limited. The compound DCB was shown 
to undergo hydrolysis in water (pH 7) at 50 ℃ into the products 2,5-dichlorobenzoic acid and 
methanol. This reaction occurs over the space of approximately 79 hours implying that the 
pesticide would not be long-lived in the environment.68  
The hydrolysis of DCB by the bacterium Burkholderia cepacia (isolated from soil samples from 
Bolquère in the south of France) has been investigated.73 The results showed that this organism 
is capable of degrading DCB and are promising for the potential application of DCB in an aqueous 
formulation with minimal environmental impact. 
The low solubility and high volatility of DCB are limiting factors in the implementation of this 
pesticide as a plant growth regulator. A patent for Water Dispersible Granule Composition has 
recently been awarded by the United States Patent and Trademark Office in which DCB is 
mentioned as one of the possible agrochemical excipients.74 This formulation contains several 
components including insoluble filler, suspension adjuvants and polyvinyl alcohol. Cyclodextrin 
inclusion may provide an alternative approach to the solubilisation of DCB, as well as the 
formation of a less volatile solid for transport and handling. 
FENTHION 
Fenthion (O,O-dimethyl O-4-methylthio-m-tolyl phosphorothioate) is an organothiophosphate 
insecticide that acts via cholinesterase inhibition. It is moderately toxic to mammals (acute 
LD50 = 250 mg kg-1) and is employed as a broad spectrum insecticide used to control various 
sucking and biting insects. It is highly toxic to birds (acute LD50 = 7.2 mg kg-1) and is also marketed 
as an avicide.67 Fenthion is used in South Africa for control of the red-billed quelea (Quelea 
quelea), a highly damaging pest.75 The application of fenthion is however problematic, causing 
environmental issues with non-target organisms.75,76 Fenthion adsorbs strongly to soil particles 
and does not move through the soil.67,77 Furthermore, due to its very low aqueous solubility it is 
often combined with severely polluting organic solvents (such as xylene and mineral oil in the 
formulation AVIGEL) which poses inhalation risks to those working with it. 
Fenthion is a highly volatile oil at room temperature, which may lead to exposure of those 
handling the material. Cyclodextrin inclusion would transform fenthion into a solid material 
aiding in handling and transport. Formation of a possible inclusion complex could also lower the 
volatility, reducing exposure through inhalation. Solubilisation of fenthion through cyclodextrin 
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inclusion may facilitate soil decontamination through the application of cyclodextrins and may 
also eliminate the need for organic solvents for fenthion application. 
ACIPIMOX 
Acipimox (a niacin derivative) is a lipid-lowering agent used in the treatment of 
hypertriglyceridaemia. It has been available since 1984 and over the course of 2013 the 
Co-ordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) 
prepared a report recommending the restriction of acipimox to its use as an additional or 
alternative treatment to reduce high triglyceride levels.78 This report was based on a study (HPS2-
THRIVE) which examined long term use of a nicotinic acid and laropiprant combination. Based 
on this study the European Medicines Agency suspended the use of this combination. Due to the 
chemical similarities between acipimox and nicotinic acid an investigation into the use of 
acipimox was subsequently required. These similarities prompted the decision to restrict the use 
of acipimox to an alternative treatment for reduction of high levels of triglycerides. Acipimox is 
of particular use for patients who are sensitive to statins or fibrates. The conclusion of the report 
was that the benefit-risk balance of acipimox-containing products was favourable for the above-
mentioned uses. 
Acipimox has been identified as a possible aid in improving insulin resistance and glucose 
tolerance in certain diabetic patients over both the short term and the long term.79,80 As this is 
most effective in a fasted state, it requires overnight doses. Supramolecular modification of 
acipimox may provide the solution in a slow release formulation. While the formation of a sodium 
salt showed no improvement over the untreated API,81 co-crystals may provide an alternative 
methodology to achieve the desired result. This requires screening and characterisation of 
several acipimox multi-component crystalline systems. Such screening can also give an indication 
of the structural features of the co-formers that would be most likely to form multi-component 
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AIMS AND OBJECTIVE 
The primary aim of this project is to create new solid-state supramolecular systems with each of 
the three selected bioactive molecules. Once such systems are identified they will be fully 
characterised. Cyclodextrin inclusion complexation was identified as the most appropriate 
method for modifying the physicochemical properties of the pesticides. Cyclodextrins are 
commercially available on an industrial scale and digested into environmentally innocuous 
products after application making them ideal for pesticide formulations. Co-crystallisation was 
selected for the investigations with acipimox as the vast library of GRAS co-formers would enable 
large variation in the changes to the physicochemical properties of the antihyperlipidemic agent. 
The specific objectives are as follows: 
1. Cyclodextrin Inclusion Complexes 
a. Attempt to form cyclodextrin inclusion complexes with DCB and fenthion with the 
native cyclodextrins by kneading and co-precipitation. Similarly, investigate 
methylated cyclodextrins TRIMEA, TRIMEB and DIMEB as potential host 
molecules. 
b. Upon identifying a new complex, characterise the product through the use of 
spectroscopic, thermal and crystallographic techniques. 
c. Investigate the phase solubility profile of the guest in the presence of native 
cyclodextrins (α-cyclodextrin, β-cyclodextrin and γ-cyclodextrin) and 
commercially available derivatised cyclodextrins (e.g. RAMEB and HPBCD). From 
these experiments determine the binding constants of the complexes. 
2. Co-crystallisation with Acipimox 
a. Screen for potential co-crystals or salts through dry grinding, liquid-assisted 
grinding and co-precipitation methods. 
b. Upon identification of a new solid phase, investigate methodologies to scale-up 
the material for comprehensive physicochemical analysis. 
c. Characterise the new form using spectroscopic, thermal and crystallographic 
methods. 
d. From the single crystal X-ray structure unambiguously identify each product as a 
salt or co-crystal. Confirm the designation using infrared spectroscopy. 
e. Investigate the differences or similarities in physicochemical properties of the 
new form relative to those of the untreated API. 
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CHAPTER 2 –  EXPERIMENTAL 
  





The host molecules α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, TRIMEA [hexakis-(2,3,6-tri-O-
methyl)-α-cyclodextrin], DIMEB [heptakis-(2,6-di-O-methyl)-β-cyclodextrin], TRIMEB [heptakis-
(2,3,6-tri-O-methyl)-β-cyclodextrin], RAMEB (randomly methylated-β-cyclodextrin) and HPBCD 
(2-hydroxypropyl-β-cyclodextrin) were all obtained from Cyclolab (Budapest, Hungary). The 
compounds all had a purity greater than 98%. DIMEB and TRIMEB were also obtained from 
Sigma-Aldrich (Germany) with a purity greater than 98%. 
CO-FORMERS 
4-aminobenzamide, 4-aminopyridine, 4-hydroxybenzamide, 4-hydroxybenzoic acid, benzamide, 
tranexamic acid (trans-4-aminocyclohexanecarboxylic acid) and urea were acquired from Sigma-
Aldrich (Germany) with a purity greater than 98%. 
BIOACTIVE MOLECULES 
Acipimox (5-carboxy-2-methyl-1-oxidopyrazin-1-ium) and fenthion (O,O-dimethyl O-4-
methylthio-m-tolyl phosphorothioate) were obtained from Sigma-Aldrich (Germany) with >99% 
purity and used as received. 2,5-dichlorobenzoic acid methyl ester (DCB) was obtained from BOC 
Sciences, Creative Dynamics Inc. (New York, USA). 
SOLVENTS 
Anhydrous acetonitrile (99.8 %) and butan-1-ol (99.9 %) were obtained from Sigma-Aldrich 
(Germany). Methanol (99.5 %), ethanol (99.9 %), propan-2-ol (99.7 %) and dimethyl sulfoxide 
(99.5 %) were acquired from KIMIX Chemical and Lab Supplies CC (Cape Town, South Africa). 
1, 4-dioxane (99 %) and propan-1-ol (99.5 %) were purchased from Merck (Pty) Ltd South Africa 
(South Africa). All the solvents were used as received. 
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SUPRAMOLECULAR SYSTEMS PREPARATION 
The cyclodextrin inclusion complexes were initially prepared using a 1:1 molar ratio of the 
pesticides and cyclodextrin host molecule. Similarly, the acipimox multi-component crystalline 
systems were prepared with an acipimox to co-former 1:1 stoichiometric ratio. 
The specific details of preparation of each multi-component system will be discussed before an 
in-depth analysis of physicochemical properties of the resulting systems.   
CYCLODEXTRIN INCLUSION COMPLEXES 
Cyclodextrin inclusion complexes were prepared in two distinct ways. These are kneading and 
co-precipitation. 
KNEADING 
Equimolar quantities of the guest and host molecules were weighed using a five place analytical 
balance. The components were combined and ground together with an agate pestle in an agate 
mortar with dropwise addition of Milli-Q water. This process was continued for 45 minutes 
during which the paste-like consistency of the sample was maintained. The paste was then 
analysed for the formation of a new phase from powder X-ray diffraction data. If evidence of a 
new product was found the paste was recrystallised from water and further analyses were 
performed. 
CO-PRECIPITATION 
For the formation of native cyclodextrin inclusion complexes the host was dissolved in Milli-Q 
water at an elevated temperature (~60-70 °C). The guest was then added to this solution over the 
course of 10 minutes, approximately 1 mg at a time. The solution was stirred at the elevated 
temperature for 4 – 6 hours and filtered through a 0.45 µm nylon filter into a clean vial. This 
solution was then allowed to slowly evaporate on the benchtop or placed in a Dewar flask which 
was allowed to cool from ~70 °C to room temperature over several days. When preparing 
inclusion complexes with the methylated cyclodextrin hosts the initial solution containing host 
and guest was prepared at low temperature (~4 °C) and placed in an oven set at 60 °C to allow 
crystallisation of the inclusion complex. 
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MULTI-COMPONENT CRYSTALLINE SYSTEMS 
Three methods were used to form co-crystals, salts and solvates. These are dry grinding (DG), 
liquid-assisted grinding (LAG) and co-precipitation. 
DRY GRINDING 
Dry grinding was used as the initial screening method. Equimolar quantities of the API and co-
former were combined in an agate mortar and ground for approximately 20 minutes using an 
agate pestle. The resulting powder was then screened for the formation of a new phase by powder 
X-ray diffraction. The appearance of new peaks and the disappearance of peaks from the 
components indicated the formation of a new phase. The new phases that arose from the grinding 
experiments were recrystallised from an appropriate solvent system. 
LIQUID-ASSISTED GRINDING 
Solvent-assisted or liquid-assisted grinding (LAG) was performed in a similar manner to the DG 
experiment detailed above, the difference being that the grinding took place with the dropwise 
addition of a predetermined solvent. The product was analysed as detailed in the Dry Grinding 
section. 
CO-PRECIPITATION 
Co-precipitation was performed by combining the API and co-former in a vial. The mixture was 
then dissolved in an appropriate solvent system. The solution was stirred at elevated 
temperatures (generally within a few degrees of the solvent boiling point) for several hours. The 
solution was then filtered through a 0.45 µm nylon filter into a clean vial. The vial was finally 
sealed with Parafilm M® and left on the benchtop with a few holes in the parafilm to form crystals 
via slow evaporation. 
THERMAL ANALYSIS 
Three major analytical techniques were used in the thermal analysis of the products obtained 
from the above experiments, namely thermogravimetric analysis (TGA), differential scanning 
calorimetry (DSC) and hot stage microscopy (HSM). 
THERMOGRAVIMETRIC ANALYSIS 
The technique of TGA is performed to determine the mass loss of a substance as a function of 
temperature. This experiment is typically performed under a controlled atmosphere, namely dry 
nitrogen gas, to prevent oxidation during the heating process. The TGA profiles obtained were 
used to determine the stoichiometry of the supramolecular constructs where the mass loss took 
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place in one-step for each component. TGA was also used to determine the amount of solvent 
present in each system and to investigate the thermal stability of the products. 
The experiments were performed on a TA Instruments TA-Q500 with Universal Analysis 2000 
software and a dry nitrogen flow rate of 60 cm3 min-1. Crystals were removed from the mother 
liquor and dried on filter paper to remove any surface solvent. The sample (3-10 mg) was 
subsequently placed in an alumina crucible and loaded into the furnace, which was heated at a 
rate of 10 K min-1 until the desired temperature was achieved. 
DIFFERENTIAL SCANNING CALORIMETRY 
The DSC experiments measured the difference in heat flow between sample and reference pans. 
As the energy requirements differ to maintain the same temperature between the pans, 
endothermic and exothermic events can be monitored. The onset temperatures, temperature 
ranges and the enthalpy changes of thermal events were determined from the experimental 
traces. The melting point of the product was compared with those of the starting materials to 
confirm the formation of a new supramolecular assembly. 
The samples were prepared in a similar manner to the TGA samples. The traces were collected 
on a TA Instruments TA-Q200 Differential Scanning Calorimeter with Universal Analysis 2000 
software and a dry nitrogen gas flowrate of 60 cm3 min-1. Crystals were surface dried on filter 
paper and a known mass of sample (1-5 mg) was then transferred to the Tzero aluminium sample 
pan. The pan was then crimped closed with a vented lid. The reference pan was prepared in an 
identical manner. A heating rate of 10 K min-1 under dry nitrogen at 60 cm3 min-1 was used. 
HOT STAGE MICROSCOPY 
HSM was used to corroborate and confirm the TGA and DSC data obtained. HSM allows one to 
visually observe physical changes that occur upon heating. The appearance of bubbles indicating 
solvent loss, changes in opacity or colour, melting and decomposition can all be observed directly 
via HSM. These changes can be difficult to glean directly from the TGA and DSC traces. However, 
by corroborating data with HSM photographs it was possible to correlate thermal events and 
hence identify them unambiguously. 
The samples were placed in silicone oil on a cover slip and heated at a rate of 10 K min-1 until 
decomposition was observed. The heating rate and temperature were controlled using a Linkam 
TP92 manual temperature control unit connected to a Linkam THMS600 hot stage which was 
mounted on a Nikon SMZ-10 stereoscopic microscope. Fitted to the microscope was a Sony Digital 
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Hyper HAD colour video used to capture the micrographs that were viewed with the Soft Imaging 
System Program, analySIS.1 
X-RAY DIFFRACTION 
Two X-ray diffraction techniques were used to obtain information regarding the newly prepared 
crystalline materials. The first was single crystal X-ray diffraction used to determine the crystal 
structure of the systems. Powder X-ray diffraction (PXRD) was used to screen for the formation 
of a new solid phase as well as to confirm the homogeneity of the bulk sample. 
SINGLE CRYSTAL X-RAY DIFFRACTION 
For single crystal X-ray diffraction, crystals of sufficient quality for diffraction were selected 
based upon their size, clarity, regularity and ability to extinguish plane-polarised light in a 
uniform fashion. Crystals selected were surface dried on filter paper and immediately placed in 
Paratone N oil2 to prevent the loss of solvent. The oil also provided a rigid support for the crystal 
during low temperature data-collections. The crystal was then mounted on a nylon loop and the 
loop mounted on a goniometer head. 
DATA-COLLECTION 
The crystal intensity data were collected on two instruments. The first was a Nonius Kappa CCD 
(Charge Coupled Device) X-ray diffractometer. The radiation source was graphite-
monochromated MoKα radiation (λ = 0.71073 Å). The radiation was provided by a Nonius FR590 
generator running at 50 kV and 30 mA. The second diffractometer used was a Bruker KAPPA 
APEX II DUO3 X-ray diffractometer with graphite-monochromated MoKα (λ = 0.71073 Å) 
radiation. The radiation was produced by using a Bruker K780 generator running at 50 kV and 
20 mA. During each collection the crystals were maintained at a temperature of either 100(2) K 
or 173(2) K using a constant nitrogen stream controlled by a Cryostream cooler (Oxford 
Cryosystems, UK). 
The programs DENZO and SCALEPACK4 were used for unit cell refinement when using the Nonius 
Kappa diffractometer. Program SAINT5 was used for unit cell refinement and data reduction when 
using the Bruker APEX II. All collected intensity data were corrected for Lorentz-polarisation (Lp) 
effects. Multi-scan absorption corrections (program SADABS6) were applied when heavy atoms 
were present in the structure. Once the intensity data were processed the crystal system was 
determined from the Laue group of the diffraction pattern and the space group was determined 
from systematic absences. This determination was verified using XPREP,7 which was also used to 
prepare the input files for structure determination and refinement. 
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STRUCTURE SOLUTION AND REFINEMENT 
Small multi-component systems were solved by the program SHELXS8 and the structure 
refinement was performed using SHELXL.8 
Isomorphous replacement was the main method used to solve cyclodextrin crystal structures. 
This was done by using the atomic co-ordinates of the rigid backbone of host molecules from 
isostructural cyclodextrin systems as trial models.9 The structure was then refined using 
SHELXH8 or SHELXL.8,10 SHELXL was used after the release of the SHELX-201310 software 
package, which is capable of refining large structures. If isomorphous replacement was not 
applicable due to the complex not belonging to any known isostructural series, SHELXD8 was used 
to solve the structure using direct methods as outlined below. 
SHELXS 
Smaller structures, such as salts and co-crystals, were solved using SHELXS.8 SHELXS makes use 
of direct methods or the Patterson function to achieve a structure solution. Only direct methods 
were required during the scope of this study. 
SHELXD 
SHELXD8 is part of the SHELX suite of programs written to deal with structures too large for the 
direct methods program SHELXS.8 The software was based on the program Shake and Bake (SnB) 
by Miller et al.11–13 Both SHELXD and SnB rely on dual-space iteration algorithms where the 
phases are calculated in reciprocal space and various strategies applied to attempt to improve the 
phase refinement; this is referred to as the “shake” part of the algorithm. These improvements 
are achieved by the use of the minimum function14,15 in the case of SnB, and the tangent formula16 
in the case of SHELXD. The tangent formula is used to derive the phases for the remaining 
reflections from the most reliable phases. Once the improved phases are obtained, a real space 
electron density map is calculated incorporating the normalised structure factors derived from 
the intensities. The highest peaks are assigned as possible atoms and subjected to a random omit 
map where a given percentage of the top peaks are randomly deleted. The remaining atoms are 
used to calculate the new phases in reciprocal space and begin the calculation again. A figure of 
merit is required to determine the validity of the trials, of which successful trials are expanded 
employing all data using peaklist optimisation. This robust method is well suited to solve large 
structures, such as cyclodextrin inclusion complexes. 
 
 




SHELXH8 is a version of SHELXL8 used for the refinement of large structures, the difference being 
that the array dimensions are specified by a parameter in SHELXH. SHELXL and SHELXH 
otherwise refine structures in the same manner. 
The refinement is based on full-matrix least-squares minimisation of the function 
∑ 𝑤(𝐹𝑜
2 − 𝐹𝑐
2)2. The residual index R1 (Expression 2.1) shows the agreement between the 
observed and calculated structure factors, Fo and Fc respectively. The lower the value of R1 the 






The residual index wR2 (Expression 2.2) shows the agreement between the squares of the 
observed and calculated structure factors, F2 (i.e. the observed and calculated intensities). 
However, this refinement enhances the deviation from unity for the goodness-of-fit (S, defined 









The weighting scheme 𝑤 in Expression 2.2 is defined in Expressions 2.3 and 2.4 where a and b 
are chosen such that there is a constant distribution of [𝑤(𝐹𝑜
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The goodness-of-fit, S, is given by Expression 2.5 where n and p are the number of reflections and 
the total number of refinement parameters respectively. S should be close to unity and the ratio 
n/p should be greater than ten for centrosymmetric space groups.17 For non-centrosymmetric 
space groups the ratio should be at least ten if the structure contains heavy atoms and not less 
than eight if the structure contains only atoms lighter than argon.17 










POWDER X-RAY DIFFRACTION 
To record PXRD traces two diffractometers were used. Some samples were analysed on a Huber 
Imaging Plate Guinier Camera 670 with a Ni-filtered CuKα radiation source (λ = 1.54060 Å). A 
Philips PW1120/00 X-ray generator running at 40 kV and 20 mA produced the radiation. The 
diffractometer was fitted with a Huber fine-focus tube PW2273/20 and a Huber Guinier 
Monochromator Series 611/15. MYLAR® polyester film coated with a thin layer of Paratone N oil2 
suspended in a flat sample holder was used to mount the samples. Samples were scanned over 
the 4°≤2θ≤40° range with a 0.005° step size and data were plotted using Microsoft Excel over the 
desired range. 
The other diffractometer used was a Bruker D8 Advance diffractometer fitted with a Lynxeye 
detector and CuKα radiation source (λ = 1.54060 Å). The generator was operated at 30 kV and 
40 mA. Samples were mounted on a Si low background sample holder and scanned over the 
4°≤2θ≤40° range with a step size of 0.01°. The data were plotted using Microsoft Excel. 
Data were analysed in various ways depending on the purpose of the scan. Screening of products 
from kneading and grinding experiments was performed by comparing the PXRD trace of the 
product with those of the starting materials. If a new phase is present the traces will differ with 
the disappearance of various peaks and appearance of new ones. If the product is not a new phase 
the trace will be a sum of the starting material traces. In the case of experiments involving 
cyclodextrins, PXRD traces of the products were compared with those for known isostructural 
series9 of cyclodextrin inclusion complexes. When a match was obtained, a definitive indication 
of complex formation resulted. In addition, the space group and approximate unit cell dimensions 
could be predicted for the new complex. An alternative approach in the determination of new 
phases is to compare the PXRD trace of the putative complex to the traces of the starting 
materials. If the diffraction patterns differ resulting from the disappearance of peaks and the 
appearance of new peaks in the complex trace one can conclude that a new phase has been 
obtained. This approach was used for cyclodextrins when the complex was not isostructural with 
a known cyclodextrin inclusion complex series. 
To confirm that the single crystal X-ray structure is representative of the bulk product, the 
powder pattern was calculated from the single crystal structure and compared with the 
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experimental PXRD pattern. The calculated PXRD pattern was prepared using software packages 
LAZY PULVERIX18 or Mercury.19,20 LAZY PULVERIX comprises two programs that run 
consecutively; LAZY is the first, where the data are prepared for the calculation of the powder 
diffraction pattern by PULVERIX. LAZY is used to derive the equivalent atomic positions, Laue-
group, systematic absence conditions, atomic scattering factors and coefficients for anomalous 
dispersion. PULVERIX then calculates the powder diffraction pattern. The positions of the 
diffraction peaks are calculated from their d-spacing and Bragg’s law. The intensities (Ihkl) of the 
peaks are calculated using Expression 2.6, where m is the reflection multiplicity factor, L is the 
Lorentz factor, P the polarisation factor and Fhkl is the calculated structure factor. The data are 




The program Mercury calculates the Lorentz-polarisation (Lp) corrected powder diffraction 
pattern. The Lp correction assumes the use of a laboratory X-ray source with fixed slit widths. 
Absorption, noise and the background are not included in the calculation while hydrogen atoms 
are assumed to have a Uiso value of 0.05 Å2. The reflections are modelled with pseudo-Voigt peak 
shapes and a full width at half maximum (FWHM) of 0.1° 2θ. The 000 reflection is generally 
excluded and the default radiation source is set as CuKα.19 The calculated pattern is then plotted 
using Microsoft Excel. 
The spacing of crystallographic planes can vary with temperature, however these changes are 
unpredictable since crystal shrinkage or expansion is typically anisotropic. Shifts thus occur in 
the diffraction peak positions resulting from changes in the d-spacings. As the PXRD patterns are 
generally calculated from low temperature structures the values of 2θ are therefore sometimes 
shifted relative to the experimental pattern collected at room temperature. 
FOURIER TRANSFORM INFRARED SPECTROSCOPY 
Fourier transform Infrared (FTIR) spectra were collected using a PerkinElmer FT-IR Spectrum 
spectrometer fitted with a Universal ATR accessory. All samples were scanned over the 4000 to 
400 cm-1 range at a rate of 4 s (cm-1)-1.  
The data were analysed using the OPUS 7.2 software package. FTIR was used to determine 
whether a proton was transferred during the formation of the multi-component crystal system 
resulting in a salt. If no proton transfer occurred the resulting product was confirmed to be a 
co-crystal. 
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ULTRAVIOLET-VISIBLE SPECTROSCOPY  
Ultraviolet-Visible light (UV-Vis) spectroscopy was used to evaluate the concentration of the API 
in solution. This was used for phase solubility experiments. Furthermore, interaction of a 
bioactive molecule with a cyclodextrin can affect absorbance properties of the API. The UV-Vis 
spectra were recorded on a Shimadzu UV-2101 spectrophotometer and a Cintra 20 UV-Visible 
spectrophotometer. Data were plotted and analysed using Microsoft Excel. 
INDUCED CIRCULAR DICHROISM 
Induced Circular Dichroism (ICD) relies on the differing absorbance of left and right circularly 
polarised light by chiral molecules. Cyclodextrins are not UV active, however the cavity is a chiral 
environment. The APIs are not chiral, but are UV active. By complexing the API with the 
cyclodextrin a chiral system that absorbs circularly polarised UV electromagnetic radiation is 
achieved. This allows one to investigate the nature of the interaction between the host and guest, 
as well as the orientation of the guest molecule within the cyclodextrin cavity based on the Cotton 
effect. 
The instrument used was a JASCO Model J-810 spectropolarimeter. Samples and blanks were 
prepared in Milli-Q water filtered through a 0.45 μm filter. The experimental parameters were as 
follows: N2 flow rate 15 cm3 min-1, response 2 s, scanning speed 100 nm min-1, range scanned 200 
– 450 nm and accumulation 4. The spectra obtained for the blanks were subtracted from the 
experimental spectra for all samples. 
NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY 
Nuclear magnetic resonance (NMR) spectroscopy was used to determine the molar ratio of the 
components in each of the supramolecular systems. Crystals were dissolved in an appropriate 
deuterated solvent and the 1H NMR spectra recorded. The proton signals were integrated and the 
molar ratio determined by direct comparison of the component signals. 
NMR spectroscopy was further used to quantitatively evaluate the concentration of acipimox for 
equilibrium solubility experiments. This method employed DMSO as an internal standard and the 
relative integration of the appropriate protons allowed calculation of the final acipimox 
concentration. 
A Bruker 300 MHz spectrometer was used to collect all spectra using the pulse program zq30.21 
The data were evaluated using the Bruker software Topspin21 and plotted using Microsoft Excel.  




1 Soft Imaging System GmbH, Digital Solutions for Imaging and Microscopy, Version 3.1 for 
Windows (Copyright 1987-2000). 
2. Paratone N oil (Exxon Chemical Co., Texas, USA). 
3. APEX2, Version 1.0-27, Bruker AXS Inc., Madison, Wisconsin, USA. 
4. Z. Otwinowski and W. Minor, Methods in Enzymology, eds. C. J. Carter and R. Sweet, 
Academic Press, 1997, pp. 307–326. 
5. Program SAINT, Version 7.60a, Bruker AXS Inc., Madison Wisconsin, USA, 2006. 
6. G. M. Sheldrick, Program SADABS, Version 2.05, University of Göttingen, Germany, 2007. 
7. XPREP, Data Preperation and Reciprocal Space Exploration, Version 5.1, © Bruker AXS 
Inc., 1997. 
8. G. M. Sheldrick, Acta Cryst., 2008, A64, 112–122. 
9. M. R. Caira, Rev. Roum. Chim., 2001, 46, 371–386. 
10. G. M. Sheldrick, Acta Cryst., 2015, C71, 3–8. 
11. R. Miller, S. M. Gallo, H. G. Khalak, and C. M. Weeks, J. Appl. Crystallogr., 1994, 27, 613–
621. 
12. I. Usón and G. M. Sheldrick, Curr. Opin. Struct. Biol., 1999, 9, 643–648. 
13. G. M. Sheldrick, H. A. Hauptman, C. M. Weeks, R. Miller, and I. Usón, in International Tables 
for Crystallography, eds. E. Arnold and M. Rossmann, Kluwer Academic Publishers, 2001, 
pp. 333–351. 
14. R. Miller, G. T. DeTitta, R. Jones, D. A. Langs, C. M. Weeks, and H. A. Hauptman, Science, 
1993, 259, 1430–1433. 
15. T. Debaerdemaeker and M. M. Woolfson, Acta Cryst., 1983, A39, 193–196. 
16. J. Karle and H. Hauptman, Acta Cryst., 1956, 9, 635–651. 
Chapter 2 – Experimental 
 
 41 
17. IUCr Webmaster, Data Validation Procedures, © International Union of Crystallography, 
http://journals.iucr.org/services/cif/checking/validlist.html, 20/08/2015 
18. K. Yvon, W. Jeitschko, and E. Parthé, J. Appl. Crystallogr., 1977, 10, 73–74. 
19. C. F. Macrae, P. R. Edgington, P. McCabe, E. Pidcock, G. P. Shields, R. Taylor, M. Towler, and 
J. van de Streek, J. Appl. Crystallogr., 2006, 39, 453–457. 
20. C. F. Macrae, I. J. Bruno, J. A. Chisholm, P. R. Edgington, P. McCabe, E. Pidcock, L. 
Rodriguez-Monge, R. Taylor, J. van de Streek, and P. A. Wood, J. Appl. Crystallogr., 2008, 
41, 466–470. 
21. Program TopSpin, Version 3.2, Bruker BioSpin GmbH, 2014. 
 
 
Chapter 3 – 2,5-Dichlorobenzoic acid methyl ester 
 
 42 
CHAPTER 3 –  2,5-DICHLOROBENZOIC ACID METHYL ESTER 
For convenience 2,5-dichlorobenzoic acid methyl ester will be abbreviated to DCB. This 
compound is a fungicide of low aqueous solubility (87 mg dm-3 at 20 ℃).1 The low solubility 








During the experimental investigation into the inclusion of 2,5-dichlorobenzoic acid methyl ester 
in cyclodextrins various hosts were tried. The inclusion in native cyclodextrins, namely 
α-cyclodextrin, β-cyclodextrin and γ-cyclodextrin was attempted before the use of methylated 
cyclodextrins was pursued. Unfortunately only γ-cyclodextrin was successful as a host compound 
from the native cyclodextrins. Of the methylated derivatives, DIMEB, TRIMEA and TRIMEB were 
attempted, and only DIMEB gave rise to an inclusion complex. 
This chapter will focus on the successful attempts at forming cyclodextrin inclusion complexes 
with 2,5-dichlorobenzoic acid methyl ester. 
γ-CYCLODEXTRIN/(2,5-DICHLOROBENZOIC ACID METHYL ESTER) 
The γ-cyclodextrin complex with 2,5-dichlorobenzoic acid methyl ester will be referred to as 
GCDDCB. 
SAMPLE PREPARATION 
10 mg (0.049 mmol) of DCB was weighed and combined with 63 mg (0.049 mmol) γ-cyclodextrin 
in an agate mortar. The mixture was kneaded using an agate pestle with dropwise addition of 
water for 30 minutes. Attempts to prepare a complex via co-precipitation did not yield single 
crystals, although powdered samples were obtained. However, this was not considered a serious 
drawback, since if single crystals had been available, the probability of guest location would have 
been very low due to predictable disorder of the guest which arises from the four-fold rotational 
symmetry centred on the cavity. The crystalline samples obtained from this preparation were 
used for all analyses presented below. 
COMPLEX STOICHIOMETRY 
A powdered sample obtained from co-precipitation experiments was dissolved in DMSO-d6 and 
analysed using 1H-NMR spectroscopy to calculate the stoichiometric ratio of the GCDDCB 
complex. The labelling scheme of the glucopyranose subunit is shown in Figure 3.1 below. 
Integration of the C1-H proton signal of γ-CD and the aromatic and methyl DCB proton signals 
showed a γ-CD:DCB ratio of 3:4 for the complex. The integration values are presented below in 
Table 3.1 and the spectrum can be seen in Figure 3.2. 




Figure 3.1: Proton labelling of γ-CD glucopyranose subunits (left) and DCB (right) 
Table 3.1: Integrals and assignment of host and guest protons used for stoichiometric confirmation 
Proton δ (ppm) 
Integration Experimental/ 
Theoretical Experimental Theoretical 
γ-cyclodextrin 
C-H1 4.93 8.00‡ 8.00 1 
O-H2 + O-H3 5.78 16.19 16.00 1.01 ≈ 1 
O-H6 4.54 8.16 8.00 1.02 ≈ 1 
2,5-dichlorobenzoic acid methyl ester 
C-H3 + C-H4 7.69 2.64 2.67 0.99 ≈ 1 
C-H6 7.90 1.35 1.33 0.98 ≈ 1 
‡Reference Integral 
 
Figure 3.2: NMR spectrum of GCDDCB in DMSO-d6 to determine the stoichiometric ratio 
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COMPARATIVE POWDER X-RAY DIFFRACTION 
The paste resulting from the kneading preparation was subjected to PXRD to investigate the 
formation of a new phase. The PXRD traces are shown in Figure 3.3. The experimental trace was 
compared to the calculated reference pattern of the γ-cyclodextrin inclusion complex of 
12-crown-4 (CSD refcode: DOCYID).3,4 The good correlation between the traces indicates that the 
materials are isostructural, crystallising in the space group P4212. This indicates that the material 
prepared by kneading is of a channel type inclusion complex. 
 
Figure 3.3: Comparative PXRD trace of the putative GCDDCB complex (blue) and the calculated 
DOCYID reference pattern (orange) 
THERMAL ANALYSIS 
The TGA and DSC traces of GCDDCB crystals prepared by co-precipitation are presented in 
Figure 3.4. As can be seen in the TGA trace, there is an immediate mass loss due to dehydration 
of the inclusion complex. From room temperature to 112 ℃ a mass loss of 13.0 ± 0.1 % (n = 2) 
was observed. This mass loss equates to 9.8 ± 0.1 water molecules per cyclodextrin molecule. The 
DSC trace corroborates the interpretation as the dehydration of the complex by the presence of 
the broad endotherm over the same temperature range. Furthermore, the HSM image at 100 ℃ 
(Figure 3.5) shows the evolution of bubbles indicating solvent loss. A second mass loss occurs 
starting at 168.0 ± 0.9 ℃ (n = 2) corresponding to the loss of DCB (calculated mass loss 17.5 %). 
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This mass loss overlaps with the beginning of the decomposition of the host at 281.9 ± 1.4 ℃ 
(n = 2), as shown in Figure 3.4. The stoichiometry of this complex (3:4) had previously been 
determined by NMR spectroscopy. The degradation of the host is present in the TGA trace as a 
large mass loss of 66.6 ± 1.0 % (n = 2). The degradation is also evident in the DSC trace over the 
same temperature range as a large endotherm and is clearly visible in the final two HSM images. 
 
Figure 3.4: Representative TGA (blue) and DSC (orange) traces for GCDDCB 
 
Figure 3.5: Hot stage micrographs showing the GCDDCB complex at various stages of heating  
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DIMEB/(2,5-DICHLOROBENZOIC ACID METHYL ESTER) 
The complex of 2,5-dichlorobenzoic acid methyl ester and DIMEB will be referred to as DMBDCB 
for convenience. 
SAMPLE PREPARATION 
This product was synthesised using a co-precipitation method. To create this inclusion complex 
64.9 mg (0.049 mmol) of DIMEB was weighed and dissolved in 3 cm3 Milli-Q water at 4 ℃. 10 mg 
(0.049 mmol) of 2,5-dichlorobenzoic acid methyl ester was slowly added to the cyclodextrin 
solution and this mixture was then stirred for 3 to 4 hours at 4 ℃. This mixture was then heated 
to 50 ℃ and cycled back to 4 ℃ several times to determine the point at which the majority of the 
complex was in solution. The mixture was then filtered through a 0.45 μm nylon filter into a clean 
vial. The vial was then placed in a 60 ℃ oven for several days until large needle-like crystals 
appeared. 
COMPLEX STOICHIOMETRY 
The stoichiometry of DMBDCB was determined via thermal analysis. A mass loss of 13.7 ± 0.6 % 
(n = 2), interpreted as guest release, was observed with an onset temperature of 142.0 ± 1.3 ℃. 
This mass loss corresponds to a complex ratio of 1:1 (calculated mass loss = 13.3 %). 
Furthermore, no solvent loss is observed for this complex indicating that there are no waters of 
crystallisation present.  
THERMAL ANALYSIS 
The thermal analysis of DMBDCB (Figure 3.6) show that there is no solvent loss. A mass loss of 
13.7 ± 0.6 % (n = 2), corresponding to the release of one guest molecule per complex unit, occurs 
with an onset at 142.0 ± 1.3 ℃ in two steps, with the second continuing smoothly until 
decomposition of the host at 357.1 ± 1.3 ℃. Since the first distinct mass loss of (~8%) 
corresponds to one half of the total guest mass loss, a possible explanation is that the complex 
undergoes a rearrangement from a 1:1 to a 2:1 complex. Subsequent guest loss would not 
necessarily have a similar thermal profile. Figure 3.7 showing the derivative with respect to 
temperature clearly exposes the presence of the mass loss. Pure DCB melts at a temperature of 
39.9 ℃ and decomposes over a very large range from 49.9 ℃ to 170.0 ℃; as such it is reasonable 
that the slow two-step mass loss occurring upon heating the complex is the loss of DCB. This is 
expanded upon in the discussion. The endotherms in the DSC trace corroborate this 
interpretation with a small endotherm at 149 ℃ corresponding to the loss of half the guest 
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molecules and rearrangement of the complex. The second endotherm from 345-392 ℃ 
corresponds to decomposition of the host molecule. This analysis is further evidenced by the hot 
stage microscopy images (Figure 3.8) where there is no apparent solvent loss in the images; the 
crystals then begin to become opaque in line with the mass loss beginning at 149 ℃ until 
decomposition is clearly visible in the final image at 308 ℃. 
 
Figure 3.6: Representative TGA (blue) and DSC (orange) traces for DMBDCB 
 
Figure 3.7: TGA trace (blue) showing the derivative with respect to temperature (orange) and 
mass loss 




Figure 3.8: Hot stage micrographs showing the DMBDCB complex at various stages of heating 
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CRYSTAL STRUCTURE ANALYSIS 
The stoichiometry of the complex was determined to be 1:1 from TGA experiments as described 
above. 
DATA COLLECTION AND SPACE GROUP DETERMINATION 
Data were collected on a Bruker KAPPA APEX II DUO diffractometer. The X-ray diffraction pattern 
was determined to have mmm Laue symmetry, which in turn indicated that the crystal system 
was orthorhombic. The space group was determined to be P212121 by examining the systematic 
absences. The conditions limiting reflection were hkl: none, h00: h = 2n, 0k0: k = 2n, 00l: l = 2n 
confirming the assignment. The data collection was performed at 173 ± 2 K. 
STRUCTURE SOLUTION AND REFINEMENT 
The program SAINT5 was used in the unit cell refinement and data reduction. The asymmetric 
unit comprises one DIMEB molecule and one DCB molecule. The atomic positions of the 
cyclodextrin host were determined using isomorphous replacement.6 To perform this structure 
solution the atomic coordinates of the rigid backbone structure of an isostructural complex were 
used as a trial model. A CSD search was undertaken to determine if any DIMEB complexes with 
unit cell data close to those of the DMBDCB complex existed. Eleven isostructural DIMEB 
complexes were found in the CSD.4 A good match was found in the inclusion complex of 
2,4-dichlorophenoxyacetic acid and DIMEB (refcode: PABNEM).4,7 The DIMEB backbones of the 
DMBDCB and DIMEB/(2,4-dichlorophenoxyacetic acid) complexes have very similar atomic 
co-ordinates. The differences in the unit cell lengths are only 0.3861 Å along the a-axis, 0.4916 Å 
along the b-axis and 0.2399 Å along the c-axis. 
The rigid backbone selected for isomorphous replacement included the non-hydrogen atoms of 
the glucose rings without the conformationally flexible methoxy substituents. The remaining 
non-hydrogen atomic co-ordinates were determined through subsequent electron density 
difference maps. The glucopyranose subunits were labelled G1 through G7 to uniquely identify 
atoms. All host non-hydrogen atoms were refined anisotropically. The hydrogen atoms of the 
glucopyranose subunits were revealed in the difference Fourier map; once located they were 
added using a riding model with a Uiso value 1.2 to 1.5 times that of the parent atom.  
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Table 3.2: Crystallographic data for the single crystal X-ray structure of DMBDCB 
Chemical formula C56H98O35·C8H6Cl2O2 
Molar Mass (g mol-1) 1536.37 
Crystal system Orthorhombic 
Space group P212121 
Unit cell parameters  
a (Å) 15.2721(8) 
b (Å) 18.4884(10) 
c (Å) 28.2751(15) 
α = β = γ (°) 90.0 
Volume (Å3) 7983.7(7) 
Z 4 
Densitycalcd.  (g cm-3) 1.278 
μ [MoKα] (mm-1) 0.168 
F (000) 3272 
Temperature (K) 173(2) 
Crystal size (mm) 0.08 x 0.10 x 0.23 
Range scanned θ (°) 1.5 - 27.2 
Index ranges h: -19, 19; k: -23, 23; l: -34, 24 
ϕ and ω scan angles (°) 0.50 
Total number of frames 695 
Dx (mm) 39.71 
Total number of reflections 50 871 
Number of independent reflections 17 658 
Number of reflections with I > 2σ(I) 11 630 
Rint 0.056 
R1 [I > 2σ(I)] 0.0429 
wR2 0.0902 
S 0.987  
Number of parameters 951 
Number of reflections omitted 11 
Parameters a, b in w = 1/[σ2(FO2)+(aP)2+(bP)] a = 0.0369; b = 0 
(δ/σ)mean   <0.001 
Δρ excursions (e Å-3) -0.22; 0.27 
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MODELLING OF 2,5-DICHLOROBENZOIC ACID METHYL ESTER 
Once the non-hydrogen atoms of the host molecule were modelled the remaining high electron 
density peaks were assigned to the guest molecule. The molecule was not found to be disordered 
and furthermore no restraints were required during its refinement. All of the guest non-H atoms 
were refined anisotropically. The hydrogen atoms were located in the difference Fourier map and 
then included in idealised positions with a Uiso value of 1.2 to 1.5 times that of the parent atom. 
GEOMETRIC ANALYSIS OF DMBDCB  
The asymmetric unit of DMBDCB comprises a monomeric complex; this is shown in Figure 3.9. 
The numbering schemes for the guest and host molecules are presented in Figure 3.10. 
 
Figure 3.9: The asymmetric unit of the complex DMBDCB. Thermal ellipsoids for the host atoms are 
drawn at the 50% probability level and the guest atoms are drawn in space-filling mode. 
 
Figure 3.10: Numbering scheme of the glucopyranose rings (left) and guest molecule (right) 




The torsion angles of the primary methoxy substituents are listed in Table 3.3; this torsion angle, 
ω, is the O5-C5-C6-O6 dihedral angle. It was found that five of the substituents are directed away 
from the cyclodextrin cavity, while the G1 and G3 primary methoxy substituents are directed 
inwards. No intermolecular contacts smaller than the sum of the van der Waals radii were found 
between the host and guest molecules. The mean close contact distance involving non-hydrogen 
atoms was found to be 3.700 ± 0.131 Å. These values fall outside the range of intermolecular 
distances indicating interactions of atoms present in the structure. This shows that there is no 
steric hindrance for the positioning of the guest molecule at the primary end of the cyclodextrin 
cavity. 
Table 3.3: Torsion angles (ω) for DMBDCB 








‡Mean e.s.d. 0.3° 
Table 3.4 shows the geometric analysis parameters of the DMBDCB complex. The data show that 
the DIMEB molecule adopts a circular shape. This can be seen by the very slight variation in the l, 
D and ϕ parameters where the mean values are 5.055 ± 0.084 Å, 4.390 ± 0.051 Å and 128.4  1.9° 
respectively. From the minimal deviations in the values it is clear that the circular shape of the 
cavity is not distorted. The shape of the macrocyclic structure is maintained by the well-known 
intramolecular O3(n+1)–H···O2n hydrogen bonds. The deviation of the O4 atoms from the O4 
least-squares mean plane are small. The tilt angles τ2 are all positive indicating that the primary 
rims of the glucopyranose subunits are all tilting inwards towards the cavity. 
There are three known structures of uncomplexed DIMEB hydrates (CSD refcodes: BOYFOK04,4,8 
QIYKEO4,9 and CEQCUW4,10). BOYFOK04 (DIMEB·15H2O) has been chosen for the principal 
comparison with the complexed DIMEB molecule as these have the most similar geometric 
parameters (Tables 3.4 and 3.5). A brief comparison with the other two structures is presented 
below. 
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Upon examination of BOYFOK04, relatively small differences between its parameters and those 
of DIMEB in the DIMEBDCB complex were observed for the tilt angles, τ2, and the O4 to O4n 
centroid distance, l. The ranges of τ2 are similar in both structures (DMBDCB: 3.4° ≤ τ2 ≤ 24.9° and 
BOYFOK04: 2.8° ≤ τ2 ≤ 27.6°). The cavities of the respective DIMEB molecules maintain similarly 
“round” shapes as evidenced by l (DMBDCB: 4.96 Å ≤ l ≤ 5.18 Å and BOYFOK04: 
4.90 Å ≤ l ≤ 5.24 Å). As can be seen from these values, the two DIMEB structures maintain similar 
shapes whether or not DCB is complexed. Several DIMEB inclusion complexes contain host 
molecules that are elliptically distorted to accommodate guest molecules, an example of this 
being the DIMEB inclusion complex of 3-(-6-methoxy-pyridin-3-yl)-5-(4-methylsulfonylphenyl)-
pyridin-2-amine.11 In this case the DIMEB molecule is distorted elliptically to include the 
4-(methylsulfonyl)phenyl ring. The guest in DMBDCB is instead included with guest atoms 
abutting the primary methoxy groups, allowing the circular shape of the cavity to be maintained 
(see Guest Inclusion section below). 
Another feature common to both structures is the ‘self-inclusion’ of one of the primary methoxy 
moieties in an adjacent DIMEB molecule; details of this ‘self-inclusion’ are found in the Crystal 
Packing section below. 
The other two hydrated DIMEB structures show similar ranges in the τ2 tilt angles and the 
distance l. The τ2 values range thus: QIYKEO: 4.1° ≤ τ2 ≤ 29.7° and CEQCUW: 3.6° ≤ τ2 ≤ 24.3°. The 
variations in l are 4.45 Å ≤ l ≤ 5.19 Å and 4.91 Å ≤ l ≤ 5.26 Å for QIYKEO and CEQCUW 
respectively. These values indicate that these DIMEB hydrates similarly maintain their circular 
shape. Self-inclusion is also present in both these structures, but it is much less pronounced in 
CEQCUW. 
Table 3.4: Geometric analysis parameters for DMBDCB 
Residue l (Å) D (Å) ϕ (°) d (°) αa (Å) D3b (Å) τ2c (°) 
G1 5.145 4.364 127.2 -6.5 -0.163 2.986 17.7 
G2 5.122 4.396 130.3 -3.9 0.181 2.836 3.4 
G3 4.962 4.384 129.9 5.9 0.014 2.864 24.9 
G4 4.994 4.407 125.4 -0.2 -0.147 2.893 17.0 
G5 5.177 4.287 129.9 -0.8 0.046 2.806 6.4 
G6 5.019 4.459 130.2 -6.6 0.091 2.966 19.5 
G7 4.964 4.434 126.3 11.8 -0.022 2.785 15.0 
a mean e.s.d.: 0.002 Å; b mean e.s.d.: 0.003 Å; c mean e.s.d.: 0.1°. 
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Table 3.5: Geometric analysis parameters for DIMEB·15H2O (ref code: BOYFOK04)4,8 
Residue l (Å) D (Å) ϕ (°) d (°) α (Å) D3 (Å) τ2 (°) 
G1 5.094 4.356 125.9 2.5 -0.112 2.848 11.0 
G2 4.896 4.408 127.7 3.4 -0.057 3.043 11.0 
G3 5.082 4.471 131.6 0.1 0.187 2.860 27.6 
G4 5.237 4.296 128.3 -8.7 -0.067 2.953 18.0 
G5 4.901 4.402 123.9 8.0 -0.132 2.809 2.8 
G6 4.987 4.442 132.5 1.7 0.119 2.826 18.6 
G7 5.196 4.367 129.3 -7.7 0.062 2.952 14.1 
 
GUEST INCLUSION 
The guest is partially included in the primary end of the cyclodextrin cavity. The primary methoxy 
groups extend the volume of the cavity allowing for the inclusion of DCB. Lichtenthaler et al. 12,13 
have shown that the primary end of methylated cyclodextrins is relatively hydrophilic compared 
to the secondary end of the cavity. This could account for the inclusion of the relatively polar ester 
moiety rather than the non-polar aromatic portion of the molecule at the primary side. The 
aromatic ring and chloro-substituents extend beyond the cyclodextrin cavity. The C1 atom of the 
aromatic ring is located 2.33(1) Å above the least-square plane through the seven O6 atoms of the 
cyclodextrin. The portion of the guest outside of the cavity is nestled in interstitial spaces between 
adjacent DIMEB molecules. 
There are very few conformational differences between the DIMEB-included DCB and 
uncomplexed DCB (refcode: ROFSAH)4,14 molecules. The O1-C7-C1-C6 and the O2-C7-C1-C2 
torsion angles are -37.3(4)° and -40.6(4)° respectively in the uncomplexed structure (numbering 
in Figure 3.10) while they are -40.0(6)° and -43.1(5)° in the DIMEB inclusion complex. As can be 
seen from this comparison the conformational differences between these solid state structures of 
DCB are minimal. 
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HYDROGEN BONDING INTERACTIONS 
There are seven well-known intramolecular hydrogen bonding interactions involved in linking 
adjacent glucopyranose subunits in the DIMEB molecule. These interactions are the 
O3(n+1)-H···O2n bonds listed below in Table 3.6 
Table 3.6: O3(n+1)–H···O2n Hydrogen bonding parameters 
D–H···A D···A (Å) Angle (°) 
O3G1–H···O2G7 2.785(3) 179 
O3G2–H···O2G1 2.986(4) 171 
O3G3–H···O2G2 2.836(4) 176 
O3G4–H···O2G3 2.864(4) 157 
O3G5–H···O2G4 2.893(3) 168 
O3G6–H···O2G5 2.806(3) 176 
O3G7–H···O2G6 2.966(3) 175 
The intramolecular interactions listed above are essential in stabilising the circular nature of the 
cyclodextrin. There are also several systematic weak C-H···O interactions that are involved with 
maintaining the same circular structure. The primary rim of the cavity maintains its shape 
through three C-H···O interactions between C6Gn donors and O5G(n-1) acceptors listed in 
Table 3.7 below. 
Table 3.7: C-H···O interactions stabilising the primary rim of DIMEB 
D–H···A D···A (Å) Angle (°) 
C6G2-H···O5G1 3.213(4) 129 
C6G5-H···O5G4 3.285(4) 130 
C6G7-H···O5G6 3.204(4) 121 
Only one hydrogen bond is formed between the host and guest molecules. The Cl1 atom acts as a 
hydrogen bond acceptor15 to the C6G6-H weak hydrogen bond donor. Other than this weak 
hydrogen bond the inclusion of the guest relies on hydrophobic interactions and van der Waals 
forces. 
  




The complexes stack in columns arising from a 21-axis parallel to the a-axis. The O4 least-squares 
planes of successive DIMEB molecules in each column are inclined at 52.1 °. A combination of 
these factors gives rise to cage type complex columns. The G2 primary methoxy group of each CD 
molecule is included in the secondary side of the cavity of the 21-related molecule, as can be seen 
in Figure 3.11. There is no interaction between the ‘self-included’ primary methoxy group and the 
DCB guest molecule of the adjacent complex. The ‘self-inclusion’ of the cyclodextrin closes off the 
secondary end of the cavity preventing access for guest inclusion from this direction. This 
arrangement results in a close packed column of host and guest molecules. In this packing 
arrangement the guest is only partially included via the primary end of the cyclodextrin cavity. 
This results in the aromatic portion of the molecule being encapsulated in the interstitial spaces 
as shown in Figure 3.12. The anti-parallel arrangement of columns arising from the twofold screw 
axes parallel to the b- and c-axes can be seen in Figure 3.13. The columns interact via weak van 
der Waals forces.  
 
Figure 3.11: Cut-away figure showing the self-inclusion of DIMEB molecules in DMBDCB. The guest 
molecules have been omitted for clarity. 




Figure 3.12: Stereo diagram illustrating the arrangement of the aromatic moiety of DCB in the 
interstitial spaces between DIMEB molecules 
 
Figure 3.13: Packing of host molecules in DMBDCB viewed along [0 1 0] highlighting the 
anti-parallel column arrangement. The guest molecules have been omitted for clarity 
   




The calculated PXRD pattern (based on the refined X-ray crystal structure of the complex) shows 
good agreement with the experimental pattern of the bulk samples of DMBDCB. The slight 
differences in the 2θ positions of the peaks result from the low temperature collection of the 
single crystal intensity data, while the powder diffraction data were collected at room 
temperature. Upon cooling there is an angular shift in the peak positions most likely due to 
anisotropic contraction and/or expansion of the unit cell. 
 
Figure 3.14: The PXRD trace recorded for bulk sample (blue) and the computed PXRD pattern 
based on the single crystal X-ray structure of DMBDCB (orange) 
As described in the section pertaining to structure solution and refinement, the complex chosen 
for isomorphous replacement was DIMEB2,4-dichlorophenoxyacetic acid (refcode: PABNEM).4,7 
The differences between the unit cell parameters of this complex and those of the complex 
DMBDCB are small (Δa = 0.3861 Å, Δb = 0.4916 Å and Δc = 0.2399 Å) as described above. As can 
be seen in Figure 3.15, the DIMEB backbones of the two complexes have very similar atomic co-
ordinates. The packing arrangements of the two complexes are very similar, as shown in 
Figure 3.16. 




Figure 3.15: Overlay of PABNEM (green) and DMBDCB (blue) host molecules 
 
Figure 3.16: Overlay of packed PABNEM (green) host and DMBDCB (blue) host molecules viewed 
along the [1 0 0] direction   
Chapter 3 – 2,5-Dichlorobenzoic acid methyl ester 
 
 61 
PHASE SOLUBILITY ANALYSIS 
Phase solubility analysis is a technique used for determining the effect of a host molecule on the 
solubility of a guest. The method employed is described below. 
SAMPLE PREPARATION 
The cyclodextrin phase solubility of DCB was investigated with five cyclodextrins, namely α-CD, 
β-CD, γ-CD, hydroxypropyl β-cyclodextrin (HPBCD) and randomly methylated β-cyclodextrin 
(RAMEB). 
To perform these experiments aqueous stock solutions of the five cyclodextrins were prepared. 
These were then diluted to the desired concentrations using Milli-Q water and transferred to 
polytop vials. All solutions used in the experiments had a volume of 5 cm3. An excess of DCB was 
added to each vial and these mixtures were stirred for 72 hours at 750 rpm at a constant 
temperature of 30 ± 0.5 ℃. Once the mixtures were equilibrated they were filtered through a 
0.45 μm nylon filter. The intrinsic solubility (S0) of DCB was determined in a similar manner; a 
saturated aqueous solution of DCB was prepared, stirred and filtered under the same conditions 
as the cyclodextrin solutions. The absorbances of the filtered solutions were read using UV-Vis 
spectroscopy. These solutions were diluted as needed to obtain an absorbance between 0.1 and 
1. The concentration of DCB calculated using the molar absorptivity value was obtained from the 
Beer-Lambert plot.   
UV-VISIBLE SPECTROPHOTOMETRY 
Figure 3.17 shows the calibration curve used to calculate the molar absorptivity of DCB from the 
Beer-Lambert law (Expression 3.1). 
Expression 3.1 
𝐴 = 𝑐𝑙 
The path length, l, was 1 cm; therefore, the expression shows that if the calibration plot is linear 
the molar absorptivity, ϵ, is equal to the slope of the plot of A versus the concentration c. From the 
slope the molar absorptivity was determined to be 1150.1 M-1 cm-1. 




Figure 3.17: Beer-Lambert calibration curve for DCB in water at 30 ℃ for λmax = 290.56 nm 
PHASE SOLUBILITY 
The phase solubility results are presented as a function of the apparent solubility of DCB with 
increasing cyclodextrin concentration. The profiles are classified as either A- or B-type by Higuchi 
and Connors.16–18 A-type profiles show linear increases in guest solubility with increasing 
cyclodextrin concentration. There are three sub-categories of A-type profiles, namely AL, AP and 
AN. AL-type curves are characterised by linear increases in apparent guest concentration with 
increasing host concentration while AP- and AN-type show deviations from linearity at higher 
cyclodextrin concentrations. AP-type plots show positive deviation while AN-type plots deviate 
negatively. Both of these deviations are due to changes in the physical nature of the solution. 
B-type behaviour is the result of the formation of partially soluble complexes. There are two 
subtypes, BS- and BL-type, where BS-type behaviour is due to the formation of a moderately 
soluble complex where the total apparent concentration of the guest increases up to a point 
where the complex precipitates out of solution. In the case of the BL-type profiles the complex 
formed is highly insoluble and immediately precipitates, and therefore these profiles do not give 
rise to an initial increase in apparent guest concentration as in the BS-type profile.16–18 
The results of the phase solubility experiments with α-CD and γ-CD are excluded from the report 
due to their unreliability. They were erratic due to the precipitation of the complexes within 24 
hours. Experiments involving the host compound RAMEB gave equally erratic results which are 
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therefore not presented here. The results obtained when β-CD and HPBCD were employed are 
presented below as the absorbance readings were all reliable and above 0.01 units. 
β-CYCLODEXTRIN 
Shown below in Figure 3.18 is a representative phase solubility plot showing the solubility 
variation for DCB with increasing concentration of β-CD. It is clear from the profile that the system 
follows B-type behaviour, namely BS. This is indicated by the initial linear increase in apparent 
solubility of DCB, followed by a plateau and a decrease in concentration. This is most likely due 
to the β-CD/DCB complex having low solubility and precipitating at higher concentrations of 
β-CD.17 
 
Figure 3.18: Representative phase solubility plot for β-CD with DCB 
As the profile is of the type BS it is possible to calculate the binding constant from Expression 3.2 






The binding constant was calculated for each repeat of the experiment and the average binding 
constant was found to be 737 ± 108 M-1. This is a relatively low value indicating that the complex 
is not very stable in solution. For the guest DCB, the greatest solubility enhancement was found 
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at a β-CD concentration of 12.0 mM where the apparent solubility of DCB was increased by a 
factor of 6.4. 
HPBCD 
The phase solubility profile of DCB with HPBCD (Figure 3.19) indicates that the system follows a 
BS profile. This is unexpected for HPBCD as this cyclodextrin usually shows A-type solubility 
behaviour with guest molecules. As in the case with β-CD, this would imply that an insoluble 
complex is formed with DCB and precipitates at higher cyclodextrin concentrations. 
 
Figure 3.19: Representative phase solubility plot for HPBCD with DCB 
The binding constant was calculated in a similar manner to that obtained using β-CD as host as 
both systems are of type BS. The average binding constant was found to be very small at 
412 ± 53 M-1. HPBCD usually forms complexes with larger binding constants of several 
thousand M-1. The solubility enhancement was also lower than expected for HPBCD. The increase 
in apparent solubility was 10.6-fold to 5.65⨯10-3 M using HPBCD at a concentration of 30.1 mM. 
  




STOICHIOMETRY AND THERMAL ANALYSIS 
The stoichiometry of the GCDDCB and DMBDCB complexes presented in this chapter were 
determined via 1H-NMR spectroscopy and TGA respectively. The DMBDCB complex was found to 
have a 1:1 host-guest ratio, while for the GCDDCB complex the ratio is 3:4. 
Of the two complexes only GCDDCB contains water in the crystal structure. This is evident from 
the TGA trace, showing an initial mass loss of 13.0 ± 0.1 % (n = 2) from room temperature to 
100 ℃; this corresponds to 9.8 ± 0.1 water molecules per cyclodextrin subunit. This is 
corroborated by the DSC trace showing a broad endotherm indicative of solvent loss. The 
changing slope of the mass loss indicates that the process is occurring in multiple steps. DMBDCB 
does not have any waters of crystallisation as evidenced by no mass loss in the TGA trace until 
142.0 ± 1.3 ℃. The DSC trace and the HSM images are consistent with the data obtained from the 
TGA experiment.  
The enhancement of the thermal stability of DCB due to inclusion is significant. Pure DCB melts 
at 39.9 ℃ and begins to decompose at 49.9 ℃. The DMBDCB complex only shows a mass loss due 
to the guest release beginning at 142.0 ± 1.3 ℃ and the resulting material (DIMEB) only begins to 
decompose at 357.1 ± 1.3 ℃. The GCDDCB complex shows a mass loss attributed to loss of DCB 
beginning at 168.0 ± 0.9 ℃, which continues until decomposition of the residual cyclodextrin 
beginning at 281.9 ± 1.4 ℃. These results show that cyclodextrin complexation of DCB greatly 
improves its thermal stability.  
CONFORMATIONS OF HOST AND GUEST MOLECULES 
At the time of writing there are 10 isostructural γ-cyclodextrin inclusion complexes crystallising 
in the tetragonal space group P4212 in the CSD.4 The complexes have the unusual Z’ value of ¾ 
owing to the presence of six symmetry-independent glucose residues. In principle, only included 
guest molecules having internal four-fold rotational symmetry can generally be unambiguously 
located using X-ray diffraction. The mean unit cell parameters of the 10 isostructural complexes 
used when confirming the presence of an inclusion complex between γ-CD and DCB are as 
follows: a = b = 23.7 ± 0.1 Å, c = 23.1 ± 0.3 Å, α = β = γ = 90°. The host molecules in these 
complexes maintain a round shape stabilised by the well-known O3(n+1)–H···O2n hydrogen 
bonding network. The weaker C6n-H···O5(n+1) interactions are also systematically present in 
these structures further stabilising the round shape of the γ-cyclodextrin molecule.19 
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The geometric parameters, specifically l, D and ϕ, of the DMBDCB complex indicate that the 
DIMEB molecule maintains a ‘round’ shape by virtue of the intramolecular O3(n+1)–H···O2n 
hydrogen bonds. The variation in the parameters are minimal showing that the molecule 
maintains its regular heptagonal arrangement. The tilt angles, τ2, indicate that all of the 
monomeric subunits tilt inwards at the primary side showing that the truncated toroidal shape is 
maintained during inclusion of the DCB molecule. 
The DCB molecule shows very little conformational difference between the uncomplexed solid 
form and the complexed form. The torsion angles O1-C7-C1-C6 and O2-C7-C1-C2 are very similar 
with differences of approximately 3° between the two structures. The chlorine atom, Cl1, is 
located in such a way as to minimise the steric interactions between the host and guest. 
CRYSTAL PACKING 
The γ-cyclodextrin inclusion complex with DCB packs in one of the less common space groups, 
P4212. Of the 800,309 crystal structures in the CSD4 (at the time of writing) only 58 crystallise in 
P4212, and of those, 10 are γ-cyclodextrin inclusion complexes. The three independent 
cyclodextrin molecules are centred on the crystallographic four-fold rotation axis. The 
γ-cyclodextrins stack in columns parallel to the c-axis. Channels arise from the stacked 
cyclodextrin cavities and the interstitial spaces with diameters of approximately 8 Å and 7 Å 
respectively. These large spaces allow for the free movement of solvent molecules within the 
crystal structure. This may be the reason the TGA trace indicates a multi-step solvent loss process. 
The repeating A-B-C unit is shown in Figure 3.20 and comprises three cyclodextrin molecules. 
The columns are built from translations of these units. The interactions are head-to-tail, head-to-
head and tail-to-tail for the A-C, B-C and A-B units respectively. This arrangement is maintained 
via a hydrogen bonding network where the secondary hydroxyls of A and B hydrogen bond with 
each other. The primary hydroxyls of B and C interact while the primary hydroxyls of A hydrogen 
bond to the secondary hydroxyls of C.19,20 




Figure 3.20: Host molecules of the γ-CD/methanol (refcode: NUNRIX)4,19 inclusion complex 
repeating unit which form infinite columns. Hydrogen atoms have been omitted for clarity 
DMBDCB packs in cage type columns arising from the twofold screw axis parallel with the a-axis. 
The O4 mean planes of sequential DIMEB molecules form an angle of 52.1°. The G2 primary 
methoxy substituent is included in the adjacent DIMEB molecule causing the cavity to be closed 
from the secondary side. The columns are crystallographically related by the 21-axes parallel to 
the b and c cell axes, resulting in close packed columns. The columns interact via van der Waals 
interactions. Due to the closed off nature of the cavity the DCB molecule is located with the 
majority of the molecule in the interstitial spaces. The ester moiety is included in the extended 
primary end of the DIMEB molecule, while the aromatic portion of DCB protrudes into the 
interstitial spaces. 
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A total of 22 DIMEB inclusion complexes were found in the CSD crystallising in seven space 
groups. Of these structures 11 are isostructural with the DMBDCB complex and of these, six of 
these include the guest molecule via the primary end of the host. A further eight complexes 
crystallise in the same space group (P212121); however, these are not isostructural with the 
DMBDCB inclusion complex. 
PHASE SOLUBILITY 
Phase solubility experiments with DCB were performed with α-CD, β-CD, γ-CD, HPBCD and 
RAMEB. It was found that the α-CD and γ-CD complexes were very insoluble in water as they 
precipitated at low cyclodextrin concentrations in a short period of time. RAMEB enhanced the 
solubility of DCB, but the results were erratic and unreliable. This may be due to aggregation of 
the complexes in solution, or other complications inherent to the system. 
β-CD and HPBCD phase solubility data with DCB exhibited BS profiles. This profile is characterised 
by an initial linear increase in apparent guest concentration followed by a plateau and finally a 
decrease in apparent solubility. This arises due to the formation of a partially soluble complex 
that increases the apparent concentration of the guest. The maximum concentration of the 
complex is reached with addition of further cyclodextrin and the complex precipitates. While any 
uncomplexed guest remains, the system is in equilibrium; however, once the guest is consumed 
the addition of any further cyclodextrin causes precipitation, decreasing the apparent 
concentration of the guest.17 
The BS-type behaviour exhibited by DCB with β-CD and HPBCD detailed above allowed for the 
binding constant calculations indicating values of 737 ± 108 M-1 and 412 ± 53 M-1 respectively. 
These binding constants are lower than expected signifying that the complexes are not 
particularly stable in solution. The enhancement in solubility was similarly lower than expected 
with enhancement factors of 6.4 and 10.6 at 12.0 mM and 30.1 mM for β-CD and HPBCD 
respectively. 
  




The data presented here show that DCB can form an inclusion complex with both native and 
derivatised cyclodextrins, imparting beneficial physicochemical changes to the compound. In the 
solid state the thermal stability of DCB was markedly improved by inclusion in γ-cyclodextrin and 
DIMEB.  
In solution the solubility of DCB was increased using both β-cyclodextrin and HPβCD by factors 
of 6.4 and 10.6 respectively. However, these cyclodextrins both exhibit BS-type behaviour with 
DCB indicating that the solubility enhancement is only valid until the solution is saturated with 
the partially soluble complexes. 
The inability to assess the solubility enhancement with γ-CD was due to complex precipitation 
(as reported above). With DIMEB as the host, on the other hand, paucity of this material due to its 
high cost precluded phase solubility analysis, which was the reason for choosing RAMEB as an 
alternative. 
Due to the high cost of many chemically modified cyclodextrins this study has been limited to a 
few selected host compounds. Future exploration of the vast library of such commercially 
available hosts may yield alternative stable, water soluble solid complexes with DCB.  
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CHAPTER 4 –  FENTHION 
Fenthion is an organothiophosphate insecticide, avicide and acaricide. The mode of action is 
cholinesterase inhibition. Fenthion has a low aqueous solubility of 54-56 mg dm-3.1 Owing to the 
low melting point of 7 ℃1 fenthion is an oil at room temperature and no crystal structure has been 
reported thus far. 
This chapter pertains to the inclusion of fenthion in cyclodextrin host molecules. There are two 
parts to this chapter. Part one focuses on complexation in solution studies performed at the 
Universidad Nacional de Córdoba as part of a bilateral exchange program. The second part 
pertains to three solid-state inclusion complexes. 
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PART 1 – COMPLEXATION IN SOLUTION 
The interactions between cyclodextrins and guest molecules can differ in solution and the solid-
state. It is therefore highly beneficial to investigate the interactions in both states. The main 
method of investigation applied to fenthion cyclodextrin inclusion in solution is that of induced 
circular dichroism. The cyclodextrins investigated in this study are α-cyclodextrin (α-CD), 
β-cyclodextrin (β-CD), γ-cyclodextrin (γ-CD), hexakis (2,3,6-tri-O-methyl)-α-cyclodextrin 
(TRIMEA), heptakis (2,6-di-O-methyl)-β-cyclodextrin (DIMEB) and heptakis 
(2,3,6-tri-O-methyl)-β-cyclodextrin (TRIMEB). 
INDUCED CIRCULAR DICHROISM 
Induced circular dichroism (ICD) was used to investigate the inclusion of fenthion in solution. The 
application of this technique relies on the ability of fenthion to absorb ultraviolet (UV) 
electromagnetic radiation, while cyclodextrin molecules do not absorb in the UV region of the 
electromagnetic spectrum. Furthermore, fenthion is achiral, so will not rotate plane polarised 
light. Cyclodextrin molecules, being chiral, will rotate plane polarised light. If a chromophore is 
included in the cyclodextrin cavity it will induce chirality on the system, rotating plane polarised 
light in the UV region of the electromagnetic spectrum. 
Observations of the change in signal will indicate whether a complex is formed in solution and 
can provide information pertaining to the relative orientation of the two molecules. 
SAMPLE PREPARATION 
Owing to the low aqueous solubility of fenthion a co-solvent was required. The solvent 
1,4-dioxane was selected for this purpose and 2% solutions with water were found to be sufficient 
for the requirements of the study. 
A stock solution of fenthion was made in 1,4-dioxane. This was mixed with cyclodextrin stock 
solutions. These mixtures were diluted with Milli-Q water to obtain samples of varying 
cyclodextrin concentration, but constant fenthion concentration (2.278⨯10-5 mol dm-3) and 2% 
1,4-dioxane. 
β-CYCLODEXTRIN 
The low solubility of fenthion required the use of a 4 cm cuvette to obtain absorbance readings of 
an appropriate intensity. 
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From signal changes (Table 4.1) in the ICD spectra (Figure 4.1) it is clear that there is an 
interaction between the chromophore of fenthion and β-CD. The solid-state information 
(presented below) would indicate that the chromophoric moiety is embedded within the β-CD 
cavity as the whole molecule is encapsulated by two β-CD molecules. If the same mode of 
inclusion occurs in solution it would be reasonable to infer that the effect observed in the ICD 
spectra is a negative Cotton effect. This would indicate that the transition dipole of fenthion 
aligned perpendicularly to the axis of symmetry of the cyclodextrin cavity. 
There is a strong correlation between the maxima in the UV-Vis spectra and the ICD signal. There 
are some further correlations in the region around 280 nm where we see a signal above the 
background noise in the ICD spectra and a shoulder in the UV-Vis spectra. The correlation 
between the two plots suggests that the chromophoric moiety of fenthion is in a chiral 
environment giving rise to the ICD signal. Previous work has shown that the use of cyclodextrins 
as host molecules can cause a slight displacement in the maxima of ICD spectra.2 
Table 4.1: Induced circular dichroism signals for β-CD with fenthion in solution 



































Figure 4.1: ICD (top) and UV-Vis spectra (bottom) of β-CD with fenthion in 2 % 1,4-dioxane 
solutions 
The signal measured in the ICD spectrum is ellipticity. This is a measure of the degree to which 
linearly polarised light becomes elliptically polarised when passed through a circular dichroic 
sample. While observable changes, with β-CD concentration, are present in the absorbance and 
ellipticity signal they are erratic and follow no known profile. The changes indicate that there is 
an interaction between β-CD and fenthion in solution. As the profile for the changes in the 
observed signals could not be found it was not possible to calculate the binding constants for this 
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interaction. It is possible that there is more than one type of interaction between β-CD and 
fenthion occurring in solution, making calculations problematic. Without a well-defined mode of 
inclusion it is not possible to calculate the binding constants. 
OTHER CYCLODEXTRINS 
Further ICD experiments were performed with several cyclodextrins in order to observe the 
relative strengths of the respective interactions with the fenthion molecule. The cyclodextrins 
α-CD, β-CD, γ-CD, TRIMEB, DIMEB and TRIMEA were tested with fenthion. Experiments with the 
native cyclodextrins were performed at cyclodextrin concentrations of 10 mM. However, due to 
the limited supply of the derivatised cyclodextrins the experiments were carried out using 
concentrations of 5, 2.5 and 1 mM for TRIMEB, DIMEB and TRIMEA respectively. 
The changes in the ICD signals are presented in Table 4.2. These changes are clearly visible in the 
ICD spectra in Figure 4.2, where a signal change can be seen when fenthion is combined with each 
of the cyclodextrins. From the similarities in the profile one can infer that the mode of interaction 
between fenthion and each of the cyclodextrins is similar. The solid-state data for these 
complexes, presented in forthcoming sections, show the inclusion of the chromophores in the 
cyclodextrin cavities. If the mode of inclusion is similar in solution then the observed changes in 
the ICD spectra are indicative of a negative Cotton effect. The negative Cotton effect observed in 
all the spectra indicates that the orientation of the transition dipole of fenthion is perpendicular 
to the axis of symmetry of the cyclodextrins. 
Table 4.2: Induced circular dichroism signals for various cyclodextrins with fenthion in solution  
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During the experiments the concentration of fenthion was kept constant. The changes in signal 
strength with changing cyclodextrin point to variations in the strength of interaction with each 
cyclodextrin. Normalising for concentration, the strengths of the interactions between fenthion 
and the various host molecules are in the order 
DIMEB > TRIMEA > TRIMEB > β-CD > γ-CD > α-CD. 
 
Figure 4.2: ICD (top) and UV-Vis spectra of various cyclodextrins with fenthion in 2 % 1, 4-dioxane 
solutions 
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The binding strength trend outlined above has also been observed with the fenthion analogue 
fenitrothion.2–4 The profiles observed for α-CD, β-CD, γ-CD and DIMEB with fenitrothion and 
fenthion are similar, while those for TRIMEA and TRIMEB are inverted. In the solid-state the 
complexes TRIMEB/fenthion and TRIMEB/fenitrothion are isostructural.5 However, the 
solid-state structures of TRIMEA/fenthion and TRIMEA/fenitrothion differ significantly. The 
TRIMEA/fenitrothion complex has a 2:1 host-guest stoichiometry6 while the TRIMEA/fenthion 
complex has a 1:1 stoichiometric ratio (detailed below). The ICD spectra indicate that the 
complexes TRIMEA/fenthion and TRIMEA/fenitrothion differ in solution as well as in the solid-
state. The TRIMEB/fenthion and TRIMEB/fenitrothion complexes, while similar in the solid-state, 
must have differing modes of inclusion in solution. The profiles of the signals further imply that 
that the modes of interaction of these guest molecules with α-CD, β-CD, γ-CD and DIMEB are 
similar for both fenthion and fenitrothion.   
While it is possible to use ICD and UV-Vis spectroscopy to investigate association constants, to do 
so requires a well determined mode of inclusion. In the case of the β-CD complex the data did not 
fit any of the established models generally used in these calculations. For the remaining 
complexes the association constants were not investigated due to the limited supplies of the 
derivatised cyclodextrins. Therefore, ICD and UV-Vis spectroscopy were used as qualitative 
techniques to describe the presence of complexes in solution. 
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PART 2 – COMPLEXATION IN THE SOLID-STATE 
Fenthion was included in three cyclodextrin host molecules in the solid-state. The cyclodextrins 
successfully forming inclusion complexes with fenthion were β-CD, TRIMEA and TRIMEB. The 
results of the experiments performed on the complexes obtained are presented in this section of 
the chapter. 
  




The investigation of the inclusion complex of β-CD with fenthion was problematic. The production 
of the inclusion complex did not give rise to a crystal suitable for a high quality single crystal data 
collection. Therefore, the results presented pertaining to the structure of the inclusion complex 
provide only an overview of the structural features. An in depth analysis of the structural details 
and interactions would not be reliable due to the poor quality of the refined single crystal model. 
The inclusion complex of fenthion in β-cyclodextrin will be referred to as BCDFEN. 
COMPLEX PREPARATION 
The BCDFEN complex was prepared via co-precipitation. One drop of the fenthion oil (23 mg, 
0.0823 mmol) was added to an aqueous solution (4 cm3) containing an equimolar quantity of 
β-cyclodextrin (93 mg, 0.0823 mmol). The mixture was stirred at an elevated temperature of 
approximately 50 ℃ for 6 hours and then filtered through a 0.45 μm nylon filter into a clean vial. 
The filtered product was allowed to cool slowly in a Dewar™ flask over several days and large, 
block-like crystals were observed. 
CONFIRMATION OF STOICHIOMETRY 
The stoichiometry of the complex was confirmed via NMR spectroscopy. Crystals from the 
co-precipitation preparation were dissolved in DMSO-d6 for analysis by 1H-NMR spectroscopy. 
The labelling schemes of the β-CD glucopyranose subunit and fenthion are presented in 
Figure 4.3. Integration of the C-H1 proton signal of β-CD was used as the reference integral. The 
C-H1a,b,c and C-H9a,b,c methyl protons of fenthion were integrated and together these showed a 
β-CD to fenthion ratio of 2:1. The integration values and NMR spectrum are presented in Table 4.3 
and Figure 4.4 respectively. 
 
Figure 4.3: Proton labelling of β-CD glucopyranose subunits (left) and fenthion (right) 
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Table 4.3: Integrals and assignment of host and guest protons used for stoichiometric confirmation 
Proton δ (ppm) 
Integration Experimental/ 
Theoretical Experimental Theoretical 
β-cyclodextrin 
C-H1 4.87 14‡ 14 1 
O-H6 4.46 13.11 14 0.94 ≈ 1 
Fenthion 
C-H1a,b,c 2.30 3.05 3 1.02 ≈ 1 
C-H9a,b,c 2.49 3.04 3 1.01 ≈ 1 
C-H15a,b,c + 
C-H16a,b,c 
3.87, 3.82 5.62 6 0.94 ≈ 1 
C-H5 + C-H6 7.06 2.04 2 1.02 ≈ 1 
‡Reference Integral 
 
Figure 4.4: NMR spectrum of BCDFEN crystals in DMSO-d6 to determine the stoichiometric ratio 
  




Thermal analysis comprising DSC, TGA and HSM were performed on single crystals of BCDFEN 
with a 2:1 stoichiometry. The TGA and DSC traces are shown in Figure 4.5. It was found that the 
complex had a water loss of 14.1 ± 0.7 % (n = 2) equating to approximately 24 water molecules 
per inclusion complex unit. 
The TGA trace shows an immediate mass loss from room temperature to 90.0 ± 7.1 ℃ due to the 
expulsion of water from the complex. This is corroborated by both the DSC trace and the HSM 
images (Figure 4.6) where a broad solvent loss endotherm is seen and bubbles begin to appear 
respectively. A large mass loss representing decomposition of the complex begins at 
203.2 ± 4.5 ℃. The DSC trace shows an endotherm characteristic of decomposition in the same 
region. The HSM images at 280 ℃ show a clearly degraded crystal. 
 
Figure 4.5: Representative TGA (blue) and DSC (orange) traces for BCDFEN 
 
Figure 4.6: Hot stage micrographs showing the BCDFEN complex at various stages of heating  
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CRYSTAL STRUCTURE ANALYSIS 
DATA COLLECTION AND SPACE GROUP DETERMINATION 
The single crystal intensity data were collected on a Bruker Apex Duo II diffractometer. The X-ray 
diffraction pattern was determined to have1 Laue symmetry, indicating a triclinic space group. 
As β-cyclodextrin is chiral the only choice was the space group P1. The data collection was 
performed at 100 ± 2 K. 
STRUCTURE SOLUTION AND REFINEMENT 
The program SAINT7 was used in data reduction and unit cell refinement. The asymmetric unit 
comprises two β-CD molecules, one fenthion molecule and 21.7 waters of crystallisation. The 
positions of the host atoms were determined by isomorphous replacement.8 The atomic 
coordinates of the rigid backbone structure of an isostructural complex were used as a trial 
model. After a CSD9 search for suitable candidates, the β-CD inclusion complex of 
N-acetyl-L-phenylalanine (refcode: AGAZOX)9,10 was selected from the 33 isostructural 
complexes. The backbones of the β-CD molecules of the two structures have similar atomic 
co-ordinates. The differences in the magnitudes of the unit cell dimensions are Δa: 0.038 Å; Δb: 
0.056 Å; Δc: 0.041 Å; Δα: 0.38°; Δβ: 0.36° and Δγ: 0.04°. 
The rigid backbone used for isomorphous replacement consisted of the non-hydrogen atoms of 
the glucose rings. The primary -OH groups were excluded in the rigid backbone trial model due 
to their conformational flexibility. Subsequent electron density difference maps were used to 
locate the remaining non-hydrogen atomic co-ordinates. The glucopyranose subunits were 
labelled A1 through A7 and B1 through B7 for the respective β-CD molecules. Once the hydrogen 
atoms were located in the difference Fourier map they were assigned using a riding model with 
a Uiso value 1.2 to 1.5 times that of the parent atom. 
A total of 21.7 water molecules of crystallization per complex unit were located in the crystal 
structure, in good agreement with the TGA data (24 water molecules). Sixteen of these water 
molecules were located with full occupancy. Twelve of the oxygen atoms were refined 
anisotropically, while the remaining showed unrealistic thermal ellipsoids, and were therefore 
refined isotropically. To determine the s.o.f.s of the partially occupied water molecules the Uiso 
values for the fully occupied counterparts were averaged. The Uiso values of the partially occupied 
waters were then fixed to this value and the s.o.f.s allowed to vary freely. Once the occupancies 
converged, these values were fixed and the Uiso values allowed to vary freely. Combined, the 
partially occupied waters summed to 5.7 water molecules.  
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Table: 4.4: Crystallographic data for the single crystal X-ray structure of BCDFEN 
Chemical formula 2(C42H70O35)·(C10H15O3PS2)·21.7(H2O) 
Molar Mass (g mol-1) 2912.22 
Crystal system Triclinic 
Space group P1 
Unit cell parameters  
a (Å) 17.852(8) 
b (Å) 15.334(7) 
c (Å) 15.431(7) 
α (°) 103.134(8) 
β (°) 113.029(8) 
γ (°) 99.227(8) 
Volume (Å3) 3636(3) 
Z 1 
Densitycalcd (g cm-3) 1.322 
μ [MoKα] (mm-1) 0.156 
F (000) 1 524 
Temperature (K) 100(2) 
Crystal size (mm) 0.15⨯0.13⨯0.05 
Range scanned θ (°) 2.0 – 24.9 
Index ranges h: -21, 21; k: -18, 18; l: -18, 18 
ϕ and ω scan angle (°) 0.5 
Dx (mm) 50 
Total number of reflections 56 328 
Number of independent reflections 24 176   
Number of reflections with I > 2σ(I) 12 453 
Rint 0.0656 
R1 [I > 2σ(I)] 0.1208 
wR2 0.3384 
S 1.22 
Number of parameters 1 538 
Number of reflections omitted 76 
Parameters a, b in 
w = 1/[σ2(FO2)+(aP)2+(bP)] 
a = 0.2000; b = 0 
(δ/σ)mean 0.039 
Δρ excursions (e Å-3) -1.418; 2.187 
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MODELLING OF THE FENTHION 
Initially one guest molecule was modelled; however, large residual electron density peaks 
surrounding the fenthion molecule indicated the presence of a second image of the molecule. Two 
guest molecules could not be present simultaneously due to their close proximity, thus indicating 
disorder. During modelling it was found that the disordered components of the fenthion molecule 
shared several atoms, namely P11, O13 and C16 (Figure 4.7) of the phosphorothioate moiety. All 
other atoms were found to be disordered over two positions due to the presence of a rotamer. 
The angle S14A-P11-S14B arises from the rotamer and is 89.5°. The two guest components were 
assigned and refined with site-occupancy factors of x and 1-x. The final value of x was found to be 
0.530(14). Once the occupancy of the fenthion components converged it was decided that the Uiso 
values of each component be assigned as free variables. The relative orientation of the disordered 
components is shown in Figure 4.7. 
During refinement of the structure it was necessary to apply appropriate restraints to the 
phosphorothioate moiety bonds. The bond lengths of the guest molecule in the complex 
β-CD/fenitrothion4 were used to obtain reasonable DFIX restraints to apply to the bonds in 
fenthion. 
 
Figure 4.7: Disorder of the fenthion guest molecule with the major component in blue, the minor 
component in green and the common atoms in red. Hydrogen atoms have been omitted for clarity. 
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GEOMETRIC ANALYSIS OF THE BCDFEN STRUCTURE 
The asymmetric unit comprises a hydrated 2:1 host-guest inclusion complex. This is shown in 
Figure 4.8 (water molecules excluded). The numbering scheme of the host and guest molecules 
are presented in Figure 4.9. 
 
Figure 4.8: The asymmetric unit of the complex BCDFEN (water molecules excluded). Thermal 
ellipsoids for the host atoms are drawn at the 50% probability level and the guest atoms are 
drawn in space-filling mode 
 
Figure 4.9: Numbering scheme of the glucopyranose rings (left) and the guest molecule (right) 




The data presented below can be seen in detail in Appendix C. The range of values presented 
below provides an indication of the geometry of the cyclodextrin host molecules. 
The primary torsion angle, ω, is a measure of the O5-C5-C6-O6 dihedral angle. This angle indicates 
the orientation of the C6-O6 bond, and hence whether this bond is directed towards, or away 
from, the host cavity. All the primary C6-O6 substituents, other than that of A7, are directed away 
from the cyclodextrin cavities. The primary hydroxyl group directed towards the cavity has an ω 
angle of 59°. The substituents that are directed away from the cyclodextrin cavities have torsion 
angles that fall within the range -69° ≤ ω ≤ -54°. 
The geometric parameters l, D and ϕ all fall within a narrow range for each cyclodextrin. This 
indicates that both cyclodextrins maintain a ‘round’ shape. The ranges of these values are: 
4.894 Å ≤ l ≤ 5.218 Å, 4.287 Å ≤ D ≤ 4.478 Å and 125.7° ≤ ϕ ≤ 131.5° for the cyclodextrin labelled 
A and 4.997 Å ≤ l ≤ 5.079 Å, 4.342 Å ≤ D ≤ 4.405 Å and 126.9° ≤ ϕ ≤ 129.6° for the cyclodextrin 
labelled B. The circular shape of the cyclodextrins is maintained by the hydrogen bonds 
O3(n+1)-H···O2. 
The tilt angles τ2 are all positive indicating that the primary ends of the cyclodextrins are oriented 
inwards, i.e. towards the centre of the cavity. The angle formed between the O4 mean planes of 
the two β-CD host molecules is 1.0(3)°, which shows that they are almost parallel. 
GUEST INCLUSION AND CONFORMATION 
The fenthion molecule is disordered over two positions within the cyclodextrin cavity where the 
major component has a s.o.f of 0.530(14). The disordered components share three atoms, namely 
P11, O13 and C16, as seen in Figure 4.7. 
The two disordered components are positioned such that their phosphorothioate moiety is at the 
primary rim of the cyclodextrin cavity of the host designated A, as shown in Figure 4.10a. The 
methoxy groups of the phosphorothioate moiety protrude slightly from the primary rim of the 
cavity. The fenthion molecule extends only slightly into the secondary end of the cyclodextrin 
molecule B. A large void remains in the second cyclodextrin cavity (Figure 4.11); however, this 
void is not large enough to accommodate a second guest molecule. 




Figure 4.10: a. Relative positions of the disordered fenthion molecule in the β-CD dimer; b. cross-
sectional view of the complex; c. view from the primary rim of host molecule A and d. view from the 
primary rim of host molecule B 
 
Figure 4.11: Cross sectional view showing void space (blue) relative to the fenthion guest (green) 
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INTRA- AND INTERMOLECULAR INTERACTIONS 
HOST INTERACTIONS 
Various hydrogen bonds were identified in the complex host molecules. Both intra- and 
intermolecular interactions are observed. The intramolecular hydrogen bonds identified were 
the O3(n+1)-H···O2n interactions which stabilise the ‘round’ conformation of the host molecules. 
These hydrogen bonds have O···O donor to acceptor distances ranging from 2.72 Å to 2.86 Å. 
The two cyclodextrin molecules are linked by inter-host hydrogen bonds. Four hydrogen bonds 
are responsible for linking the dimeric host system. These occur between the O3n atoms on the 
respective cyclodextrins. 
Sixteen hydrogen bonds were identified between the β-CD dimers; ten of these are of the type 
O-H···O while the remaining six are weak C-H···O interactions. Of these, only one is between layers 
while the remaining hydrogen bonds link the β-CD dimers within a given layer.  
The parameters of the above hydrogen bonds are available in Appendix C. 
GUEST INTERACTIONS 
Only one identifiable interaction between the host and guest molecules is present in the structure. 
This interaction is between the minor component of the disordered guest and the host. The 
interaction is the C3B-H···O4A5 weak hydrogen bond with C···O distance of 3.47(5) Å and a 
hydrogen bond angle of 148°. The association of fenthion and β-CD is primarily due to van der 
Waals forces and hydrophobic interactions. 
Present in each fenthion component is one weak C-H···S intramolecular interaction between the 
C1-H and S8 atoms. The major component has a C1···S8 distance of 2.55(8) Å while the minor 
component has a distance of 2.75(8) Å. The hydrogen bonding angles (C1-H···S8) for the major 
and minor components are 122° and 113° respectively. 
CRYSTAL PACKING 
The complex BCDFEN comprises two β-cyclodextrin molecules in a head-to-head dimeric 
arrangement. Within the cavity formed there is a partially disordered fenthion molecule. The 
dimers stack to form channels parallel to the a-axis. The water molecules present in the BCDFEN 
structure can be found in the interstitial spaces between these channels. The channels and water 
molecules are visible in Figure 4.12 where one can see the inclusion of the guest within the 
cyclodextrin structures. 




Figure 4.12: Packing diagram of the BCDFEN complex viewed along [1 0 0] 
As is common amongst β-CD complexes that crystallise in the space group P1 the packing motif 
is classified as ‘intermediate-type packing’. The layers of the β-CD dimers are essentially parallel 
where the angle between subsequent O4n least-squares mean planes is 1.0°. In this arrangement 
the O4n centroids are offset by approximately 6 Å (RA = 6.042 Å and RB = 6.055 Å) between layers. 
The offset of these layers is clear from Figure 4.13. The ‘cage-like’ term used by Saenger11 is 
justified as this large offset causes the cyclodextrin cavities, and by extension the included guests, 
to be isolated from one another.  
 
Figure 4.13: Packing diagram of the β-CD host molecules of the BCDFEN complex viewed along 
a. [0 1 0] and b. [0 0 1] 
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The section on structure solution and refinement explained the choice of the complex 
β-CD/(N-acetyl-L-phenylalanine) (refcode: AGAZOX)9,10 for use in isomorphous replacement. 
Figure 4.14 shows the good match of the atomic co-ordinates of the host molecule backbones. 
 
Figure 4.14: Overlay of AGAZOX (green) and BCDFEN (blue) host molecules 
  




The inclusion complex of fenthion with TRIMEA will be referred to as TMAFEN. 
COMPLEX PREPARATION 
The complex was prepared via co-precipitation, during which TRIMEA (101.2 mg; 0.0826 mmol) 
was weighed into a vial and dissolved to make a 3 cm3 aqueous solution. A drop of fenthion 
(23 mg; 0.0826 mol) was added to the vial and the solution stirred at 4 ℃ for 3 to 4 hours. The 
mixture was then filtered through a 0.45 μm nylon filter into a clean vial and left to crystallise in 
a 60 ℃ oven. Small colourless block-like crystals appeared after 3 days. 
CONFIRMATION OF STOICHIOMETRY 
The complex stoichiometry was confirmed by NMR spectroscopy. Crystals obtained by 
co-precipitation were dissolved in DMSO-d6 for analysis by 1H-NMR spectroscopy. Labelling of the 
protons on the methylated glucopyranose subunits of TRIMEA and fenthion are shown in 
Figure 4.15. The integration of the C-H1 proton on TRIMEA was used as the reference integral. 
Integration of the C-H1a,b,c, C-H15a,b,c and C-H16a,b,c methyl protons were integrated for fenthion and 
showed a stoichiometric ratio of 1:1 for TMAFEN. The table of integration values and the NMR 
spectrum can be found in Table 4.5 and Figure 4.16 respectively. 
 
 
Figure 4.15: Proton labelling of TRIMEA methylated glucopyranose subunits (left) and fenthion 
(right) 
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Table 4.5: NMR spectroscopy proton assignment and integration of TMAFEN 
Proton δ (ppm) 
Integration Experimental/ 
Theoretical Experimental Theoretical 
TRIMEA 
C-H1 5.01 6.00‡ 6.00 1 
C-H9a,b,c 3.27 17.99 18 0.99 ≈ 1 
C-H7a,b,c 3.41 17.78 18 0.99 ≈ 1 
Fenthion 
C-H1a,b,c 2.29 2.90 3 0.97 ≈ 1 
C-H15a,b,c + 
C-H16a,b,c 
3.82, 3.87 5.76 6 0.96 ≈ 1 
‡Reference Integral 
 
Figure 4.16: NMR spectrum of TMAFEN in DMSO-d6 to determine the stoichiometric ratio 
  




The TGA trace of the TMAFEN complex (Figure 4.17) shows a mass loss of 0.5 ± 0.1 % (n = 2) from 
room temperature to 109.1 ± 5.9 ℃, interpreted as the loss of 0.4 ± 0.1  of a water molecule. There 
is no endotherm relating to the mass loss of the partially occupied water molecule due to the 
negligible thermal energy relating to this event. The DSC trace shows two endotherms coinciding 
with the second and third mass losses in the TGA trace. The second endotherm is consistent with 
melting followed by a mass loss in the TGA trace. The HSM images (Figure 4.18) corroborate the 
above interpretation. At 100 ℃ some bubbling, indicative of solvent loss, is observed. At 230 ℃ 
the crystals have clearly melted with some further bubbling. In the micrograph taken at 300 ℃, 
the decomposed cyclodextrin is clearly visible. 
 
Figure 4.17: Representative TGA (blue) and DSC (orange) traces for TMAFEN 
 
Figure 4.18: Hot stage micrographs showing the TMAFEN complex at various stages of heating  
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CRYSTAL STRUCTURE ANALYSIS 
DATA COLLECTION AND SPACE GROUP DETERMINATION 
The intensity data were collected using a Bruker Kappa Apex II DUO diffractometer. The Laue 
symmetry was determined to be 2/m indicating the monoclinic crystal system. The conditions 
limiting reflections were hkl: none, h0l: none, 0k0: k = 2n. These conditions indicate the space 
groups P21 or P21/m, but since the host molecule is chiral the correct space group P21 was chosen 
for the analysis. The asymmetric unit contains one fenthion molecule, one TRIMEA molecule and 
a partial water molecule. 
STRUCTURE SOLUTION AND REFINEMENT 
Table 4.6 shows the crystallographic data and data-collection parameters. The program SAINT7 
was used for unit cell refinement and data reduction. SADABS12 was used to correct absorption 
using the multi-scan method. A search of the CSD9 was undertaken, but no suitable structures 
were found for isomorphous replacement. The structure was then solved using SHELXD,13 
employing ab initio methods. Once a reasonable solution was found with SHELXD the host 
molecule atoms were assigned and the structure was refined using SHELXL.13 The glucopyranose 
subunits were labelled with the suffixes G1 – G6. 
Disordered methyl groups on TRIMEA were modelled by allowing the s.o.f.s to vary by assigning 
the major component variable x and the minor component 1-x and the atoms were refined 
isotropically. The C7 methyl group on residue G6 and the O6-C9 methoxy substituent on residue 
G5 were found to be disordered with the major components having s.o.f.s 0.58(1) and 0.51(1) 
respectively. All ordered atoms were treated anisotropically.  
The complete fenthion molecule was found to be disordered over two positions. The s.o.f.s were 
linked to free variables, as in the case of the methoxy groups above. The major component was 
refined to have a s.o.f. of 0.71(1). Once the hydrogen atoms were located in the difference Fourier 
map they were placed in idealised positions using a riding model. The temperature factors in the 
riding model were 1.2 to 1.5 times those of their parent atoms. 
From the residual electron density in the structure, a water molecule with partial occupancy was 
located at the primary rim of the cyclodextrin cavity. The occupancy of the water molecule was 
determined from the TGA trace and set as 0.4. With this occupancy the Uiso value was found to be 
0.17(1) Å2. The large relative error in the TGA mass loss makes exact estimation of the s.o.f. 
problematic. As no other evidence for the occupancy of the water molecule is available it is 
possible that the occupancy has been overestimated and therefore the Uiso value remains large.  
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Table 4.6: Crystallographic data and data-collection parameters for TMAFEN 
Chemical Formula C54H94O30·C10H15O3PS2·(H2O)0.4 
Crystal system Monoclinic 
Molar Mass (g mol-1) 1493.53 
Space group P21 
Unit cell parameters  
a (Å) 11.2135(6) 
b (Å) 22.9575(12) 
c (Å) 15.4666(9) 
α (°) 90.0 
β (°) 104.238(1) 
γ (°) 90.0 
Volume (Å3) 3860.4(4) 
Z 2 
Densitycalcd. (g cm-3) 1.285 
μ [MoKα] (mm-1) 0.173 
F (000) 1 592 
Temperature (K) 173(2) 
Crystal size (mm) 0.25⨯0.30⨯0.43 
Range scanned θ (°) 1.4 – 27.2 
Index ranges h: -14, 14; k: -29, 29; l: -19, 19 
ϕ and ω scan angle (°) 0.50 
Dx (mm) 40 
Total number of reflections 57 806 
Number of independent reflections 17 099 
Number of reflections with I > 2σ(I) 15 158 
Rint 0.022 
R1 [I > 2σ(I)] 0.0469 
wR2 0.1154 
S 1.024 
Number of parameters 900 
Number of reflections omitted 14 
Parameters a, b in 
w = 1/[σ2(FO2)+(aP)2+(bP)] 
a = 0.0582; b = 2.2093 
(δ/σ)mean <0.001 
Δρ excursions (e Å-3) -0.67; 0.72 
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MODELLING OF THE FENTHION GUEST MOLECULE 
Initially the guest was easily modelled after the early refinements of the host molecule. After 
preliminary assignment of the guest molecule several large electron density peaks remained 
around the phosphorothioate moiety. Several of the remaining fenthion atoms had unacceptably 
large thermal parameters, suggesting that the molecule was disordered. From the X-ray data, a 
second component was modelled. The guest components, labelled with suffixes A and B, were 
refined with global s.o.f.s. of x and 1-x. The value of x refined to 0.71(1) for the major component, 
A. Two distance restraints were applied to the thioester moiety of the minor component. The 
thioester and phosphorothioate moieties of the major and minor components required FLAT 
restraints to maintain reasonable geometry. The hydrogen atoms were placed in idealised 
positions, with Uiso values of 1.2 to 1.5 times that of the parent atom, after they were located in 
the difference Fourier map. The partial hydrogen atoms of the water molecule were not found in 
the difference Fourier map and are not included in this structure. 
GEOMETRIC ANALYSIS OF TMAFEN 
The asymmetric unit of the inclusion complex TMAFEN comprises one host and one guest 
molecule and a water molecule with partial occupancy. The asymmetric unit is shown in 
Figure 4.19. The numbering schemes for the guest and host molecules are shown in Figure 4.20. 
 
Figure 4.19: The asymmetric unit of the complex TMAFEN. Thermal ellipsoids for the host atoms 
are drawn at the 50% probability level and the guest and water atoms are drawn in space-filling 
mode. The minor disorder components have been omitted for clarity 




Figure 4.20: Numbering scheme of the glucopyranose rings (left) and the guest molecule (right). 
The minor component is not shown here for clarity. The major component is designated by the 
suffix A and the minor component by the suffix B 
HOST CONFORMATION 
The torsion angles of the primary methoxy substituents, ω, are listed in Table 4.7. From these 
values it was found that four of these groups are directed towards the cyclodextrin cavity and the 
G3 and G6 groups are directed outwards. When these data are combined with the τ2 tilt angles 
listed in Table 4.8 one can conclude that the primary end of the TRIMEA cavity is closed off, 
restricting access from this end of the cyclodextrin. 
Table 4.7: Torsion angles (ω) for TMAFEN 







‡Mean e.s.d. 0.4° 
Tables 4.8 and 4.9 show the geometric parameters for TMAFEN and uncomplexed TRIMEA 
(refcode: TEVCEC)9,14 respectively. The TRIMEA molecules in these crystal structures are 
conformationally similar. However, the geometric parameters show that the host molecule in 
TMAFEN has a slightly elliptically distorted O4n hexagon compared to TEVCEC: 
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3.952 Å ≤ l ≤ 4.533 Å, 4.172 Å ≤ D ≤ 4.421 Å and 109.8° ≤ ϕ ≤ 126.5°. The corresponding 
parameters for TEVCEC are 4.041 Å ≤ l ≤ 4.375 Å, 4.095 Å ≤ D ≤ 4.469 Å and 116.1° ≤ ϕ ≤ 122.8°. 
The inclusion of fenthion in the TMAFEN complex causes the distortion of the hexagon. However, 
the included portion of fenthion is not parallel to the elliptical distortion of the cavity 
(Figure 4.21). The aromatic plane of fenthion forms an angle of approximately 60° to the long axis 
of the ellipse. The O4G2···O4G5 distance, parallel to the thiomethyl group, is 8.463(3) Å. The 
longest transannular distance, 8.942(3) Å and the shortest, 7.937(4) Å (O4G1···O4G4 and 
O4G3···O4G6 respectively) are inclined at approximately 60° to the O4G2···O4G5 transannular 
line. This shows that the planar portion of the guest is not included parallel to the longest 
distortion of the hexagon. The view from the primary end of the cyclodextrin cavity (Figure 4.21) 
illustrates the distortion. The large tilt angle observed for glucopyranose subunit G2 is caused by 
the steric hindrance arising from the protrusion of the fenthion phosphorothioate moiety. This 
has the effect of shortening the O4G2···O4G5 and O4G3···O4G6 transannular distances. 
 
Figure 4.21: View from the primary end of TMAFEN illustrating the O4Gn transannular distances 
The tilt angles, τ2, are similar in TMAFEN and TEVCEC, having ranges 6.4° ≤ τ2 ≤ 40.4° and 
9.0° ≤ τ2 ≤ 42.4°, respectively. These large tilt angles close off the primary end of the cavity giving 
the TRIMEA molecules a ‘bowl’ shape rather than the usual torus seen in native cyclodextrins. 
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The conformational similarity of the TRIMEA molecules in TMAFEN and TEVCEC can be seen in 
Figure 4.22. The primary ω torsion angles in TMAFEN further show that the methoxy substituents 
close off this end of the cyclodextrin cavity. 
In TMAFEN, the methyl substituents on the O2 atoms of all the glucose subunits are directed 
outwards from the cavity while those on the O3 substituents are directed inwards. The 
alternating arrangement of the O2Gn and O3Gn methoxy groups is most likely due to the steric 
hindrance that occurs between the methyl groups attached to these atoms. To compensate for the 
steric hindrance the τ2 angles increase to maximise the distance between methoxy substituents 
on the secondary end of the cavity; this has the additional effect of narrowing the primary end of 
the cavity. 
Table 4.8: Geometric parameters for the host molecule in the complex TMAFEN 
Residue l (Å) D (Å) Φ (°) d (°) αa (Å) D3b (Å) τ2c (°) 
G1 4.533 4.229 121.0 -12.1 -0.373 3.431 6.4 
G2 4.213 4.202 126.5 23.3 0.030 3.325 40.4 
G3 3.952 4.260 112.0 -11.3 0.355 3.332 10.7 
G4 4.442 4.172 119.8 -10.7 -0.381 3.356 10.2 
G5 4.249 4.292 125.3 21.5 0.023 3.180 34.1 
G6 4.018 4.421 109.8 -10.1 0.347 3.825 27.1 
a mean e.s.d: 0.013 Å; b mean e.s.d: 0.004 Å; c mean e.s.d: 0.1° 
Table 4.9: Geometric parameters for uncomplexed TRIMEA (refcode: TEVCEC)9,14 
Residue l (Å) D (Å) Φ (°) d (°) α (Å) D3a (Å) τ2 (°) 
G1 4.255 4.132 117.6 -17.8 0.352 3.441 12.1 
G2 4.322 4.095 122.8 26.5 0.131 3.429 42.4 
G3 4.041 4.433 117.4 -7.8 -0.487 3.510 9.0 
G4 4.222 4.112 116.1 -16.8 0.364 3.598 17.2 
G5 4.375 4.230 122.0 25.9 0.112 3.309 38.7 
G6 4.083 4.469 116.2 -6.8 -0.472 3.332 9.8 
a mean e.s.d: 0.006 Å 
The e.s.d. values for α and τ2 were not available from the publication14 
 




Figure 4.22: Overlay of TEVCEC (green) and TMAFEN (blue) host molecules  
GUEST INCLUSION 
The inclusion of fenthion in the complex TMAFEN will be described using the major component 
due to the similarity in atomic co-ordinates of the two disordered components. As shown in 
Figure 4.19 the thiomethyl portion of fenthion is included within the TRIMEA cavity. The aromatic 
and phosphorothioate moieties extend into the interstitial spaces between cyclodextrin 
molecules. The tilt angles of the glucopyranose subunits, combined with the primary methoxy 
substituent of the TRIMEA molecule close off the cavity, isolating the thiomethyl group from the 
external environment. The penetration of the thiomethyl group is minimal as indicated by the fact 
that the methyl only extends 0.037 Å above the O4Gn least-squares plane. Meanwhile, the sulfur 
atom is located 1.501 Å below the same plane and only 0.281 Å above the secondary oxygen atom 
(O2 and O3) least-squares plane. 
The guest molecule fenthion is disordered over two positions with the major component having 
a s.o.f. of 0.71(1). The respective aromatic planes of the major and minor components intersect at 
5.0(1)°. Both the major and minor components include in the same manner and occupy almost 
overlapping atomic coordinates, except for the phosphorothioate moiety, as can be seen in 
Figure 4.23. 




Figure 4.23: Disorder of the fenthion guest molecule (major component: blue, minor component: 
green) viewed perpendicular (left) and parallel (right) to the aromatic planes 
The selected torsion angles shown in Table 4.10 illustrate the differences in the major and minor 
component conformations. As can be seen from the torsion angle S14-P11-O10-C4 the major 
component is in a (-)-gauche conformation while the minor component is in the (+)-gauche 
conformation. The remaining substituents of fenthion remain in similar conformations in the 
major and minor components. The phosphorothioate groups of both components are in a 
tetrahedral arrangement about the phosphorus atom. In the minor component the tetrahedral 
arrangement is slightly distorted with the O10B-P11B-O12B angle being only 99.8(7)°. The angles 
O12B-P11B-S14B and O13B-P11B-S14B were found to be 114.2(5)° and 112.4(5)° respectively. 
Table 4.10: Selected torsion angles (°) for the major and minor components 
Torsion Angle Major Minor 
O10-C4-C5-C6 -171.7(6) -179(1) 
S8-C7-C6-C5 179.8(6) 175(1) 
C1-C2-C3-C4 -179.9(7) -171(1) 
S14-P11-O10-C4 -37.7(5) 66(1) 
 
INTRA- AND INTERMOLECULAR INTERACTIONS 
HOST INTERACTIONS 
Unlike the host cyclodextrins β-CD and DIMEB, TRIMEA is fully methylated and as such has no 
hydroxyl groups available for hydrogen bonding. There are eight intramolecular interactions 
within the host molecule, all of the type C-H···O. These have D···A distances ranging from 
2.782(4) Å to 3.152(5) Å and D-H···A angles from 101° to 140°.  
There are three inter-host interactions that occur during packing of the crystal structure. There 
is no classical hydrogen bonding present in this structure and the inter-host interactions are of 
the C-H···O type. These hydrogen bonds are listed in Table 4.11 below. 
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Table 4.11: Inter-host interactions of TMAFEN 
Interaction D···A (Å)‡ D-H···A (°) Symmetry Operator 
C2G3-H···O5G1 3.315 170 (2-x, 1/2+y, 1-z) 
C9G3-H···O3G1 3.373 139 (2-x, 1/2+y, 1-z) 
C2G4-H···O6G6 3.322 150 (2-x, 1/2+y, 2-z) 
‡Mean e.s.d.: 0.004 Å 
GUEST INTERACTIONS 
Two hydrogen bonding interactions of the form C-H···O occur between the guest and host 
molecules, namely C5A-H···O2G1 and C3A-H···O5G2‡ (‡ = 1+x, y, z). The first occurs within the 
asymmetric unit while the second occurs with a translated TRIMEA molecule The D···A distances 
are 3.271(7) Å and 3.328(6) Å and the D-H···A angles 148° and 171° respectively. 
WATER INTERACTIONS 
The water molecule with partial occupancy is in a position indicative of hydrogen bonding with 
the host molecule. As the hydrogen atoms were not located in the difference Fourier map the 
interactions were determined from short intermolecular contacts. The water oxygen atom was 
found to be 2.89(2) Å from O6G2 and 2.86(3) Å from O7G5. These values are less than the sum of 
the respective van der Waals radii indicative of hydrogen bonding. The angle O6G2···OW1···O7G5 
is 102.1(7)°, which is close to the H-O-H angle of 104.5° typically found for water molecules. 
CRYSTAL PACKING 
The TMAFEN complex crystallises in a column type arrangement in space group P21. The 
complexes pack in a head-to-tail arrangement along the a-axis. The columns are then arranged 
anti-parallel to one another along both the b- and c-axes. The inter-host interactions listed in 
Table 4.11 show the three non-classical hydrogen bonds that stabilise the close interaction of the 
columns. The anti-parallel columns are shown in Figure 4.24. The aromatic and phosphorothioate 
moieties of the fenthion guest molecule are located in interstitial spaces due to the diminutive 
size of the TRIMEA cavity; this is shown in the stereo diagram Figure 4.25. 




Figure 4.24: Packing diagram down the c-axis showing the anti-parallel columns of TMAFEN 
 
Figure 4.25: Stereo diagram illustrating the arrangement of the phosphorothioate moiety of 
fenthion in the interstitial spaces between TRIMEA molecules  
  




The PXRD trace (Figure 4.26) for the bulk sample shows good agreement with the pattern 
calculated from the refined X-ray crystal structure of the complex. The slight differences in the 2θ 
angles result from the powder diffraction pattern having been collected at room temperature 
while the single crystal intensity data were collected at 173(2) K. When the crystal is cooled there 
are angular shifts in peak positions, most likely resulting from anisotropic contraction of the unit 
cell. 
 
Figure 4.26: The PXRD trace recorded for the bulk sample (blue) and the computed PXRD pattern 
based on the single crystal X-ray structure of TMAFEN (orange)  





The complex TMBFEN was prepared via a co-precipitation experiment. To perform this, TRIMEB 
(118 mg; 0.0826 mmol) was weighed into a vial and dissolved in 3 cm3 MilliQ water. This solution 
was cooled to 4 ℃ and a drop of fenthion (23 mg; 0.0826 mmol) was added to the solution and 
stirred for several hours. The solution was then heated to 40 ℃ and stirred for another hour. The 
solution was then cycled several times between 4 ℃ and 40 ℃ for half an hour in an attempt to 
determine the point at which the largest amount of the complex was in solution. At this point the 
solution was filtered into a clean vial through a 0.45 μm nylon filter. This was then left to 
crystallise in a 60 ℃ oven and plate-like crystals were obtained after four days. 
ASSESSMENT OF STOICHIOMETRY 
The stoichiometry of the complex was confirmed by thermal analysis. The TGA trace (Figure 4.27) 
showed a mass loss of 15.9 ± 0.7 % (n = 2) from 122.3 ± 0.9 ℃ to 217.2 ± 0.5 ℃. This equated to a 
host-guest ratio of 1:1 (calculated mass loss = 16.3 %). No solvent loss was observed for this 
complex indicating that there is no water present in the complex. 
THERMAL ANALYSIS 
In the TGA trace, no mass loss occurs until 122.3 ± 0.9℃ (n = 2) indicating that there is no water 
present in the structure. The DSC trace also shows no thermal events over this range. At 
152.4 ± 0.1 ℃ (n = 2) there is the onset of a melting endotherm in the DSC that coincides with a 
15.9 ± 0.7 % (n = 2) mass loss in the TGA. This mass loss correlates with the loss of fenthion from 
a 1:1 complex. This would imply that upon melting, the fenthion guest is released from the 
complex. There is no other thermal event over the range of the DSC trace. In the TGA trace, there 
is a large mass loss indicative of decomposition starting at 299.6 ± 5.0 ℃. The same behaviour can 
be seen in the HSM images (Figure 4.28). 
The hot stage micrographs show the melt onset at 144 ℃ and the complex is completely melted 
at 155 ℃, which corroborates the interpretation of the TGA and DSC traces.  
 




Figure 4.27: Representative TGA (blue) and DSC (orange) traces for TMBFEN 
 
Figure 4.28: Hot stage micrographs showing the TMBFEN complex at various stages of heating 
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CRYSTAL STRUCTURE ANALYSIS 
DATA COLLECTION AND SPACE GROUP DETERMINATION 
The intensity data were collected on a Bruker Kappa Apex II DUO diffractometer. It was found 
that the crystal system is orthorhombic, as indicated by the mmm Laue symmetry of the X-ray 
diffraction pattern. Systematic absences were investigated and the space group was identified as 
P212121. The conditions limiting reflection were hkl: none, h00: h = 2n, 0k0: k = 2n, 00l: l = 2n 
confirming the assignment. The asymmetric unit contains a 1:1 TMBFEN complex.  
STRUCTURE SOLUTION AND REFINEMENT 
The software program SAINT7 was used in data reduction and unit cell refinement. Absorption 
corrections were performed using the multi-scan method employed by SADABS.12 The 
asymmetric unit of TMBFEN is made up of one host molecule and one fenthion molecule. No water 
molecules are present in the structure. The position of the host atoms was determined using the 
isomorphous replacement method.8 A search of the CSD9 resulted in twelve isostructural TRIMEB 
inclusion complexes. The complex of TRIMEB with p-iodophenol (refcode: CAMPIP)9,15 was 
deemed the most suitable due to the similarities in the host atomic co-ordinates and unit cell 
parameters (|Δa| = 0.0873 Å, |Δb| = 0.203 Å, |Δc| = 0.714 Å). The O6, C7, C8 and C9 atoms of each 
subunit were not included in the trial model, as these residues are flexible within structures. The 
glucopyranose subunits were labelled using the notation G1 - G7. Two groups are disordered in 
the host structure, namely the C9G3 and C7G6 methyl groups. They are disordered over two 
positions and were assigned s.o.f.s of x for the major component and 1-x, where x is linked to a 
free variable. The values of x refined to 0.66(3) and 0.52(5) for C9G3 and C7G6 respectively. The 
hydrogen atoms were placed in idealised positions using a riding model. The isotropic 
temperature factors were 1.2 - 1.5 times those of the parent atoms. All ordered non-hydrogen 
atoms were treated anisotropically. The data were collected at 100 ± 2 K. The crystallographic 
data for the TMBFEN complex are presented in Table 4.12. 
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Table 4.12: Crystallographic data and data-collection parameters for TMBFEN 
Chemical formula C63H112O35·C10H15O3PS2 
Molar mass (g mol-1) 1707.83 
Crystal system Orthorhombic 
Space group P212121 
Unit cell parameters  
a (Å) 15.084(2) 
b (Å) 21.164(3) 
c (Å) 27.491(3) 
α = β = γ (°) 90.0 
Volume (Å3) 8776.5(18) 
Z 4 
Densitycalcd (g cm-3) 1.292 
μ [MoKα] (mm-1) 0.165 
F (000) 3664 
Temperature (K) 100(2) 
Crystal size (mm) 0.298 ⨯ 0.12 ⨯ 0.054 
Range scanned θ (°) 1.5 ≤ θ ≤ 25.1 
Index ranges h: -9, 17; k: -25, 25; l: -32, 32 
ϕ and ω scan angle (°) 0.50 
Dx (mm) 50 
Total number of reflections 73 047 
Number of independent reflections 15 526 
Number of reflections with I > 2σ(I) 11 248 
Rint 0.075 
R1 [I > 2σ(I)] 0.0530 
wR2 0.1190 
S 1.013 
Number of parameters 1 052 
Number of reflections omitted 11 
Parameters a, b in 
w = 1/[σ2(FO2)+(aP)2+(bP)] 
a = 0.0686; b = 3.8356 
(δ/σ)mean <0.001 
Δρ excursions (e Å-3) -0.61, 0.62 
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MODELLING OF THE FENTHION GUEST MOLECULE 
After initial refinement of the trial model and assignment of the remaining host atoms, several 
large electron density peaks were observed in the cyclodextrin cavity. These were assigned as the 
guest atoms. After their identification in the Fourier difference map hydrogen atoms were placed 
in idealised positions with temperature factors 1.2-1.5 those of the parent atoms. No disorder 
was observed in the guest structure and no restraints were required during refinement. All 
non-hydrogen atoms were treated anisotropically for fenthion. 
GEOMETRIC ANALYSIS OF TMBFEN 
The asymmetric unit of TMBFEN comprises one TRIMEB molecule with a fenthion molecule 
included in the host molecule. The asymmetric unit can be seen in Figure 4.29. The numbering 
schemes of the host and guest are presented in Figure 4.30. 
 
Figure 4.29: The asymmetric unit of the complex TMBFEN. Thermal ellipsoids for the host atoms 
are drawn at the 50% probability level and the guest atoms are drawn in space-filling mode. 
 
Figure 4.30: Numbering scheme of the glucopyranose rings (left) and the guest molecule (right) 




The torsion angles, ω, of the primary methoxy groups G3, G5 and G7 show that they are directed 
towards the cavity of the cyclodextrin. The remaining primary methoxy groups are directed 
outwards. The groups that are positioned towards the centre of the cavity create a ‘lid’ at the 
primary end of the cavity. This closes off this side of the cyclodextrin. This ‘lid’ conformation is 
evident in Figure 4.31c. 
Table 4.13: Torsion angles (ω) for TMBFEN 








‡Mean e.s.d. 0.5° 
In a manner analogous to the TMAFEN structure, the secondary methoxy groups alternate their 
orientation towards and away from the cyclodextrin cavity: the O2Gn-C7Gn groups are all 
directed away from the cavity while the O3Gn-C8Gn groups are directed towards the cavity. This 
alternating arrangement most likely occurs to minimise the steric hindrance between the large 
methyl groups. The tilt angles, τ2, are distributed over a large range to further compensate for this 
steric hindrance. 
The geometric parameters of the TMBFEN inclusion complex are presented in Table 4.14. As can 
be seen from the large range of tilt angles (12.7° ≤ τ2 ≤ 42.8°) the cyclodextrin is in a distorted, 
saddle-like conformation. This is further shown by the large deviations of the O4 atoms from the 
O4n mean plane (|0.007| Å ≤ α ≤ |0.567| Å) and the large torsion angles involving the O4 atoms 
(-21.4° ≤ d ≤ 23.9°). 
A search of the CSD9 showed that this structure is isostructural with twelve TRIMEB inclusion 
complexes, and is most similar to the inclusion complex of TRIMEB with fenitrothion5,6. 
There are three known structures of uncomplexed TRIMEB hydrates (CSD refcodes: HEZWAK,9,16 
WAGLOG9,17 and WAGLUM9,17). WAGLOG (TRIMEB·3H2O) has been selected for the principal 
comparison with TMBFEN as these cyclodextrins have similar geometric parameters, as shown 
in Tables 4.14 and 4.15. 
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The WAGLOG and TMBFEN host molecules show relatively little difference between their 
geometric parameters. The tilt angles of the two TRIMEB molecules show similar ranges where 
TRIMEB in TMBFEN has τ2 angles ranging from 12.9° to 42.8°, while the range in WAGLOG is 
somewhat larger, from 4.3° to 66.5°. The difference is likely due to the inclusion of fenthion 
limiting the ability of the glucopyranose subunits to tilt to the same extent as in the hydrated 
structure. The ‘round’ shape of the TRIMEB cavities is only slightly distorted as evidenced by the 
relatively small range of parameter l (TMBFEN: 4.666 Å ≤ l ≤ 5.211 Å and WAGLOG: 
4.673 Å ≤ l ≤ 5.485 Å). The distortion is less pronounced in the TMBFEN inclusion complex than 
in WAGLOG. 
The other TRIMEB hydrates show much greater distortion from the ‘round’ shape of the 
cyclodextrin cavity, especially HEZWAK (HEZWAK: 3.933 Å ≤ l ≤ 5.947 Å and WAGLUM: 
4.591 Å ≤ l ≤ 5.496 Å). The vastly different conformation of HEZWAK, having a glucopyranose 
ring in the 4C1 arrangement, gives rise to the large differences in geometric parameters to the 
other TRIMEB structures. All three of the TRIMEB hydrates show varying degrees of 
‘self-inclusion’, not present in the TMBFEN structure. 
Table 4.14: Geometric parameters of TMBFEN 
Residue l (Å) D (Å) Φ (°) d (°) αa (Å) D3b (Å) τ2c (°) 
G1 5.174 4.421 124.0 0.6 0.567 3.817 36.4 
G2 5.163 4.429 131.9 -21.4 -0.321 3.476 12.7 
G3 4.826 4.289 129.3 4.2 -0.355 3.246 34.5 
G4 4.911 4.479 124.0 19.6 0.408 3.098 28.5 
G5 5.211 4.268 123.6 -12.9 0.237 3.395 16.5 
G6 5.081 4.508 137.9 -17.2 -0.529 3.458 12.9 
G7 4.666 4.258 121.1 23.9 -0.007 3.347 42.8 
a mean e.s.d.: 0.002 Å; b mean e.s.d.: 0.005 Å; c mean e.s.d.: 0.1° 
Table 4.15: Geometric parameters of TRIMEB·(3H2O) (refcode: WAGLOG)9,17 
Residue l (Å) D (Å) Φ (°) d (°) α (Å) D3 (Å) τ2 (°) 
G1 4.722 4.413 112.4 3.1 0.799 4.059 42.5 
G2 5.485 4.243 135.5 -29.3 -0.369 3.605 9.1 
G3 4.808 4.468 126.7 11.3 -0.467 3.318 43.1 
G4 4.818 4.420 129.5 10.1 0.484 3.184 27.5 
G5 5.037 4.433 117.6 2.7 0.178 3.406 17.1 
G6 5.364 4.171 135.3 -39.5 -0.448 3.872 4.3 
G7 4.673 4.548 129.5 36.0 -0.178 3.395 66.5 
The e.s.d.s were not available from the publication17  




The phosphorothioate moiety of fenthion is deeply embedded within the cyclodextrin cavity. The 
thiomethyl and methyl substituents of fenthion protrude beyond the secondary rim of the 
TRIMEB cavity. 
The inclusion of fenthion slightly distorts the cyclodextrin from the uncomplexed conformation 
as seen in the change in the G6 tilt angle. In the inclusion complex the glucopyranose ring is tilted 
further outwards from the cavity when fenthion is included in the structure. The lack of 
stabilisation from traditional hydrogen bonding allows the distortions to occur more easily than 
in the parent β-cyclodextrin host molecule. The mode of inclusion is depicted in Figure 4.31. 
 
Figure 4.31: Figures showing the inclusion of fenthion in the cyclodextrin cavity. a. protrusion of 
the thiomethyl moiety from the cavity, b. cut-away cyclodextrin showing the depth of penetration 
of fenthion, c. view from the primary rim and d. view from the secondary rim 
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INTRA- AND INTERMOLECULAR INTERACTIONS 
The complex TMBFEN does not contain any classical hydrogen bond donors. As a result, weak 
hydrogen bonds and van der Waals forces are the only intra- and intermolecular interactions in 
the structure. The cyclodextrin host molecule is stabilised by twenty weak hydrogen bonds. Many 
of these interactions serve to stabilise the severe tilt angles that occur in TRIMEB inclusion 
complexes. Four of these occur between C6Gn and O5G(n-1) atoms with a donor to acceptor 
distance ranging from 3.128(6) Å to 3.194(6) Å. The other major stabilising interactions are the 
C5Gn-H···O4G(n+1) with D···A distances from 2.772(6) Å to 2.832(6) Å. 
There is one intramolecular interaction present within the fenthion guest molecule. This takes 
place between the C15-H and S14 atoms with the following hydrogen bonding parameters: D···A: 
3.329(9) Å, D-H···A: 116°. 
There are four host-host interactions, which are listed in Table 4.16. These occur between 
symmetry-related complex units and aid in stabilising the crystal packing arrangement.  There 
are no hydrogen bonding interactions between the host and guest molecules in the TMBFEN 
inclusion complex. 
Table 4.16: Hydrogen bonding interactions in TMBFEN 
Type Interaction D···A (Å) D-H···A (°) Symmetry Operator 
Host-Host C2G4-H···O6G1 3.383(6) 150 (3/2-x, 1-y, 1/2+z) 
C9G1-H···O3G4 3.198(7) 124 (3/2-x, 1-y, 1/2+z) 
C9G2-H···O3G7 3.138(8) 120 (1+x, y, z) 
C9G4-H···O3G1 3.310(7) 130 (3/2-x, 1-y, 1/2+z) 
CRYSTAL PACKING 
The complex TMBFEN packs in the screw-channel mode. The columns formed comprise 
monomeric complex units arranged in a head-to-tail manner along the b-axis. The O4n least-
squares planes of successive TRIMEB molecules are inclined at 9.0° and the O4n centroids are 
offset by 3.8 Å. The channel that arises is undulating rather than linear due to this incline and 
offset. The columns pack in an anti-parallel arrangement arising from the 21-axes parallel to the 
crystal a- and c-axes as shown in Figure 4.32. The columns interact via weak hydrogen bonding 
as outlined in the section on Intra- and Intermolecular Interactions. 
Fenthion is deeply embedded in the cyclodextrin cavity, residing close to the ‘lid’ formed by the 
primary methoxy substituents. The fenthion molecule is larger than the cyclodextrin cavity and 
therefore can only be partially included in the cavity. Thus, the thiomethyl moiety of fenthion is 
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nested in the interstitial spaces created by the arrangement of the host molecules, as can be seen 
in Figure 4.33. 
 
Figure 4.32: Packing of the TMBFEN complex viewed along [1 0 0] highlighting the anti-parallel 
column arrangement 
 
Figure 4.33: Stereo diagram illustrating the arrangement of the thioester moiety of fenthion in the 
interstitial spaces between TRIMEB molecules 
 
 




The PXRD trace (Figure 4.34) calculated from the refined X-ray crystal structure of TMBFEN 
shows good agreement with the experimental pattern of the bulk samples of the complex. The 
slight differences in the 2θ peak locations result from the single crystal intensity data having been 
collected at low temperature, while the powder diffraction data were collected at room 
temperature. Cooling the sample for single crystal intensity data collection results in an angular 
shift in the peak positions, most likely due to anisotropic contraction of the unit cell. 
 
Figure 4.34: The PXRD trace recorded for the bulk sample (blue) and the computed PXRD pattern 
based on the single crystal X-ray structure of TMBFEN (orange) 
In the section describing the structure solution and refinement, the choice of the complex 
CAMPIP9,15 for isomorphous replacement was outlined. The differences in the unit cell 
parameters of CAMPIP and TMBFEN are within reasonable limits for isomorphous replacement 
(|Δa| = 0.0873 Å, |Δb| = 0.203 Å, |Δc| = 0.714 Å). The backbones of the TRIMEB molecules occupy 
similar atomic co-ordinates, as shown in Figure 4.35. The differences in the atomic co-ordinates 
were not significant enough to cause any issues in structure refinement. The packing 
arrangements of the two complexes are similar, as shown in Figure 4.36. Differences arise in 
atomic co-ordinates during packing due to the differences in unit cell parameters. 




Figure 4.35: Overlay of CAMPIP (green) and TMBFEN (blue) host molecules 
 
Figure 4.36: Overlay of packed CAMPIP (green) host and TMBFEN (blue) host molecules viewed 
along the [1 0 0] direction  
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THERMOGRAVIMETRIC ASSESSMENT OF KINETIC PARAMETERS FOR COMPLEX 
DISSOCIATION 
The complex TMBFEN was presented in a journal article by Cruickshank et al. (including the 
author of the present thesis as a co-author) based on a study performed in the Centre for 
Supramolecular Chemistry Research (UCT).5 The complex is isostructural with two other TRIMEB 
complexes presented in the same paper [TRIMEB/fenitrothion (TMBFENT) and 
TRIMEB/acetochlor (TMBACE)]. The structural similarities among the three complexes are 
illustrated in the stereo diagrams viewed from a common direction in Figure 4.37. 
The inclusion of the phosphorothioate moiety in TMBFENT and TMBFEN occurs in a similar 
manner. This moiety is deeply embedded in each of these complexes positioned close to several 
methoxy groups at the primary rim. The location of the aromatic portions of fenitrothion and 
fenthion are similar in their respective TRIMEB complexes. In the TMBACE complex the guest 
positioning is different whereby the aromatic moiety is fully encapsulated by the host molecule. 
The TGA traces of the three complexes all display two-step mass losses where the first 
corresponds to the loss of a single guest molecule being released from the inclusion complex. The 
second mass loss is attributed to host decomposition. The DSC traces show that the guest loss and 
fusion of the complex partially overlap with the loss of the guest beginning before the fusion 
event. 
The kinetics of guest loss upon heating was investigated by isothermal and non-isothermal 
methods for these three complexes. The isothermal results were used to determine the 
mechanism of guest release, while both methods were used to determine the activation energies 
of guest loss for each of the complexes. The kinetics results are explained in further detail below. 
 




Figure 4.37: Stereoviews of the complexes a. TMBFENT, b. TMBFEN and c. TMBACE with host 
residue numbering to illustrate structural similarities. Reproduced from Cruickshank et al. 
(2013).5 
  










𝑔(𝛼) = 𝑘𝑡 
In these expressions, α is the fractional mass loss [(mt – m0)/(m∞ – m0)] at reaction time t, k is the 
rate constant and f(α) and g(α) are functions describing the reaction mechanism. 
In solid-state kinetics it is common that more than one model can be used to describe a particular 
process. The F1 model, based on the apparent order of a reaction in solution, does not have the 
same significance in the solid-state. The mechanism of first-order reactions in the solid-state 
involves random nucleation and growth of such sites that does not extend beyond individual 
crystallite nucleation sites. The activation energies presented in Table 4.17, obtained from this 
model for the three complexes, are not statistically different, suggesting that the kinetics of 
melting and guest release is not dependent on the complex structure. 
The second model is the 3D model, which applies to diffusion-limited reactions that take place at 
a phase interface between TRIMEB and the inclusion complex. As the guest dissociates it diffuses 
towards the crystal surface and then desorbs from the surface. Using this model one can conclude 
that the guest release kinetics are dependent on the physical properties or structure of the 
complexes. This was deduced from the statistically different activation energies of the three 
complexes (Table 4.17). 
Table 4.17: Activation energies determined from isothermal experiments for the TRIMEB/guest 
complexes 
Complex 
Activation Energy (kJ mol-1) 
F1 3D 
TMBFENT 126 ± 4 114 ± 1 
TMBFEN 129 ± 10 109 ± 9 
TMBACE 130 ± 13 86 ± 8 
The process under study is complicated as there are two simultaneous events occurring, viz. 
complex fusion and guest loss. Even with these complications, the 3D diffusion model appears to 
Chapter 4 – Fenthion 
 
 120 
be a reasonable one as it is consistent with the crystal packing arrangements of the complexes. 
The guest molecules are isolated from one another and there are no directional constraints on 
their diffusion. 
NON-ISOTHERMAL METHOD 
The method developed by Ozawa, Flynn and Wall18,19 was modified to obtain activation energies 
to compare with those determined via the isothermal technique. This is a model-free 
isoconversional method. 
Expression 4.3: 
log 𝛽𝛼 = log
𝐴𝛼𝐸a𝛼
𝑔(𝛼)𝑅




In Expression 4.3, βα is the heating rate, Eaα is the activation energy, Tα is the temperature at each 
conversion level and g(α) is the kinetic model employed. By plotting log(βα) versus the reciprocal 
temperature the activation energy could be calculated from the slope of the plot. The activation 
energies for each complex at a given conversion level are presented in Table 4.18. 




Activation Energy (kJ mol-1) 
TMBFENT TMBFEN TMBACE 
8 142.9 130.1 185.5 
12 158.2 155.3 157.8 
16 167.7 160.6 138.0 
20 166.8 150.4 123.0 
Average 158 ± 12 149 ± 13 151 ± 27 
The variation in the activation energies for TMBFENT and TMBFEN shows no trend and the 
relative errors are less than 10 %. This error is within the conventionally accepted range for 
isoconversional methods. The decreasing trend in the TMBACE complex activation energies as a 
function of conversion can be explained by the significantly lower melting point of this complex. 
Thus the reciprocal temperature values recorded at the 12, 16 and 20 % conversions were lower 
than the reciprocal fusion temperature of the complex. 
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FURTHER CONSIDERATIONS RELATING TO THE ABOVE STUDY 
There have been several studies investigating the dissociation of a guest molecule from native 
cyclodextrins. Researchers who investigated the thermal dissociation of benzyl alcohol and 
cinnamaldehyde from their β-CD inclusion complexes have reported activation energies of 158 
and 160 kJ mol-1, respectively.20,21 The values obtained for the above β-CD complexes are similar 
to those obtained by the non-isothermal method for TMBFENT, TMBFEN and TMBACE. 
Furthermore, the guest loss process for these β-CD complexes occurs via a diffusion-based 
mechanism, as proposed for the TRIMEB complex guest losses. 
The thermal stabilities of the TMBFENT, TMBFEN and TMBACE complexes assessed in this study 
show that a relatively high energy barrier exists for the thermal release of these guest molecules 
from their complexes. This means that the solid-state complexes should remain intact during 
normal handling and storage of the material. As these pesticides are liquids at room temperature 
this indicates that their inclusion complexes would be safer to use and easier to transport. 
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PHASE SOLUBILITY ANALYSIS 
Phase solubility analysis is a method to determine the effect of a host compound on the solubility 
of a guest molecule. 
SAMPLE PREPARATION 
The phase solubility of fenthion was investigated with five cyclodextrins, namely α-CD, β-CD, 
γ-CD, hydroxypropyl β-cyclodextrin (HPBCD) and randomly methlylated β-cyclodextrin 
(RAMEB). 
Due to the extremely low aqueous solubility of fenthion,1 a co-solvent was required. The solvent 
1,4-dioxane was determined to be an appropriate medium. Aqueous 2 % (H2O:dioxane 98:2 v/v) 
dioxane solutions were found to be sufficient for this study. 
Stock solutions of the cyclodextrins were prepared in 2 % dioxane aqueous solutions, then diluted 
to the desired concentrations and transferred to polytope vials. The vials all contained 5 cm3 of 
the cyclodextrin solutions, to which an excess of fenthion was added. The mixtures were stirred 
at 1000 rpm for 72 hours at a constant temperature of 25 ± 0.5 ℃. Once the mixtures reached 
equilibrium they were filtered through a 0.45 μm nylon filter. To determine the intrinsic solubility 
(S0) of fenthion; a vial was set up in a similar manner, without the cyclodextrin. The absorbance 
of the filtered solutions were read using UV-Vis spectroscopy. If required, the filtered solutions 
were diluted to obtain an absorbance between 0.1 and 1. The concentration of fenthion was 
calculated from the molar absorptivity value obtained from the Beer-Lambert plot. 
UV-VISIBLE SPECTROPHOTOMETRY 
The calibration curve used to calculate the molar absorptivity of fenthion using the Beer-Lambert 
law (Expression 4.4) is shown in Figure 4.38. 
Expression 4.4 
𝐴 = 𝑐𝑙 
The path length, l, was 1 cm; therefore, the expression indicates that the calibration plot is linear. 
The molar absorptivity, ϵ, is equal to the slope of plot of absorbance versus the fenthion 
concentration. From the slope it was found that the molar absorptivity is 11838 mol-1 dm3 cm-1. 




Figure 4.38: Beer-Lambert calibration curve for fenthion in 2% aqueous 1,4-dioxane at 25 ℃ for 
λmax = 251.00 nm 
PHASE SOLUBILITY 
The results of the phase solubility experiments are presented as a function of the apparent 
solubility of fenthion with increasing cyclodextrin concentration. The profiles are classified as A- 
or B-type by Higuchi and Connors.22–24 The profiles described as A-type show linear increases in 
apparent guest solubility with cyclodextrin concentration. The sub-categories are AL-, AP- and 
AN-type. The classification AL-type curves are characterised by linear increases in apparent 
solubility of the guest while AP- and AN-type show deviations from linearity at higher host 
concentrations. AP-type plots show a positive deviation while AN-type show negative deviations, 
due to changes in the physical nature of the solution. The profiles classified as B-type are the 
result of formation of partially soluble complexes. There are two B-type sub-categories; BS and 
BL. The BS-type plot shows an increase in apparent solubility up to a point where the complex 
precipitates out of solution. The complex formed in BS-type is generally moderately soluble. In 
the case of the BL-type profiles the complex is highly insoluble and precipitates immediately and 
so there is no initial increase in apparent guest concentration as seen in the BS-type profile. 22–24  
The experiments of α-CD and γ-CD with fenthion formed insoluble complexes which precipitated 
out at low cyclodextrin concentrations and were not pursued. 




A representative phase solubility plot showing the variation in apparent fenthion concentration 
with increasing β-CD concentration is shown in Figure 4.39. The plot follows B-type behaviour, 
specifically BS. This shows an initial linear increase in apparent concentration of fenthion, 
followed by decrease. The behaviour is most likely due to the BCDFEN complex having low 
solubility and precipitating at higher β-CD concentrations.23 
 
Figure 4.39: Representative phase solubility plot for β-CD with fenthion 
From the linear portion of a BS-type profile it is possible to calculate the binding constant from 






The binding constant for each repeat of the experiment was calculated and the average binding 
constant was found to be 789 ± 170 M-1. A 5.0-fold increase in the apparent fenthion 
concentration at a β-CD concentration of 4.3 mM was observed. 
  




The profile of the fenthion phase solubility with HPBCD (Figure 4.40) shows AN profile. This 
negative deviation from linearity could be due to several effects. These may be solvent effects 
altering the bulk properties of the media and/or self-association of the cyclodextrin at high 
concentrations.23 
 
Figure 4.40: Representative phase solubility plot for HPBCD with fenthion 
The binding constant for the system could be calculated from Expression 3.5 from the linear 
portion of the plot. The average binding constant was found to be 1863 ± 26 M-1 (n = 2). The 
binding constants of complexes formed with HPBCD are usually in the order of several thousand 
M-1. The maximum solubility enhancement due to HPBCD from all experiments was found to be 
85.9-fold at a HPBCD concentration of 50.2 mM. 
  




The phase solubility of RAMEB with fenthion was found to follow an AP profile. This can be seen 
in Figure 4.41. The positive deviation from linearity suggests the formation of higher order 
complexes at higher cyclodextrin concentration.23 
 
Figure 4.41: Representative phase solubility plot for RAMEB with fenthion 
The binding constant was calculated in a similar manner to that of obtained when using HPBCD 
as host as both systems are of type A. The average binding constant was found to be 
3582 ± 106 M-1. It was found that RAMEB increased the apparent solubility of fenthion 189.7-fold 
at a host concentration of 49.6 mM. 
  




INDUCED CIRCULAR DICHROISM 
Induced circular dichroism experiments were performed at the Universidad Nacional de Córdoba 
over the course of two international exchanges. Two sets of experiments were performed, the 
first with varying concentrations of β-CD to observe changes in the ICD signals due to the 
cyclodextrin concentrations. The second set was performed with α-CD, β-CD, γ-CD, DIMEB, 
TRIMEA and TRIMEB to observe differences in the ICD signals with differing cyclodextrins. 
The experiments with β-CD showed that fenthion and β-CD interact in solution. The nature of the 
interaction was assumed to be between the chromophoric moiety of the fenthion molecule and 
the cyclodextrin cavity. This would indicate that the effect observed in the ICD spectra is a 
negative Cotton effect. A negative Cotton effect implies that the transition dipole of fenthion is 
perpendicularly aligned relative to the axis of symmetry of the cyclodextrin cavity. Variations in 
the absorbance values in the UV-Vis spectra were also observed. These changes further serve to 
confirm an interaction between fenthion and β-cyclodextrin. These changes were erratic and 
therefore modelling the stoichiometric ratio in solution was not possible. As the stoichiometric 
ratio could not be determined it was not possible to confirm the binding constant value between 
β-CD and fenthion obtained from the phase solubility studies using the ICD technique. 
In the experiment performed with the different cyclodextrins it was observed that the ICD profiles 
were similar. This would imply that the mode of interaction is similar across the cyclodextrins 
tested. As in the case of β-cyclodextrin above, it would suggest that there is a negative Cotton 
effect. This indicates that the transition dipole of fenthion is oriented perpendicularly to the axis 
of symmetry of each of the cyclodextrin cavities.  
The differences in the ICD signals with constant fenthion concentration point to a variation in the 
strength of binding between fenthion and the various cyclodextrins. The relative strengths of 
interaction, after normalising for cyclodextrin concentration, were found to be: 
DIMEB > TRIMEA > TRIMEB > β-CD > γ-CD > α-CD 
The same trend has been observed in the complexation of fenitrothion, an analogue of fenthion.3 
The profiles of the ICD signals were similar for α-CD, β-CD, γ-CD and DIMEB, but a different profile 
was observed for TRIMEA and TRIMEB. These different signals would imply that the modes of 
interaction are different for fenthion and fenitrothion with TRIMEA and TRIMEB. In the solid-
state the complexes TRIMEA with fenitrothion and TMAFEN show different modes of inclusion. 
TRIMEA/fenitrothion is a complex with a 2:1 host to guest stoichiometric ratio while that of 
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TMAFEN is 1:1. In the solid-state TMBFEN and TMBFENT are isostructural.4 This indicates that 
the modes of association differ in solution. 
STOICHIOMETRY AND THERMAL ANALYSIS 
The stoichiometries of the BCDFEN and TMAFEN complexes were determined via 1H-NMR 
spectroscopy. The TMBFEN complex stoichiometry was determined by TGA. The BCDFEN 
complex was found to have a 2:1 stoichiometric ratio and the TMAFEN and TMBFEN complexes 
a 1:1 ratio. 
From the TGA profiles it was determined that BCDFEN and TMAFEN both contain water 
molecules in their crystal structure. The initial mass loss (14.1 ± 0.7 %) in the BCDFEN TGA trace 
indicated that the complex contained approximately 24 waters within the asymmetric unit. The 
protracted mass loss (0.5 ± 0.1 %) in the TMAFEN TGA trace was determined to be due to the 
presence of 0.4 ± 0.1 of a water molecule in the structure. The TMBFEN complex did not show the 
presence of any waters of crystallisation in the thermal analysis. 
Fenthion occurs as an oil at room temperature, having a melting point of 7.5 ℃.1 The boiling point 
of fenthion is 90 ℃ and it is a volatile oil with a vapour pressure of 0.37 mPa at 25 ℃.1 The 
inclusion in cyclodextrin hosts enables a solid-state formulation of the pesticide. In the BCDFEN 
and TRIMEA complexes the guest is released only upon decomposition. In TMBFEN the guest is 
released from 122.3 ± 0.9 ℃ to 217.2 ± 0.5 ℃. It is clear that the thermal stability of fenthion is 
greatly improved by inclusion in cyclodextrin host molecules. The improvement of the thermal 
stability and solid formulation would increase the ease of use of the pesticide, as well as 
facilitating the handling of the product. 
CONFORMATIONS OF HOST AND GUEST MOLECULES 
In the BCDFEN complex the primary torsion angles, ω, showed that all but one residue (C6A7) 
point away from the cyclodextrin cavity. The geometric parameters, specifically l, D and ϕ, of the 
BCDFEN complex indicate that the host molecules A and B both maintain a ‘round’ shape. This 
conformation is maintained by the well-known O2n···H-O3(n+1) hydrogen bonding network at 
the secondary rim of the cyclodextrins. The tilt angles, τ2, indicate that the cyclodextrin residues 
tilt inwards at the primary side. The two independent host molecules are approximately parallel, 
with their O4n least-squares planes inclined at an angle of 1.0(3)°. 
The primary methoxy substituents in the TMAFEN complex form a ‘lid’ preventing access from 
this end of the cyclodextrin cavity. This is evident from the torsion angles, ω, where four of the 
groups are directed towards the centre of the cavity while the G3 and G5 substituents are directed 
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outwards. The geometric parameters l, D, and ϕ indicate that the host molecule is slightly 
distorted into an elliptical conformation. Strong steric repulsion between the secondary methyl 
groups in TMAFEN causes the glucopyranose subunits to tilt inwards at the primary end. These 
large tilt angles indicate that the host molecule adopts a ‘bowl’ configuration. 
The torsion angles, ω, of the complex TMBFEN indicate that the primary methoxy groups G3, G5 
and G7 are directed towards the cyclodextrin cavity. These three groups form a ‘lid’ at the primary 
end of the cavity. The remaining four primary methoxy groups are directed outwards from the 
cyclodextrin cavity. The O4n atoms of the host molecule, TRIMEB, adopt a ‘round’ shape and can 
be seen from the geometric parameters l, D and ϕ. The tilt angles, τ2, cover a large range showing 
that the host molecule adopts a bowl-like configuration. The tilt angles of the trihydrate TRIMEB 
structure span a larger range that those of TMBFEN. 
The conformations of the host molecules of TMAFEN and TMBFEN show several similarities. In 
both, the primary ends of the cyclodextrin cavities are closed off by the methoxy substituents. The 
large tilt angles, combined with the primary methoxy groups mean that the hosts have a ‘bowl’ 
conformation. The large tilt angles are required to accommodate the steric interference of the 
methylated secondary substituents. The glucopyranose subunits are able to adopt these large tilt 
angles as there is no stabilisation from the O2n···H-O3(n+1) hydrogen bonding network that is 
present in non-derivatised cyclodextrin hosts. The major differences between TMAFEN and 
TMBFEN occur in the mode of guest inclusion. In TMAFEN, the thioester group of fenthion is 
included in the cyclodextrin cavity. The phosphorothioate moiety extends into the interstitial 
spaces between complex subunits. In TMBFEN the mode of inclusion is reversed: the 
phosphorothioate moiety is in close proximity to the primary end of the cyclodextrin cavity while 
the thioester group extends beyond the secondary rim of the cyclodextrin into the interstitial 
spaces between TRIMEB molecules. 
The BCDFEN inclusion complex has a very different mode of inclusion to that of TMAFEN and 
TMBFEN. In BCDFEN the stoichiometry is two β-CD molecules to one fenthion molecule. The 
fenthion molecule is completely encapsulated within the cyclodextrin dimer. The host molecules 
both maintain their ‘round’, symmetrical shape owing to the stabilising presence of the 
O2n···H-O3(n+1) hydrogen bonding network. These interactions also prevent the glucopyranose 
subunits tilting inwards. 
In two of the inclusion complexes presented here, the fenthion guest is disordered. In BCDFEN 
the guest is partially disordered over two positions, the two components being rotamers. There 
are three common atoms in the structure, namely P11, O13 and C16. The rotamer gives rise to an 
angle of 89.5° between the S14A-P11-S14B atoms in the phosphorothioate groups. In TMAFEN 
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the whole guest molecule is disordered over two positions. The major and minor components 
occupy similar atomic co-ordinates and have the same molecular conformation. 
INTRA- AND INTERMOLECULAR INTERACTIONS 
The three complexes presented here all display various intra- and intermolecular interactions. In 
the case of the BCDFEN complex there are fourteen O2n···H-O3(n+1) hydrogen bond interactions 
that maintain the circular shape of the two cyclodextrin molecules. Between the cyclodextrins in 
the dimer there are four O3An···O3Bn interactions. The dimers interact through sixteen hydrogen 
bonds. Ten of these are O-H···O hydrogen bonds, with nine linking adjacent dimers within a layer 
while the remaining interaction is between layers. There are a further six C-H···O weak hydrogen 
bonds between dimers within layers. 
The complexes TMAFEN and TMBFEN both comprise host molecules that are permethylated 
preventing the formation of classical hydrogen bonds with the hosts. Notably missing is the 
O2n···H-O3(n+1) hydrogen bonding network found in native and partially methylated 
cyclodextrins. The TMAFEN complex has sixteen intramolecular host interactions. These 
interactions are all C-H···O hydrogen bonds with D···A distances ranging from 2.782(4) Å to 
3.152(5) Å. The host molecules interact with one another through similar C-H···O hydrogen 
bonds. The D···A distances for intermolecular host interactions range from 3.315(4) Å to 
3.373(4) Å. TMAFEN has one partially occupied water molecule at the primary rim of the 
cyclodextrin cavity. As the hydrogens could not be modelled the determination of interactions 
was based on close contact distances, of which there are two. The water molecule interacts with 
the O6G2 atom of TRIMEA with a close contact distance of 2.89(2) Å. The second interaction is 
between the water molecule and the minor disorder component of the O6 atom on the G5 residue 
with a close contact distance of 2.86(3) Å. The angle O6G2-O1W-O6G5 is 102.1(7)°, which is close 
to the H-O-H angle (104.5°) present in water. The complex TMBFEN has eighteen intramolecular 
hydrogen bonds, also of the type C-H···O, with donor acceptor distances 
2.801(6) Å ≤ D···A ≤ 3.194(6) Å. The intermolecular host interactions are of the same type and 
there are four such interactions which range from 3.138(8) Å to 3.383(6) Å.  
The fenthion molecules in two of the complexes interact with their hosts through various weak 
molecular interactions. The BCDFEN complex has one weak hydrogen bonding interaction 
between β-CD and fenthion. The complex TMAFEN has two host-guest interactions. The first 
(C5A-H···O2G1) is within the asymmetric unit and the second [C3A-H···O5G2‡ (‡:1+x, y, z)] occurs 
between the fenthion molecule and a TRIMEA molecule in the same column. There are no 
hydrogen bonding interactions between fenthion and the host in the TMBFEN complex. All 
Chapter 4 – Fenthion 
 
 131 
remaining host-guest interactions in all three complexes are hydrophobic interactions, owing to 
the nature of the cyclodextrin cavities. 
CRYSTAL PACKING 
Of the three inclusion complexes presented here, two are isostructural with other known 
complexes. The BCDFEN complex was found to be isostructural with the series S. Lubhelwana 
termed B7.25 This isostructural series has been shown to have the intermediate packing 
arrangement where the β-CD complex dimers are slightly offset along their axis of symmetry. In 
the case of BCDFEN the centroids are offset by approximately 6 Å. The complex TMBFEN 
crystallises in the isostructural series named BD3 by S. Lubhelwana.25 This series is characterised 
by the presence of TRIMEB inclusion complexes packed in anti-parallel head-to-tail columns. 
These columns are in a screw-channel configuration along the a-axis. 
The complex TMAFEN was not found to be isostructural to any known cyclodextrin inclusion 
complex. A comprehensive search of the CSD9 showed that there are 16 TRIMEA inclusion 
complexes, 10 of which crystallise in the space group P21. Nine of these have a similar mode of 
inclusion to that of TMAFEN, but the packing arrangements of the inclusion complexes differ. The 
differences in unit cell dimensions also cover a large range of values significantly different from 
those of the TMAFEN complex. The complex crystallises in the space group P21 in a column-type 
arrangement. These columns are made up of head-to-tail complex units arranged parallel to the 
a-axis. The columns are packed anti-parallel along the b- and c-axes and interact via weak 
hydrogen bonding interactions. The portion of the guest molecule protruding from the 
cyclodextrin cavity is positioned in the interstitial spaces between complex units. 
PHASE SOLUBILITY 
Phase solubility experiments of fenthion with α-CD, β-CD, γ-CD, HPBCD and RAMEB were 
performed. The α-CD and γ-CD systems were not pursued due to precipitation of the complexes 
at low cyclodextrin concentrations. 
The phase solubility experiments with β-CD displayed a BS-type profile, which is characterised by 
a linear increase in apparent guest concentration. This initial increase was followed by a decrease 
in apparent concentration. This is due to the formation of a partially soluble complex that 
increases the apparent solubility of fenthion. Once the maximum concentration of the complex is 
reached addition of further β-CD causes the complex to precipitate. The remaining guest is 
consumed by the addition of any further cyclodextrin, causing further precipitation which 
decreases the apparent concentration of the guest.23 
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The phase solubility profiles of fenthion with HPBCD and RAMEB both displayed A-type solubility. 
The phase solubility with HPBCD exhibits AN behaviour where after an initial linear increase in 
apparent concentration the profile deviates negatively. There are several explanations for this 
deviation including changes due to the solution bulk properties and/or self-association of the 
cyclodextrin at higher concentration.23 In the case of fenthion with RAMEB, the system shows 
AP-type behaviour whereby there is positive deviation from linearity in apparent fenthion 
concentration. This positive deviation suggests the formation of higher order complexes at 
elevated cyclodextrin concentrations. 
The linear portions of the three systems allowed for calculation of binding constants. The values 
were found to be 789 ± 170 M-1, 1863 ± 26 M-1 and 3582 ± 106 M-1 for β-CD, HPBCD and RAMEB 
respectively. The enhancement factors for these three systems showed improvement of the 
apparent solubility of fenthion, which has an experimental intrinsic solubility of 
3.55⨯10-5 mol dm-3. The solubilisation of fenthion with β-CD was 5.0-fold at 4.3 mM cyclodextrin 
concentration. The increase in apparent fenthion concentration with HPBCD and RAMEB were 
were 85.9-fold and 189.7-fold at 50.2 mM and 49.6 mM respectively. 
CONCLUSION 
Both native and derivatised cyclodextrins have been shown capable of including the 
organothiophosphate pesticide fenthion, both in solution and in the solid state. Inclusion of this 
pesticide has allowed the formulation of a solid-state product. The thermal stability of fenthion 
was also greatly improved via cyclodextrin inclusion. The complex TMBFEN was shown to have 
an energy barrier that prevents the loss of fenthion.5 The energy barrier is such that guest loss 
would not occur under normal transport thermal conditions. These factors combined allow one 
to conclude that use of this pesticide would be both safer and easier when it is included in 
cyclodextrin host molecules. The solubilisation of fenthion with the cyclodextrins β-CD, HPBCD 
and RAMEB show promise for an aqueous formulation of the pesticide, eliminating the need for 
organic solvents. 
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CHAPTER 5 –  ACIPIMOX 
This chapter is focused on the formation of multi-component crystalline systems with the 
antihyperlipidemic agent acipimox. Acipimox is used as an additional treatment in type IIb and 








The supramolecular modification of acipimox was investigated through the creation and 
physicochemical characterisation of multi-component molecular crystalline systems. Many 
attempts were made with various Generally Recognised as Safe (GRAS) co-former compounds to 
form co-crystals and other multi-component crystals. Successful multi-component crystalline 
systems were obtained with only six of these, in the forms of salts, co-crystals and solvates. 
Screening experiments included dry grinding, liquid-assisted grinding and co-precipitation with 
acipimox, a GRAS co-former compound and different solvents. Once a successful 
multi-component crystal was obtained the synthetic procedure was optimised to reproducibly 
obtain the desired product. 
Presented in this chapter are successful attempts at creating multi-component crystalline 
systems. The co-formers successfully employed were 4-aminobenzamide, 4-aminopyridine, 
benzamide, isonicotinamide, tranexamic acid and urea. A full list of co-formers used in attempts 
to form multi-component crystalline systems is available in Appendix D. 
  




The multi-component crystalline system comprising acipimox and 4-aminobenzamide will be 
referred to as ACPABEN. 
SAMPLE PREPARATION 
ACPABEN was prepared by both liquid-assisted grinding and co-precipitation. Liquid-assisted 
grinding was performed by weighing out 10 mg acipimox (0.065 mmol) and 9 mg (0.065 mmol) 
4-aminobenzamide. The components were combined in an agate mortar. This mixture was 
ground together using an agate pestle, with the dropwise addition of isopropanol, for 20 minutes.  
To prepare the co-crystal via co-precipitation, acipimox (10 mg, 0.065 mmol) was dissolved in 
3 cm3 butan-1-ol. The co-former 4-aminobenzamide (9 mg, 0.065 mmol) was added to this 
solution and the resulting mixture was stirred at 50 ℃ for 3 to 4 hours. The resulting solution was 
then filtered through a 0.45 μm nylon filter into a clean vial and sealed with Parafilm™. The vial 
was placed on the benchtop to form crystals by slow evaporation. After several days small 
needle-shaped crystals were observed. 
In attempting to form this co-crystal via co-precipitation several alcohols were tested as solvents 
(methanol, ethanol, propan-1-ol, isopropanol and butan-1-ol). These were all successful in 
forming the desired product. However, only butan-1-ol gave rise to the single crystals required 
for analysis. Therefore, all analyses were performed on products obtained from butan-1-ol. 
  




The stoichiometry of ACPABEN was confirmed using 1H-NMR spectroscopy. Crystals obtained 
from co-precipitation were dissolved in DMSO-d6 and analysed using 1H-NMR spectroscopy. The 
relative integration of the acipimox methyl peak (C-H11a,b,c), set as the reference integral, and the 
4-aminobenzamide aromatic peaks showed a stoichiometric ratio of 1:1. The proton labelling 
scheme of each component of the system is shown in Figure 5.1. The integration values and the 
spectrum are presented below in Table 5.1 and Figure 5.2 respectively. 
 
 
Figure 5.1: Proton labelling of acipimox (left) and 4-aminobenzamide (right) 
Table 5.1: Integrals and assignment of component protons used for stoichiometric determination 
Proton δ (ppm) 
Integration Experimental/ 
Theoretical Experimental Theoretical 
Acipimox 
C-H11a,b,c 2.42 3.00‡ 3.00 1 
C-H2 8.69 1.01 1 1.01 ≈ 1 
C-H5 8.76 1.01 1 1.01 ≈ 1 
4-aminobenzamide 
C-H13 + C-H17 6.56 2.05 2 1.03 ≈ 1 
C-H14 + C-H16 7.61 2.08 2 1.04 ≈ 1 
‡Reference Integral 




Figure 5.2: 1H-NMR spectrum of ACPABEN in DMSO-d6 used to determine the stoichiometric ratio 
  




The thermal analysis of ACPABEN, presented in Figure 5.3, shows that there are no solvent 
molecules present in the structure. Upon melting at 201.1 ± 0.1 ℃ (n = 2) a mass loss of 
52.8 ± 0.7 % (n = 2) occurs, followed immediately by a second mass loss of 41.0 ± 0.5 %. The first 
mass loss corresponds to the loss of acipimox (calculated mass loss 53.1 %), while the second is 
the decomposition of the 4-aminobenzamide component. The DSC trace shows the melting 
endotherm with no significant heat flow event following. This would indicate that the loss of 
acipimox and decomposition occur simultaneously with the melting of the co-crystal. 
The HSM micrographs (Figure 5.4) provide further evidence for the interpretation of the thermal 
analysis results. In the micrograph taken at 201 ℃, the loss of acipimox is seen in the bubbling. 
The melting at the edges of crystals, combined with the visible bubbling, confirms the 
interpretation of simultaneous melting and decomposition. The final micrograph shows the 
decomposed product. 
 
Figure 5.3: Representative TGA (blue) and DSC (orange) traces for ACPABEN 
 
Figure 5.4: Hot stage micrographs showing the ACPABEN crystals at various stages of heating  
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CRYSTAL STRUCTURE ANALYSIS 
DATA COLLECTION AND SPACE GROUP DETERMINATION 
Crystal intensity data were collected using a Nonius KappaCCD diffractometer. The program 
LAYER2 was used to determine the crystal system and space group of the co-crystal. The crystal 
system was established as triclinic from the observed Laue symmetry1. The computer program 
XPREP3 was used to determine the space group P1. The program calculated an |E2-1| value of 
1.101, which indicated centrosymmetry.3 The data collection was performed at 173 ± 2 K. 
STRUCTURE SOLUTION AND REFINEMENT 
The software program DENZO4 was used for unit cell refinement and data reduction. The 
asymmetric unit of ACPABEN comprises one acipimox molecule and one 4-aminobenzamide 
molecule. The atomic positions were determined using SHELXS, employing direct methods.5 The 
atoms were placed at these positions and refined using SHELXL.5,6 All the non-hydrogen atoms 
were refined isotropically initially and subsequently anisotropically. The positions of hydrogen 
atoms were determined from the difference Fourier map and the position of the carboxylic acid 
proton was found on the acipimox moiety. It was also found that the distinctly different carboxylic 
bond lengths supported the placement of this atom with C-O bond length values of 1.216(2) Å and 
1.302(2) Å. These values are consistent with carboxylic acid bond lengths. No additional proton 
was located on the amine moiety of 4-aminobenzamide. The two components were present in 
their neutral state, so the system ACPABEN was therefore designated a co-crystal. Once the 
determination of the hydrogen atoms was completed they were placed in idealised positions 
using a riding model with a Uiso value 1.2 – 1.5 times that of the parent atom. The crystallographic 
data and refinement parameters for ACPABEN are presented in Table 5.2. 
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Table 5.2: Crystallographic data for the single crystal X-ray structure of ACPABEN 
Chemical Formula C6H6N2O3·C7H8N2O 
Molar mass (g mol-1) 290.28 
Crystal System Triclinic 
Space Group P1 
Unit cell parameters  
a (Å) 6.9367(3) 
b (Å) 6.9835(3) 
c (Å) 14.7422(9) 
α (°) 89.607(2) 
β (°) 81.704(3) 
γ (°) 63.317(3) 
Volume (Å3) 630.06(6) 
Z 2 
Densitycalcd. (g cm-3) 1.556 
μ [MoKα] (mm-1) 0.118 
F (000) 304 
Temperature (K) 173(2) 
Crystal size (mm) 0.31⨯0.16⨯0.07 
Range scanned θ (°) 1.40 – 28.28 
Index ranges h: -9, 9; k: -9, 9; l: -19, 19 
ϕ and ω scan angles (°) 1.0 
Dx (mm) 45 
Total number of reflections 6 085 
Number of independent reflections 3 106 
Number of reflections with I > 2σ(I) 2 251 
Rint 0.0450 
R1 [I > 2σ(I)] 0.0554 
wR2 0.1200 
S 1.052 
Number of parameters 195 
Number of reflections omitted 16 
Parameters a, b  
in w = 1/[σ2(FO2)+(aP)2+(bP)] 
a = 0.0764; b = 0.1011 
(δ/σ)mean <0.001 
Δρ excursions (e Å-3) -0.34; 0.40 
  




The ACPABEN asymmetric unit (Figure 5.5) consists of one acipimox molecule and one 
4-aminobenzamide molecule. These two components are hydrogen bonded through the 
supramolecular synthon between the acipimox carboxylic acid and the 4-aminobenzamide amide 
group. 
 
Figure 5.5: The asymmetric unit of the co-crystal ACPABEN with numbering scheme of acipimox 
(left) and 4-aminobenzamide (right). Thermal ellipsoids are drawn at the 50 % probability level 
HYDROGEN BONDING 
Both components are present in their neutral state. Within this crystal structure there are two 
hydrogen bonding synthons, shown in Figure 5.6. One is the carboxylic acid – amide synthon 
characterised by the R2
2(8) ring. The second hydrogen bond is that between the pyrazine oxide 
group of acipimox and the primary amine of 4-aminobenzamide. When these two hydrogen 
bonding synthons are combined an infinite ribbon is formed, denoted as a C(15) chain. Thus the 
hydrogen bonding network, N, can be denoted by the graph set notation N = C(15) R2
2(8). The 
infinite ribbons are shown in Figure 5.7. 
The infinite ribbons interact with adjacent ribbons via three C-H···O hydrogen bonds which aid 
in stabilising the overall structure of the co-crystal. The hydrogen bonding parameters are 
presented in Table 5.3. As the hydrogen atoms are placed in geometrically idealised positions, the 
values of the D-H and H···A distances are omitted. The idealised positions of the hydrogen atoms 
mean that e.s.d. values are not available for the hydrogen bond angles. This applies to all crystal 
structure analyses reported in this chapter. There is one intramolecular interaction, C2-H···O8, 
which occurs in the acipimox molecule. 




Figure 5.6: Hydrogen bonding motifs showing the carboxylic acid – amide synthon (left) and the 
pyrazine oxide – amine (right) synthons 
Table 5.3: Hydrogen bonding parameters for hydrogen bonds in ACPABEN 
Hydrogen 
Bond Label 
D-H···A D···A (Å) Angle (°) 
Symmetry 
Operator 
1 O9-H···O19 2.529(2) 172 (x, y, z) 
2 N20-H···O8 2.792(2) 164 (x, y, z) 
3 N21-H···O10 2.935(2) 143 (1+x, y, -1+z) 
4 C2-H···O8 2.663(2) 100 (x, y, z) 
5 C5-H···O8 3.186(2) 139 (1+x, y, z) 
6 C11-H···O10 3.465(2) 158 (1-x, 2-y, 2-z) 
7 C17-H···O9 3.400(2) 166 (1+x, y, z) 
 
 
Figure 5.7: Infinite ribbons formed by the hydrogen bonding network N1 = C(15) 𝑅2
2(8) linked by 
C-H···O hydrogen bonds (5, 7). The intramolecular hydrogen bonds labelled 4 and 6 in Table 5.3 
have been omitted for clarity  




As described in the section above, the pair comprising acipimox and 4-aminobenzmide of the 
asymmetric unit link through a hydrogen bond to form infinite ribbons which propagate 
horizontally in Figure 5.7. These ribbons are hydrogen bonded to one another by the 
intermolecular C-H···O weak hydrogen bonds to form layers. The layers interact through π-π 
stacking interactions between the aromatic ring of acipimox and that of 4-aminobenzamide with 
centroid-to-centroid distances less than 5 Å.7 Relevant data are presented in Table 5.4. The 
centroids of the aromatic rings are offset by approximately 1.6 Å and the angle of intersection 
between the aromatic least-squares planes is 1.83(6)° in both interactions.  
Table 5.4: π-π interaction parameters 
Ring Interaction Centroid Distance (Å) Symmetry Operator 
Cg(A)···Cg(B) 3.719(1) (-x, 2-y, 1-z) 
Cg(A)···Cg(B) 3.604(1) (1-x, 1-y, 1-z) 
Cg refers to the centroid of a ring and the symmetry operator in column 3 refers to the second Cg listed in column 1 
Ring A: C1-C2-N3-C4-C5-N6 
Ring B: C12-C13-C14-C15-C16-C17 
The crystal packing can be seen in Figure 5.8 where the layers formed through π - π stacking are 
clearly visible. 
 
Figure 5.8: Packing of the ACPABEN co-crystal viewed along [1 0 0] highlighting the layers formed 
through π - π stacking 
  




The experimental PXRD pattern of the bulk samples of ACPABEN shows good agreement with the 
pattern calculated from the refined single crystal structure of the co-crystal. Cooling the crystal 
for intensity data collection results in anisotropic contraction of the unit cell. As the bulk sample 
PXRD pattern was collected at room temperature this results in slight differences in the angular 
positions of the peaks. 
 
Figure 5.9: The PXRD trace recorded for the bulk sample (blue) and the computed PXRD pattern 
based on the single crystal X-ray structure of ACPABEN (orange) 
  




The refined single crystal structure of ACPABEN showed the position of the carboxylic acid proton 
on the acipimox molecule. As no proton transfer took place, ACPABEN was designated a 
co-crystal. Infrared spectroscopy was performed to determine whether the spectrum of 
ACPABEN was in accordance with this designation. By close inspection of characteristic peaks, 
the presence of relevant functional groups could be observed. A second purpose of recording FTIR 
spectra was to investigate the use of infrared spectroscopy as a rapid identification method for 
the co-crystal. This was done by observation of characteristic absorption peaks as well as direct 
comparison with the API and co-former spectra. 
The infrared spectrum of ACPABEN (Figure 5.10) shows a signal characteristic of a carboxylic 
acid carbonyl peak at 1685 cm-1. A second characteristic peak distinctive of carboxylic acids, the 
C-O stretching peak, at 1274 cm-1, was also observed in the FTIR spectrum. The presence of these 
peaks indicates that no proton transfer took place from the carboxylic acid of acipimox during the 
formation of ACPABEN. This supports the designation of this crystalline system as a co-crystal. 
A second purpose of using FTIR spectroscopy was to investigate this technique as a possible 
means of rapid identification of the co-crystal ACPABEN in future batches of the material. The 
peaks present at 3408 cm-1 and 3449 cm-1 are indicative of the presence of an O-H group (as part 
of a carboxylic acid moiety) and a hydrogen bonded primary amine. It was not possible to 
unambiguously assign these peaks, as the absorption peaks for these functional groups are 
known to occur in the same region. 
The comparison of the co-crystal spectrum with the spectra of the starting materials could also 
be used to confirm the formation of a new phase. Differences in signal positions of functional 
groups in the component and multi-component system spectra will serve to identify a new phase. 
A shift in the position of the carbonyl carboxylic acid peak from 1701 cm-1 in the acipimox 
spectrum to 1685 cm-1 in that of ACPABEN is observed. A similar shift is seen for the N-H signal 
at 3462 cm-1 in the 4-aminobenzamide spectrum to either 3449 cm-1 or 3408 cm-1 in the 
ACPABEN spectrum. Through intermolecular interactions between the components the profile of 
the spectrum of the co-crystal differs significantly from those of the starting materials. Therefore, 
by comparison one can establish unequivocally the formation of a new phase. 




Figure 5.10: FTIR spectra for ACPABEN (blue), acipimox (orange) and 4-aminobenzamide (grey)  




The multi-component crystalline system of acipimox with 4-aminopyridine has been assigned the 
codename ACPAPYR. 
SAMPLE PREPARATION 
The ACPAPYR crystalline system was produced in three ways: two methods rely on 
mechanochemical action, while the third is production via co-precipitation. 
Dry grinding and liquid-assisted grinding were the mechanochemical methods employed. Dry 
grinding was performed by weighing equimolar quantities of acipimox (10 mg, 0.065 mmol) and 
4-aminopyridine (6 mg, 0.065 mmol). These were combined in an agate mortar and ground 
together using an agate pestle for 10 minutes. Liquid-assisted grinding was performed employing 
the same procedure with the additional step of dropwise addition of isopropanol. 
Co-precipitation of ACPAPYR involved dissolving acipimox (10 mg, 0.065 mmol) in 5 cm3 
propan-1-ol and adding an equimolar quantity of 4-aminopyridine (6 mg, 0.065 mmol) to the 
solution. The resulting mixture was stirred for 2 to 4 hours at 60 ℃ and then filtered through a 
0.45 μm nylon filter into a clean vial. The vial was sealed using Parafilm™ pierced with several 
holes and allowed to stand on the benchtop to form crystals via slow evaporation. Over the course 
of several days plate-shaped crystals were observed. The precipitate obtained before filtration 
was found to be the desired product in powder form. 
  




The stoichiometry of ACPAPYR was determined using 1H-NMR spectroscopy. The plate-like 
crystals obtained from co-precipitation were dissolved in DMSO-d6 and subjected to 1H-NMR 
spectroscopy. The relative integration of the methyl group of acipimox (set as the reference 
integral) and the 4-aminopyridine aromatic peaks served to determine a 1:1 stoichiometric ratio. 
The proton labelling schemes of the two components are shown in Figure 5.11. The integration 
values and 1H-NMR spectrum are presented in Table 5.5 and Figure 5.12 respectively. 
 
Figure 5.11: Proton labelling of acipimox (left) and 4-aminopyridine (right) 
 
Table 5.5: Integrals and assignment of component protons for stoichiometric determination 
Proton δ (ppm) 
Integration Experimental/ 
Theoretical Experimental Theoretical 
Acipimox 
C-H11a,b,c 2.38 3.00‡ 3.00 1 
C-H2 8.55 0.99 1.00 0.99 ≈ 1 
C-H5 8.63 0.98 1.00 0.98 ≈ 1 
4-aminopyridine 
C-H13 + C-H17 6.78 2.02 2.00 1.01 ≈ 1 
C-H14 + C-H16 8.16 2.03 2.00 1.02 ≈ 1 
‡ Reference integral 




Figure 5.12: 1H-NMR spectrum of ACPAPYR in DMSO-d6 used to determine the stoichiometric ratio 
  




Two thermal events present in the DSC trace (Figure 5.13) of ACPAPYR were observed. The first 
was a small endotherm at 219.4 ± 0.5 ℃ (n = 2) corresponding to a possible phase change. This is 
followed by a large endotherm at 246.2 ± 0.9 ℃ resulting from simultaneous melting and 
decomposition. This coincides with a large mass loss in the TGA trace (Figure 5.13) with an onset 
temperature of 233.5 ± 1.2 ℃ (n = 2). The beginning stages of the decomposition can be seen in 
the HSM micrograph at 225 ℃ (Figure 5.14). The micrograph at 250 ℃ shows the product 
undergoing rapid and complete decomposition. 
 
Figure 5.13: Representative TGA (blue) and DSC (orange) traces for ACPAPYR 
 
Figure 5.14: Hot stage micrographs showing the ACPAPYR co-crystal at various stages of heating 
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CRYSTAL STRUCTURE ANALYSIS 
The asymmetric unit of ACPAPYR comprises two acipimox moieties and two 4-aminopyridine 
moieties.  
DATA COLLECTION AND SPACE GROUP DETERMINATION 
Intensity data were collected using a Bruker KAPPA APEX DUO II diffractometer. The X-ray 
diffraction pattern was determined to have Laue symmetry1, indicating the triclinic crystal 
system. The program XPREP3 was used to determine the space group and the |E2-1| value of 1.093 
indicated centrosymmetry. The only option was therefore P1. The crystal exhibited twinning 
with a BASF factor of 0.40, determined using program Cell_now.8 The second domain was rotated 
relative to the first by 178.4° and the approximate twin law applied to convert the data was 
(-1.000 ~0 ~0)(~0 ~1 ~0)(~0 ~0 1.000) The computer program TWINABS9 was used to scale 
the data and for absorption correction. The BASF value refined to 0.322(2) over the course of the 
structure refinement. The data collection was performed at 173(2) K. 
STRUCTURE SOLUTION AND REFINEMENT 
The program SAINT10 was used for unit cell refinement and data reduction. The atomic 
co-ordinates of the atoms comprising the asymmetric unit were determined using direct methods 
employed by the program SHELXS.5 Once the atoms were placed in these presumed positions the 
latter were refined using SHELXL.5,6 After several refinement cycles, the HKLF 5 file generated by 
the program TWINABS was used in subsequent refinement cycles. The non-hydrogen atoms were 
initially refined isotropically and later anisotropically. The location of the hydrogen atom on the 
acipimox or 4-aminopyridine moieties was investigated to determine the occurrence of a proton 
transfer. The location of the hydrogen atom was observed to be on the pyridyl nitrogen atom of 
the 4-aminopyridine moieties from the Fourier difference map. No carboxylate proton was 
observed on acipimox. The placement of the hydrogen atom was supported by the similarity in 
the C-O bond lengths of the acipimox carboxylate functional groups. The values for the first 
acipimox component were 1.240(2) Å and 1.262(2) Å while the values for the second component 
were 1.242(2) Å and 1.261(2) Å. These bonds are of length intermediate between single and 
double bonds. The locations of the hydrogen atoms, with the similarities and values of the bond 
lengths, indicated unambiguously that the compound is a salt. Once all hydrogen atoms were 
revealed in the difference Fourier map they were placed in geometrically idealised positions 
using a riding model, where the Uiso values were 1.2 – 1.5 times that of the parent atom. The 
crystallographic data are presented in Table 5.6. 
Due to the twinning problem, a data collection strategy was required where only a hemisphere of 
the data was collected, leading to zero redundancy. Therefore, the Rint value is reported as zero in 
the cif file. Nevertheless, the solution of the structure is considered of good quality as seen from 
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the reported R1 and S values of 0.0441 and 1.048 in Table 5.6. The high level of precision (C-C 
bond precision 0.0023 Å) further supports the quality of the structure solution. 
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Table 5.6: Crystallographic data for the single crystal X-ray structure of ACPAPYR 
Chemical Formula (C6H5N2O3)-·(C5H7N2)+ 
Molar mass (g mol-1) 248.25 
Crystal System Triclinic 
Space Group P1 
Unit cell parameters  
a (Å) 7.3957(15) 
b (Å) 11.620(2) 
c (Å) 13.020(3) 
α (°) 86.51(3) 
β (°) 84.62(3) 
γ (°) 87.84(3) 
Volume (Å3) 1111.3(4) 
Z 4 
Densitycalcd. (g cm-3) 1.484 
μ [MoKα] (mm-1) 0.112 
F (000) 520 
Temperature (K) 173(2) 
Crystal size (mm) 0.17⨯0.32⨯0.47 
Range scanned θ (°) 1.60 – 28.4 
Index ranges h: -9, 9; k: -15, 15; l: 0, 17 
ϕ and ω scan angles (°) 0.50 
Total number of frames 2085 
Dx (mm) 79.8 
Total number of reflections 5 444 
Number of independent reflections 5 447 
Number of reflections with I > 2σ(I) 4 221 
Rint 0.000 
R1 [I > 2σ(I)] 0.0441 
wR2 0.1153 
S 1.048 
Number of parameters 352 
Number of reflections omitted 4 
Parameters a, b  
in w = 1/[σ2(FO2)+(aP)2+(bP)] 
a = 0.0581; b = 0.1913 
(δ/σ)mean <0.001 
Δρ excursions (e Å-3) -0.24; 0.36 
  




The asymmetric unit of ACPAPYR, shown in Figure 5.15, comprises two crystallographically 
independent hydrogen bonded units. These units are each made up of one acipimox anion and 
one 4-aminopyridine cation. Each independent ion is designated the suffix A or B. The two 
components are present in their charged forms. Each acipimox moiety contains a carboxylate 
group and each 4-aminopyridine counterion has a protonated pyridyl group. The interactions 
present in this structure will be described in detail below in the section on Hydrogen Bonding. 
 
Figure 5.15: The asymmetric unit of the salt ACPAPYR with numbering schemes of acipimox (right) 
and 4-aminopyridine (left). Thermal ellipsoids are drawn at the 50 % probability level 
  




The multi-component crystalline system ACPAPYR has three hydrogen bonding synthons. The 
first, shown in Figure 5.16a., is the pyridyl-carboxylate synthon between acipimox and 
4-aminopyridine. The second is a bifurcated hydrogen bond with a hydrogen atom of the amine 
group of 4-aminopyridine as a donor and the pyrazine nitrogen and a carboxylate oxygen of 
acipimox being acceptors (Figure 5.16b.). Finally the remaining nitrogen of the amine group of 
4-aminopyridine participates in a hydrogen bond with the pyrazine oxide moiety of acipimox, as 
shown in Figure 5.16c. 
 
Figure 5.16: Hydrogen bonding synthons present in the ACPAPYR crystal structure 
The combination of these hydrogen bonds results in six patterns that link to create an infinite 
sheet. The first and second patterns have the same connectivity, but are crystallographically 
independent, N1 = R2
2(7) and N2 = R2
2(7) (Figure 5.17a.). Similarly, the third and fourth patterns, 
N3 and N4, while crystallographically independent, have the same connectivity, producing R1
2(5) 
rings. Finally the patterns N5 = R6
5(28) and N6 = R6
5(28) are similarly rings with the same 
connectivity which are crystallographically independent. These six rings are concatenated, 
sharing common molecular ions, and form infinite sheets that can be seen in Figure 5.17. The 
hydrogen bonds involved in these patterns are shown in Table 5.7. Two hydrogen bonds, 
C11A-H···O10A‡ (‡:1-x, 1-y, 1-z) and C11B-H···O10B‡ (‡:-x, 2-y, -z), aid in stabilising the packing of 
these infinite sheets into layers. 
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Table 5.7: Hydrogen bonding interactions present in ACPAPYR 
Hydrogen 
Bond Label 
D-H···A D···A (Å) Angle (°) 
Symmetry 
Operator 
1 N15A-H···O9A 2.631(2) 176 (x, y, 1+z) 
2 N15B-H···O9B 2.637(2) 177 (x, y, z) 
3 N18A-H···O10A 2.891(2) 158 (x, y, z) 
4 N18A-H···O8B 2.966(2) 153 (1+x, -1+y, z) 
5 N18A-H···N6B 3.072(2) 129 (1+x, -1+y, z) 
6 N18B-H···O8A 3.003(2) 152 (x, y, 1+z) 
7 N18B-H···N6A 3.048(2) 130 (x, y, 1+z) 
8 N18B-H···O10B 2.884(2) 153 (x, y, 1+z) 
9 C2B-H···O9B 2.727(2) 100 (x, y, z) 
10 C11A-H···O10A 3.482(2) 165 (1-x, 1-y, 1-z) 
11 C11A-H···O9B 3.548(2) 171 (x, y, z) 
12 C11B-H···O10B 3.487(2) 160 (-x, 2-y, -z) 
13 C14A-H···O8A 3.179(2) 126 (x, y, 1+z) 
14 C14B-H···O8B 3.207(2) 126 (x, y, z) 
15 C17A-H···O8B 3.190(2) 138 (1+x, -1+y, 1+z) 
16 C17B-H···O8A 3.215(2) 138 (x, y, 1+z) 
 




Figure 5.17: Figures showing a. interconnected hydrogen bonding patterns N1, N2, N3, N4, N5 and N6 
in the salt ACPAPYR and b. hydrogen bonds involved within the layers (The hydrogen bonds 
labelled 9, 10, 11, 12, 15 and 16 in Table 5.7 have been omitted for clarity) 
  




The packing of the crystal structure ACPAPYR is formed by layers of concatenated N1, N2, N3, N4 
N5 and N6 hydrogen bonding patterns. The layers stack along the a-axis and interact via two 
C-H···O hydrogen bonds and π-π stacking. The two hydrogen bonds are C11A-H···O10A‡ 
(‡:1-x, 1-y, 1-z) and C11B-H···O10B‡ (‡:-x, 2-y, -z). The π-π stacking takes place between the 
aromatic rings of acipimox ions and 4-aminopyridine ions. The least-squares planes through the 
aromatic rings intersect at an angle of 1.6(1)° for the Cg(A)···Cg(C) interactions and 1.8(1)° for the 
Cg(B)···Cg(D) interactions. The centroids of the aromatic rings are offset by approximately 1.7 Å 
in each of the four interactions. The data relevant to the π-π stacking are presented in Table 5.8. 
The close packing of the layers is clearly visible in the diagram shown in Figure 5.18. 





Cg(A)···Cg(C) 3.752(1) (1-x, 1-y, 1-z) 
Cg(A)···Cg(C) 3.781(1) (2-x, 1-y, 1-z) 
Cg(B)···Cg(D) 3.793(1) (-x, 2-y, 1-z) 
Cg(B)···Cg(D) 3.609(1) (1-x, 2-y, 1-z) 
Cg refers to the centroid of a ring and the symmetry operator in column 3 refers to the second Cg listed in column 1 
Ring A: C1A-C2A-N3A-C4A-C5A-N6A 
Ring B: C1B-C2B-N3B-C4B-C5B-N6B 
Ring C: C12A-C13A-C14A-N15A-C16A-C17A 
Ring D: C12B-C13B-C14B-N15B-C16B-C17B 
 
Figure 5.18: Packing of ACPAPYR viewed along [0 -1 0] illustrating the layers formed through π-π 
stacking and C-H···O interactions  




The PXRD pattern of the bulk material was recorded and compared to the pattern calculated from 
the refined single crystal data of ACPAPYR. The two patterns show good agreement; however, 
there are slight differences in the angular positions of peaks between the traces. This is due to the 
single crystal intensity data having been collected at 173(2) K while the PXRD trace was collected 
at room temperature. When cooling the crystal for single crystal intensity data, the unit cell 
parameters undergo contraction and/or expansion, which in turn affects the peak positions of the 
calculated PXRD trace. 
 
Figure 5.19: The PXRD trace recorded for the bulk sample (blue) and the computed PXRD pattern 
based on the single crystal X-ray structure of ACPAPYR (orange) 
  




The position of the proton on the pyridyl nitrogen of 4-aminopyridine was directly observed in 
an electron-density map during single crystal X-ray analysis of the structure of ACPAPYR. The 
carboxylic acid proton of acipimox was not present in the structure. This showed that a proton 
transfer took place during the formation of ACPAPYR, so this crystalline system was designated a 
salt. Infrared spectroscopy was carried out to determine if the spectrum of ACPAPYR reflected 
this designation. The presence of relevant functional groups was confirmed by close inspection 
of the spectrum. Infrared spectroscopy was also used to explore the use of FTIR as a rapid method 
for identification of the salt. This was done by the observation of characteristic peaks, as well as 
comparing the spectra of the salt, API and co-former. 
Two signals characteristic of carboxylate anions were observed in the FTIR spectrum of ACPAPYR 
(Figure 5.20) at 1583 cm-1 and 1358 cm-1. A slight overlap of the symmetrical stretching peak of 
the carboxylate ion (1583 cm-1) and the N-H bend (1649 cm-1) of the primary amine of the 
4-aminopyridine counterion was observed, but these are distinct enough for the proposed 
interpretation. The presence of the carboxylate anion absorption peaks indicates the occurrence 
of a proton transfer, which supports the designation of ACPAPYR as a salt. 
Several characteristic peaks are present in the new spectrum, notably the primary amine bend 
peak at 1649 cm-1 and the carboxylate absorption peaks at 1583 cm-1 and 1358 cm-1. Another 
sharp peak at 3371 cm-1 and a broad peak from 3052 cm-1 to 3224 cm-1 indicative of hydrogen 
bonded amine groups could serve to aid in the identification of ACPAPYR via FTIR spectroscopy. 
By direct comparison of the spectrum of ACPAPYR with those of acipimox and 4-aminopyridine 
it is clear that a new product has been obtained from these starting materials. The intermolecular 
interactions between the components give rise to significant differences between the spectra; for 
example, the disappearance of the carbonyl peak (1701 cm-1) and O-H signal (3554 cm-1) in the 
acipimox spectrum and the shift in the primary amine group of 4-aminoyridine (3435 cm-1). 
Therefore, through comparison of the spectra one can unequivocally establish the presence of a 
new phase and use the spectrum of the product as a reference for identifying the salt ACPAPYR.   




Figure 5.20: FTIR spectra for ACPAPYR (blue), acipimox (orange) and 4-aminopyridine (grey)  




This multi-component crystalline system has been designated the code name ACPAPYR-W. 
SAMPLE PREPARATION 
This product was prepared via co-precipitation. Co-precipitation of ACPAPYR-W was performed 
by dissolving acipimox (10 mg, 0.065 mmol) in 3 cm3 propan-1-ol and adding an equimolar 
quantity of 4-aminopyridine (6 mg, 0.065 mmol). The resulting mixture was stirred for 2 to 4 
hours at 60 ℃. A drop of water was added to solubilise the remaining suspension and the 
resulting solution was then filtered through a 0.45 μm nylon filter into a clean vial. The vial was 
sealed with Parafilm™ pierced with several holes and allowed to stand on the benchtop to form 
crystals via slow evaporation. Over the course of several days large needle-shaped crystals were 
observed. 
STOICHIOMETRY 
The stoichiometry of the product was determined using 1H-NMR spectroscopy. The 
needle-shaped crystals obtained from co-precipitation were dissolved in DMSO-d6 and subjected 
to 1H-NMR spectroscopy. The integration of the acipimox methyl protons were used as the 
reference integral. Integration of this peak and the 4-aminopyridine peaks were used to 
determine a 1:1 stoichiometric ratio. The proton labelling schemes of the two components are 
shown in Figure 5.21. The integration values and spectrum are presented in Table 5.9 and 
Figure 5.22 respectively. 
 
Figure 5.21: Proton labelling of acipimox (left) and 4-aminopyridine (right) 
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Table 5.9: Integrals and assignment of component protons for stoichiometric determination 
Proton δ (ppm) 
Integration Experimental/ 
Theoretical Experimental Theoretical 
Acipimox 
C-H11a,b,c 2.38 3.00‡ 3.00 1 
C-H2 8.54 1.02 1 1.02 ≈ 1 
C-H5 8.62 1.05 1 1.05 ≈ 1 
4-aminopyridine 
C-H13 + C-H17 6.76 2.18 2 1.09 ≈ 1 
C-H14 + C-H16 8.15 2.17 2 1.09 ≈ 1 
‡ Reference integral 
 
Figure 5.22: 1H-NMR spectrum of ACPAPYR-W in DMSO-d6 used to determine the stoichiometric 
ratio of the organic components 
  




The TGA profile of ACPAPYR-W shows two mass losses. The first, a mass loss of 11.7 ± 0.1 % 
(n = 2), equates to the loss of two water molecules per formula unit (calculated = 12.7 %). A broad 
endotherm characteristic of solvent loss is observed in the DSC trace over the same temperature 
range as the loss of the two water molecules. The second, larger mass loss corresponds to the 
decomposition of the multi-component crystal. The decomposition occurs simultaneously with 
melting at 249.2 ± 0.1 ℃ (n = 2), as is evident from the overlay of the DSC and TGA traces 
(Figure 5.23). A smaller endotherm at 206.9 ± 0.7 ℃ was observed in the DSC trace, attributable 
to a phase change of the dehydrated material. The HSM micrograph (Figure 5.24) at 108 ℃ shows 
the loss of the water molecules through bubbling. The decomposition of the resulting system can 
be seen in the micrograph at 245 ℃. 
 
Figure 5.23: Representative TGA (blue) and DSC (orange) traces for ACPAPYR-W 




Figure 5.24: Hot stage micrographs showing the ACPAPYR-W crystals at various stages of heating 
The removal of water from ACPAPYR-W results in the anhydrous salt ACPAPYR, confirmed from 
the PXRD trace of the dehydrated material. This conversion was not pursued in detail.  
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CRYSTAL STRUCTURE ANALYSIS   
DATA COLLECTION AND SPACE GROUP DETERMINATION 
The crystal intensity data were collected at 173 ± 2 K on a BRUKER APEX II Duo diffractometer. 
The Laue symmetry was found to be 2/m indicating that the crystal system is monoclinic. The 
space group was determined to be P21/c by examination of the systematic absences. The 
conditions limiting reflections to determine the assignment were hkl: none; h0l: l = 2n; 0k0, k = 2n. 
STRUCTURE SOLUTION AND REFINEMENT 
The software program SAINT10 was used for data reduction and unit cell refinement. The program 
SADABS,11 employing the multi-scan method, was used for absorption correction. The 
asymmetric unit of ACPAPYR-W comprises one acipimox moiety, one 4-aminopyridine moiety 
and two water molecules. The atomic positions of the components were determined using direct 
methods in SHELXS.5 The program SHELXL5,6 was used to refine the structure isotropically once 
the atoms were placed in the presumed positions. All non-hydrogen atoms were subsequently 
refined anisotropically. The location of the hydrogen atoms, observed from the difference Fourier 
map, was of importance to designate the product as a co-crystal or salt. The presence of a 
hydrogen atom on the pyridyl nitrogen of 4-aminopyridine, and lack of a proton on the 
carboxylate ion of acipimox, indicated that a proton transfer had taken place. The absence of a 
hydrogen atom on the carboxylate moiety of acipimox was supported by the intermediate bond 
distance of the C-O bonds. The two relevant bonds have bond distances 1.250(2) Å and 1.250(1) Å 
respectively. As the 4-aminopyridine and acipimox species are charged, the multi-component 
crystalline system can unequivocally be designated as a hydrated salt. Once the hydrogen atoms 
were located they were placed in geometrically idealised positions. A riding model was used in 
which the Uiso values are 1.2 to 1.5 those of the parent atoms. The crystallographic data and 
intensity data-collection parameters are shown in Table 5.10. 
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Table 5.10: Crystallographic data for the single crystal X-ray structure of ACPAPYR-W 
Chemical Formula (C6H5N2O3)-·(C5H7N2)+·2(H2O)  
Molar mass (g mol-1) 284.28 
Crystal System Monoclinic 
Space Group P21/c 
Unit cell parameters  
a (Å) 9.5838(8) 
b (Å) 15.2531(13) 
c (Å) 9.0906(8) 
α (°) 90 
β (°) 90.844(2) 
γ (°) 90 
Volume (Å3) 1328.7(2) 
Z 4 
Densitycalcd. (g cm-3) 1.421 
μ [MoKα] (mm-1) 0.71073 
F (000) 600 
Temperature (K) 173(2) 
Crystal size (mm) 0.46⨯0.28⨯0.11 
Range scanned θ (°) 2.1 – 27.1 
Index ranges h: -12, 7; k: -19, 16; l: -11, 11 
ϕ and ω scan angle (°) 0.50 
Total number of frames 1210 
Dx (mm) 39.8 
Total number of reflections 11 292 
Number of independent reflections 2 882 
Number of reflections with I > 2σ(I) 2 480 
Rint 0.0428 
R1 [I > 2σ(I)] 0.0345 
wR2 0.0943 
S 1.032 
Number of parameters 188 
Number of reflections omitted 4 
Parameters a, b  
in w = 1/[σ2(FO2)+(aP)2+(bP)] 
a = 0.0513; b = 0.3243 
(δ/σ)mean <0.001 
Δρ excursions (e Å-3) -0.21; 0.25 
  




The asymmetric unit of ACPAPYR-W, shown in Figure 5.25, contains one acipimox anion, one 
4-aminopyridine cation and two water molecules. The proton transfer takes place from the 
carboxylic group of acipimox to the pyridyl nitrogen of 4-aminopyridine during formation. The 
two water molecules are hydrogen bonded to the acipimox anion. The intermolecular 




Figure 5.25: The asymmetric unit of the salt ACPAPYR-W with numbering schemes of acipimox 
(right) and 4-aminopyridine (left). Thermal ellipsoids are drawn at the 50 % probability level  
 
HYDROGEN BONDING 
The ACPAPYR-W structure contains several hydrogen bonding patterns. These patterns are 
assembled from eight hydrogen bonds whose parameters are listed in Table 5.11. Four of these 
occur directly between the acipimox and 4-aminopyridine molecular ions and the remaining are 
interactions with the two water molecules. Acipimox acts as an acceptor in all seven classical 
hydrogen bonds in which this component is involved. The 4-aminopyridine cation acts as the 
donor for four of these. The water molecules act as donors for the remaining three hydrogen 
bonds and are involved in hydrogen bonding as both donors and acceptors. 
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Table 5.11: Hydrogen bonding interactions present in ACPAPYR-W 
D-H···A D···A (Å) Angle (°) Symmetry Operator 
N15-H···O8 2.781(1) 142 (1+x, y, -1+z) 
N15-H···N6 3.094(1) 141 (1+x, y, -1+z) 
N18-H···O10 2.947(1) 172 (x, y, z) 
N18-H···O9 2.826(1) 164 (1-x, 1/2+y, 1/2-z) 
O19-H···O10 2.801(1) 178 (x, y, z) 
O19-H···O8 2.767(1) 169 (1-x, 1-y, 1-z) 
O20-H···O9 2.923(1) 166 (x, y, z) 
O20-H···O19 2.801(1) 167 (1-x, 1-y, -z) 
C5-H···O20 3.450(2) 161 (x, 3/2-y, 1/2+z) 
C13-H···O19 3.495(2) 169 (x, y, z) 
C16-H···O20 3.157(2) 149 (1+x, 3/2-y, -1/2+z) 
 
The hydrogen bonds form five concatenated hydrogen bonded ring patterns. The first involves 
interactions among four water molecules and two acipimox anions about a centre of inversion 
and is described by the graph-set designator N1 = R6
6(22). This network N1 can be seen in 
Figure 5.26. 
 
Figure 5.26: Two views of the acipimox anion-water hydrogen bonding scheme in the network 
N1 = 𝑅6
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The second pattern takes the form N2 = R6
6(31) and involves three acipimox anions and three 
4-aminopyridine cations. This is shown in Figure 5.27. 
 
Figure 5.27: Acipimox anions and 4-aminopyridine cations hydrogen bonding to form the pattern 
N2 = 𝑅6
6(31) 
The pattern N3 comprises a ring with eight hydrogen bond donors and four acceptors, shown in 
Figure 5.28. This pattern forms about a centre of inversion with four acipimox anions linked 
through two water molecules and two 4-aminopyridine cations. This pattern is described by the 
graph-set designator N3 = R8
4(24) and is located at a centre of inversion. 
 
Figure 5.28: Two views of acipimox anions with 4-aminopyridine cations and water hydrogen 
bonding to form the pattern N3 = 𝑅8
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The ring N4 = R4
4(18) is formed by the interaction between two acipimox anions and two water 
molecules. This pattern is located on a centre of inversion. 
 
Figure 5.29: Two views of acipimox anions and water molecules hydrogen bonding to form the 
pattern N4 = 𝑅4
4(18) about a centre of inversion 
The final hydrogen bonded ring occurs between a single acipimox anion and a single 
4-aminopyridine counterion. The hydrogen bonding is bifurcated, linking the pyridyl N-H donor 
to the pyrazine nitrogen and carboxylate anion acceptors. The pattern, N5 = R1
2(5), is shown in 
Figure 5.30. 
 
Figure 5.30: The acipimox anion and 4-aminopyridine cation hydrogen bonding to form the 
pattern N5 = 𝑅1
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The patterns above concatenate to form a complex hydrogen bonding scheme. The patterns N2 to 
N5 interconnect forming a large, stepped layer. The layers are linked through the N1 pattern and 
the interconnectivity of the patterns can be seen in the stereo diagram Figure 5.31. 
 
Figure 5.31: Stereo diagram showing the concatenated hydrogen bonding patterns present in 
ACPAPYR-W 
  




The dihydrate of the acipimox/4-aminopyridine salt packs in layers of concatenated hydrogen 
bonding patterns N2 to N5. These layers are linked to subsequent layers through the hydrogen 
bonding pattern N1. The linking of these layers via two water molecules in the hydrogen bonding 
pattern N1 can be seen in Figure 5.32. The sequential stacking of the stepped layers is more clearly 
illustrated in Figure 5.33. 
 
Figure 5.32: Packing of ACPAPYR-W showing layers of concatenated hydrogen bonding patterns 
linked through the pattern N1 
 
 
Figure 5.33: Highlighting of the stepped layers in the packing of ACPAPYR-W  




The PXRD pattern obtained from the bulk material (collected at room temperature) shows good 
agreement with the pattern calculated from the refined single crystal structure [data collected at 
173(2) K]. The slight differences in the angular positions of the peaks arise from the differing 
temperatures of data collection. As the single crystal is cooled, the unit cell undergoes anisotropic 
contraction, which gives rise to slight angular shifts in the peak positions. The comparative PXRD 
is shown in Figure 5.34. 
 
Figure 5.34: The PXRD trace recorded for the bulk sample (blue) and the computed PXRD pattern 
based on the single crystal X-ray structure of ACPAPYR-W (orange) 
  




The lack of a proton on the carboxylate group of acipimox and the presence of a proton on the 
pyridyl nitrogen of the co-former were first observed unequivocally in a difference electron 
density synthesis during the single crystal X-ray structure determination of ACPAPYR-W. These 
observations led to the designation of ACPAPYR-W as a salt. As demonstrated previously, FTIR 
was employed to support the designation and to investigate the applicability of this method to 
rapid identification of the product. 
The infrared spectrum of ACPAPYR-W (Figure 5.35) shows two signals characteristic of 
carboxylate anions. These signals were observed at 1575 cm-1 and 1373 cm-1. The presence of 
these absorption peaks supports the designation of ACPAPYR-W as a salt. The lack of a signal 
corresponding to a carboxylic acid carbonyl bond vibration in the region of 1700 cm-1 provides 
further support for the designation. 
The formation of a new phase was confirmed by the differences between the ACPAPYR-W 
spectrum and those of the starting materials. The acipimox spectrum shows an O-H signal at 
3554 cm-1 and a carboxylic acid carbonyl signal at 1701 cm-1 which are not present in the salt 
spectrum. The counterion has a characteristic sharp amine peak at 3435 cm-1, a feature that is not 
immediately identifiable in the ACPAPYR-W spectrum. In the ACPAPYR-W spectrum the region 
from 2951 cm-1 to 3486 cm-1 is interpreted as overlapping water and hydrogen bonded amine 
peaks. This region is characteristic of the product. The characteristic signals at 1575 cm-1 and 
1373 cm-1 in the ACPAPYR-W spectrum can be used to rapidly identify the product. The region 
from 2951 cm-1 to 3486 cm-1 would further aid in this use of FTIR. 




Figure 5.35: FTIR spectra for ACPAPYR-W (blue), acipimox (orange) and 4-aminopyridine (grey) 
  




The multi-component crystalline system formed by acipimox and benzamide will be referred to 
as ACPBEN. 
SAMPLE PREPARATION 
The multi-component crystalline system of acipimox and benzamide was prepared in three ways. 
Two of these methods are mechanochemical in nature, while the third is co-precipitation. 
To perform dry grinding and liquid-assisted grinding equimolar quantities of acipimox (10 mg, 
0.065 mmol) and benzamide (8 mg, 0.065 mmol) were weighed out. The two compounds were 
combined in an agate mortar and ground together with an agate pestle for 15 minutes. This 
constituted the mechanochemical action for dry grinding. Liquid-assisted grinding was 
performed in the same manner, with the dropwise addition of a 50 % aqueous ethanol solution. 
To obtain the product via co-precipitation, 10 mg (0.065 mmol) of acipimox was weighed out and 
dissolved in 3 cm3 of a 50 % aqueous ethanol solution. An equimolar amount of benzamide (8 mg, 
0.065 mmol) was added to the solution and the resulting mixture was stirred at 40 ℃ for 2 to 3 
hours. The resulting solution was then filtered through a 0.45 μm nylon filter into a clean vial and 
placed on the benchtop to slowly evaporate. Over the course of several days plate-shaped crystals 
appeared in the solution. 
  




The acipimox to benzamide molar ratio was determined using 1H-NMR spectroscopy. Due to the 
hygroscopic nature of the deuterated solvent DMSO-d6, it was not possible to use this technique 
to determine the amount of water in the crystal. The plate-shaped crystals obtained by 
co-precipitation were dissolved in DMSO-d6 and subjected to 1H-NMR spectroscopy. The relative 
integration of the acipimox methyl group protons (set as the reference integral) and the aromatic 
protons of benzamide served to determine the 1:1 stoichiometric ratio. The proton labelling 
scheme of the components is shown in Figure 5.36. The integration values are presented in 
Table 5.12 and the 1H-NMR spectrum is shown in Figure 5.37. 
 
Figure 5.36: Proton labelling of acipimox (left) and benzamide (right) 
Table 5.12: Integrals and assignment of component protons for stoichiometric determination 
Proton δ (ppm) 
Integration Experimental/ 
Theoretical Experimental Theoretical 
Acipimox 
C-H11a,b,c 2.38 3.00‡ 3.00 1 
C-H2 8.69 1.06 1 1.06 ≈ 1 
C-H5 8.75 1.06 1 1.06 ≈ 1 
Benzamide 
C-H13 + C-H17 7.91 2.30 2 1.15 ≈ 1 
‡ Reference integral 
It should be noted that the integration of benzamide protons was problematic as the aromatic 
hydrogens partially overlap the amide hydrogens. However, the signals of C-H13 and C-H17 are 
sufficiently distinct for the purposes of stoichiometric ratio determination. 




Figure 5.37: 1H-NMR spectrum of ACPBEN in DMSO-d6 used to determine the stoichiometric ratio 
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THERMAL ANALYSIS  
The TGA profile (Figure 5.38) displays a protracted mass loss of 2.7 ± 0.2 % from 79.1 ± 0.6 ℃ 
(n = 2) to 125.0 ± 0.8 ℃. This corresponds to the loss of half a water molecule per 
multi-component crystal unit (calculated = 3.2 %). From 138.9 ± 0.8 ℃ to 203.8 ± 1.8 ℃ the TGA 
trace exhibits a large mass loss resulting from the decomposition of the dehydrated product. The 
DSC trace for ACPBEN (Figure 5.38) does not have an endotherm corresponding to the loss of the 
half water molecule as the heat flow for such an event is negligible. The DSC shows a combined 
melting and onset of degradation endotherm at 133.9 ± 1.3 ℃ (n = 2) followed immediately by a 
broad endotherm characteristic of decomposition. The hot stage micrograph at 119 ℃ 
(Figure 5.39) shows the opaque crystals resulting from dehydration. The micrograph at 139 ℃ 
shows the beginning stages of melting and decomposition. The completely decomposed product 
can be seen in the micrograph at 233 ℃. 
 
Figure 5.38: Representative TGA (blue) and DSC (orange) traces for ACPBEN 
 
Figure 5.39: Hot stage micrographs showing the ACPBEN crystals at various stages of heating  
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CRYSTAL STRUCTURE ANALYSIS 
DATA COLLECTION AND SPACE GROUP DETERMINATION 
The intensity data for the single crystal structure were collected at 173  2 K using a Bruker 
KAPPA APEX DUO II diffractometer. The crystal system was found to be monoclinic, based on the 
determined Laue symmetry 2/m. The conditions limiting possible reflections were as follows: hkl: 
h+k = 2n; h0l, l = 2n; (h = 2n); 0k0: (k = 2n), which indicate the space group C2/c (centrosymmetric) 
or Cc (non-centrosymmetric). From the value of |E2-1| = 0.968 calculated by the program XPREP3 
centrosymmetry was indicated and hence the former space group was selected for structure 
solution. This choice was vindicated by the successful structure determination and refinement. 
STRUCTURE SOLUTION AND REFINEMENT  
Data reduction and unit cell refinement were performed using the software program SAINT.10 
The multi-scan method was used by the absorption correction program SADABS.11 One acipimox 
molecule, one benzamide molecule and half a water molecule make up the asymmetric unit of 
ACPBEN. The atomic co-ordinates were determined by SHELXS5 employing direct methods. After 
the atoms were placed in their presumed positions, SHELXL5,6 was used to refine the structure. 
All non-hydrogen atoms were initially refined isotropically and later anisotropically. Careful 
inspection of the position of the carboxylic acid proton of the acipimox moiety was required to 
investigate the absence of a proton transfer. The hydrogen atom in question was located in the 
difference Fourier map on the carboxylic acid group of the acipimox molecule. The acipimox and 
benzamide molecules were both found to be present in a neutral state. This led to the designation 
of ACPBEN as a co-crystal. The designation was further supported by the distinct C-O bond 
distances of the carboxylic acid functional group of 1.214(2) Å and 1.311(2) Å. Once all the 
hydrogen atoms were located in the difference Fourier map, they were placed in idealised 
positions using a riding model. In the riding model, the Uiso values were set as 1.2 to 1.5 times 
those of the parent atoms. 
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Table 5.13: Crystallographic data for the single crystal X-ray structure of ACPBEN 
Chemical Formula C6H6N2O3·C7H7NO·(H2O)0.5 
Molar mass (g mol-1) 284.27 
Crystal System Monoclinic 
Space Group C2/c 
Unit cell parameters  
a (Å) 12.526(7) 
b (Å) 7.317(4) 
c (Å) 28.394(16) 
α (°) 90 
β (°) 93.704(11) 
γ (°) 90 
Volume (Å3) 2597(3) 
Z 8 
Densitycalcd. (g cm-3) 1.454 
μ [MoKα] (mm-1) 0.112 
F (000) 1192 
Temperature (K) 173(2) 
Crystal size (mm) 0.10⨯0.23⨯0.35 
Range scanned θ (°) 2.9 – 28.3 
Index ranges h: -16, 15; k: -9, 9; l: -37, 37 
ϕ and ω scan angle (°) 0.50 
Dx (mm) 50.0 
Total number of reflections 15 549 
Number of independent reflections 3 487 
Number of reflections with I > 2σ(I) 2 482 
Rint 0.0508 
R1 [I > 2σ(I)] 0.0389 
wR2 0.1052 
S 1.03 
Number of parameters 192 
Number of reflections omitted 3 
Parameters a, b  
in w = 1/[σ2(FO2)+(aP)2+(bP)] 
0.0498; 1.0975 
(δ/σ)mean <0.001 
Δρ excursions (e Å-3) -0.21; 0.30 
  




The asymmetric unit of the co-crystal hemihydrate ACPBEN, shown in Figure 5.40, comprises one 
acipimox molecule, one benzamide molecule and half a water molecule. The water molecule is 
located on a crystallographic two-fold rotation axis. In the asymmetric unit the components of the 
structure interact via the carboxylic acid - amide hydrogen bonding synthon. The components are 
in their neutral state. 
 
Figure 5.40: The asymmetric unit of the hemihydrated co-crystal ACPBEN with numbering 
schemes. Thermal ellipsoids are drawn at the 50 % probability level 
HYDROGEN BONDING 
There are four hydrogen bonds present between the components in this structure. The first two 
occur in the carboxylic acid – amide synthon between acipimox and benzamide (Figure 5.41a). 
The third occurs between the amide group of benzamide and the pyrazine nitrogen of acipimox 
(Figure 5.41b). The fourth hydrogen bond links the pyrazine oxygen atom of acipimox and the 
water molecule (Figure 5.41c). The hydrogen bonding parameters are shown in Table 5.14. 
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Table 5.14: Hydrogen bonding interactions in ACPBEN 
D-H···A D···A (Å) Angle (°) Symmetry Operator 
O9-H···O19 2.582(2) 170 (x, y, z) 
N20-H···O8 2.877(2) 166 (x, y, z) 
N20-H···N6 2.998(2) 117 (x, -1+y, z) 
O21-H···O10 2.825(2) 174 (1-x, -1-y, 1-z) 
C5-H···O8 3.258(2) 149 (x, 1+y, z) 
C11-H···O10 3.266(3) 128 (3/2-x, 1/2 + y, 3/2-z) 
C15-H···O21 3.386(3) 150 (x, y, z) 
The hydrogen bonds above form two hydrogen bonding patterns. Figure 5.42 shows the 
N1 = R2
2(8) synthon formed between the carboxylic acid group of acipimox and the amide group 
of benzamide. The second pattern, N2, is a large ring created from four acipimox molecules, two 
benzamide molecules and two water molecules. The water molecules are located on a two-fold 
rotation axis. This second pattern, N2 = R8
8(34), is shown in Figure 5.43. 
 
Figure 5.42: The hydrogen bonding synthon, N1 = 𝑅2
2(8), between acipimox and benzamide in 
ACPBEN 
 
Figure 5.43: The hydrogen bonding pattern, N2 = 𝑅8
8(34), occurring in ACPBEN 




The hydrogen bonding patterns N1 and N2 combine to form stepped layers, shown in Figure 5.44a. 
The stepped nature of the layers is shown in Figure 5.44b. with the water molecules shown 
linking the N1 synthon to create the N2 hydrogen bonding pattern. 
 
Figure 5.44: The connectivity of the patterns viewed along a. [1 0 0] showing the N1 and N2 
patterns and b. along [0 1 0] showing the stepped layers linked through the water molecules 
The co-crystal ACPBEN forms stepped layers made up of the network N = R2
2(8)R8
8(34). These 
layers interdigitate. The hydrogen bond C5-H···O8 occurs within the layers formed by the 
network. The interdigitated nature of the hydrogen bonding patterns can be seen in Figure 5.45 
and Figure 5.46. The packing of this structure is stabilised by C-H···O hydrogen bonds detailed in 
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Table 5.14 above. The C5-H···O8‡ (‡: x, 1+y, z) hydrogen bonds link the interdigitated layers 
stacking along the a-axis. The C11-H···O10‡ (‡: 3/2-x, 1/2 + y, 3/2-z) hydrogen bond connects the 
layers along the c-axis. 
 
Figure 5.45: Stereo diagram showing the packing of ACPBEN viewed along [0 1 0] featuring the 
interdigitating stepped layers 
The crystal packing is further stabilised by π-π stacking, whose parameters are presented in 
Table 5.15. The two π-interactions occur between the aromatic rings of acipimox and benzamide. 
In the π-π stacking interaction labelled 1 in Table 5.15, the centroids are offset by approximately 
1.2 Å. The interaction labelled 2 has a centroid-to-centroid offset of approximately 1.5 Å. In both 
π-π interactions the least-squares planes of the aromatic rings intersect at an angle of 3.2(1)°. 






1 Cg(A)···Cg(B) 3.608(2) (1-x, -y, 1-z) 
2 Cg(A)···Cg(B) 3.682(2) (3/2-x, -1/2-y, 1-z) 
Cg refers to the centroid of a ring and the symmetry operator in column 3 refers to the second Cg listed in column 1 
Ring A: C1-C2-N3-C4-C5-N6 
Ring B: C12-C13-C14-C15-C16-C17  




The PXRD pattern of the bulk material of ACPBEN was recorded to compare it with that calculated 
from the refined single crystal structure (Figure 5.46). As the two patterns show good agreement, 
the conclusion is that the single crystal used for intensity data collection was representative of 
the bulk material. The slight differences in peak positions are due to the temperatures of data 
collection, where the experimental PXRD data were collected at room temperature and the single 
crystal intensity data at 173(2) K. Upon cooling, the unit cell undergoes anisotropic contraction 
which resulted in slight differences in the location of the peaks. 
 
Figure 5.46: The PXRD trace for the bulk sample (blue) and the computed PXRD pattern based on 
the single crystal X-ray structure of ACPBEN (orange) 
  




The multi-component crystalline system ACPBEN was designated a co-crystal due to the lack of a 
proton transfer. This was deduced from the refined single crystal structure. Infrared 
spectroscopy was used to support this designation and investigated as a rapid identification 
method for this product. This was performed in a manner similar to previous systems presented 
in this study. 
The infrared spectrum of ACPBEN (Figure 5.47) showed two characteristic signals of a carboxylic 
acid group. The carbonyl stretch was observed at 1697 cm-1 and the C-O-H in plane bend was seen 
at 1420 cm-1. The peak C-O stretching peak at 1275 cm-1 provided further evidence of the 
presence of the carboxylic acid moiety. Due to the presence of water in the structure, the O-H 
carboxylic acid group absorbance peak could not be identified. Nevertheless, the presence of the 
carboxylic acid carbonyl stretching, C-O-H bending and C-O stretching peak signals indicated that 
no proton transfer took place during the formation of the product. This supports the designation 
of ACPBEN as a co-crystal. 
Rapid identification of ACPBEN by infrared spectroscopy relied on the characteristic carboxylic 
acid carbonyl and C-O stretching peaks as well as the C-O-H bending peak. The broad spectral 
region from 3120 cm-1 to 3531 cm-1, arising from the overlap of water -OH, the carboxylic acid 
hydroxyl and amide amine groups, aids in identification of the new crystalline system. By direct 
comparison with the acipimox and benzamide spectra, the formation of a new phase is evident 
from the ACPBEN spectrum. The absence of the amine peak from the benzamide spectrum 
(3361 cm-1) and the hydroxyl peak from acipimox (3554 cm-1) in the ACPBEN spectrum shows 
the formation of a new phase. The shift in the carboxylic acid carbonyl peak from 1701 cm-1 in the 
acipimox spectrum to 1697 cm-1 in the ACPBEN spectrum further supports this assessment. 
Therefore, by comparison one can conclusively establish the formation of a new phase. The 
observation of the carboxylic acid signals and the profile of the broad absorption region are 
characteristic of the ACPBEN co-crystal and can be used for rapid identification of this product.  




Figure 5.47: FTIR spectra for ACPBEN (blue), acipimox (orange) and benzamide (grey)  




The multi-component crystalline system of acipimox with isonicotinamide will be referred to as 
ACPISO. 
SAMPLE PREPARATION 
The multi-component crystalline system ACPISO was synthesised using two methods. The first 
was dry grinding and the second co-precipitation. 
To perform the dry grinding experiment 10 mg of acipimox (0.065 mmol) was combined with an 
equimolar quantity of isonicotinamide (8 mg, 0.065 mmol) in an agate mortar. These were 
ground together with an agate pestle for 15 minutes. 
To perform the co-precipitation experiment, equimolar quantities of acipimox (10 mg, 
0.065 mmol) and isonicotinamide (8 mg, 0.065 mmol) were weighed out. The acipimox was 
dissolved in 3 cm3 propan-1-ol and the isonicotinamide was then added to the solution. The 
resulting mixture was stirred at 40 ℃ for 2 to 3 hours and then filtered through a 0.45 μm nylon 
filter into a clean vial and placed on the benchtop to slowly evaporate. Over the course of several 
days small needle-shaped crystals appeared. 
STOICHIOMETRY 
1H-NMR spectroscopy was used to determine the stoichiometry of ACPISO. Crystals obtained 
from co-precipitation were dissolved in DMSO-d6 and subjected to 1H-NMR spectroscopy. The 
relative integration of acipimox methyl group protons, set as the reference integral, and the 
isonicotinamide aromatic peaks were used to determine a 1:1 stoichiometric ratio. The proton 
labelling schemes of acipimox and isonicotinamide are shown in Figure 5.48. The integration 
values of the 1H-NMR spectroscopy experiment and spectrum are shown in Table 5.16 and 
Figure 5.49 respectively. 
 
Figure 5.48: Proton labelling of acipimox (left) and isonicotinamide (right) 
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Table 5.16: Integrals and assignment of component protons for stoichiometric determination 
Proton δ (ppm) 
Integration Experimental/ 
Theoretical Experimental Theoretical 
Acipimox 
C-H11a,b,c 2.42 3.00‡ 3.00 1 
C-H2 8.69 0.94 1 0.94 ≈ 1 
Isonicotinamide 
C-H13 + C-H17 7.80 2.12 2 1.06 ≈ 1 
Overlapping Peak 
C-H5 + C-H14 + 
C-H16 
8.75 3.02 3 1.01 ≈ 1 
‡ Reference integral 
 
Figure 5.49: 1H-NMR spectrum of ACPISO in DMSO-d6 used to determine the stoichiometric ratio 
  




The TGA trace (Figure 5.50) of ACPISO shows no thermal event until 179.1 ± 2.3 ℃ (n = 2). At this 
temperature a two-step mass loss occurs. The first is a mass loss of 72.0 ± 0.3 % and the second 
24.8 ± 1.6 %. The DSC trace shows an endotherm corresponding to melting at 210.8 ± 0.5 ℃ 
(n = 2), occurring simultaneously with decomposition. The HSM micrographs (Figure 5.51) show 
partial melting at 201 ℃ and the early stages of decomposition at 210 ℃. 
A series of detailed micrographs showed melting as the crystal size underwent reduction. It is 
understood that the liquid phase dissolved into the oil. The lack of deposition of the product on 
the cover slip as the crystals underwent heating eliminated sublimation as an explanation of the 
HSM micrographs.  
 
Figure 5.50: Representative TGA (blue) and DSC (orange) traces for ACPISO 
 
Figure 5.51: Hot stage micrographs showing the ACPISO crystals at various stages of heating  
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CRYSTAL STRUCTURE ANALYSIS 
DATA COLLECTION AND SPACE GROUP DETERMINATION 
A Bruker KAPPA APEX DUO II diffractometer was used to collect the single crystal intensity data 
used for the structure determination. The intensity data were collected at 173 ± 2 K. The crystal 
system was determined to be monoclinic from the Laue symmetry, which was found to be 2/m. 
By examination of the systematic absences, namely hkl: none; h0l: l = 2n+1; 0k0, k = 2n+1, the space 
group was uniquely determined to be P21/c. 
STRUCTURE SOLUTION AND REFINEMENT 
The software program SAINT10 was used for data reduction and unit cell refinement. The program 
SADABS,11 employing the multi-scan method, was used for absorption correction. The 
asymmetric unit comprises one acipimox moiety and one isonicotinamide moiety. Direct methods 
employed by SHELXS5 were used to locate the atomic co-ordinates. The program SHELXL5,6 was 
used to refine the structure isotropically after placing atoms in their postulated positions. All 
non-hydrogen atoms were subsequently refined anisotropically. Hydrogen atoms were located 
from the Fourier difference map. Through careful inspection, a hydrogen atom was determined 
to be positioned on the pyridyl nitrogen atom of isonicotinamide. In addition, the acipimox moiety 
was devoid of a proton, featuring instead a carboxylate group. This was supported by the 
similarities in the C-O bond lengths of 1.278(2) Å and 1.235(2) Å. These distances are 
intermediate between single and double C-O bond lengths. This lead to the deduction that a 
proton transfer took place during formation of the product and therefore ACPISO was designated 
a salt. After locating the hydrogen atoms in the difference Fourier map, they were placed in 
idealised positions using a riding model with Uiso values 1.2 to .1.5 times those of the parent atoms. 
The crystallographic data for ACPISO are presented in Table 5.17 below. 
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Table 5.17: Crystallographic data for the single crystal X-ray structure of ACPISO 
Chemical Formula (C6H5N2O3)-·(C6H7N2O)+ 
Molar Mass (g mol-1) 276.26 
Crystal System Monoclinic 
Space Group P21/c 
Unit cell parameters  
a (Å) 4.1770(5) 
b (Å) 12.1709(15) 
c (Å) 24.220(3) 
α (°) 90 
β (°) 92.716(2) 
γ (°) 90 
Volume (Å3) 1229.9(3) 
Z 4 
Densitycalcd. (g cm-3) 1.492 
μ [MoKα] (mm-1) 0.115 
F (000) 576 
Temperature (K) 173(2) 
Crystal size (mm) 0.11⨯0.13⨯0.47 
Range scanned θ (°) 1.7 – 27.5 
Index ranges h: -5, 5; k: -15, 15; l: -31, 31 
ϕ and ω scan angle (°) 0.5 
Dx (mm) 50.0 
Total number of reflections 23 463 
Number of independent reflections 2 832 
Number of reflections with I > 2σ(I) 2 158 
Rint 0.041 
R1 [I > 2σ(I)] 0.0374 
wR2 0.1049 
S 1.026 
Number of parameters 182 
Number of reflections omitted 4 
Parameters a, b  
in w = 1/[σ2(FO2)+(aP)2+(bP)] 
0.0524; 0.4053 
(δ/σ)mean <0.001 
Δρ excursions (e Å-3) -0.26; 0.22 
  




The asymmetric unit of the salt ACPISO is shown in Figure 5.52. In the asymmetric unit there is 
one acipimox anion hydrogen bonded to one isonicotinamide cation. The components are in their 
respective deprotonated and protonated forms. The proton transfer occurs from the carboxylic 
acid moiety of acipimox to the pyridyl nitrogen of isonicotinamide during formation of the salt. 
Further intermolecular interactions will be expanded upon in the forthcoming section, entitled 
Hydrogen Bonding. 
 
Figure 5.52: The asymmetric unit of ACPISO with numbering scheme of acipimox (left) and 
isonicotinamide (right). Thermal ellipsoids are drawn at the 50 % probability level 
HYDROGEN BONDING 
There are three hydrogen bonding synthons present in the ACPISO structure. The first, shown in 
Figure 5.53a., are the two hydrogen bonds (N-HO and C-HO) which link the components of the 
asymmetric unit. The second, Figure 5.53b., is that between the amide group of the 
isonicotinamide cation and the carboxylate anion of acipimox. Finally, the third hydrogen 
bonding synthon is that between two isonicotinamide molecules through an amide–amide 
hydrogen bonding homosynthon, shown in Figure 5.53c.12 The hydrogen bonding parameters are 
listed in Table 5.18. 
 
Figure 5.53: Hydrogen bonding synthons between a. carboxylate and aromatic nitrogen and 
aromatic proton, b. carboxylate and amide and c. amide and amide 
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The C-H···O hydrogen bonds listed in Table 5.18 are mostly involved in stabilising the packing of 
ACPISO. Two of these interactions, however, occur within the asymmetric unit. The first is 
C2-H···O9, an intramolecular interaction within the acipimox anion. The second is C16-H···O8, 
between isonicotinamide and acipimox in the asymmetric unit, further stabilising the interaction 
between these ions, as shown in Figure 5.53a. The remaining three C-H···O will be discussed 
below.  
Table 5.18: Hydrogen bonding parameters for ACPISO 
D-H···A D···A (Å) Angle (°) Symmetry Operator 
N15-H···O9 2.557(2) 173 (x, y, z) 
N20-H···O19 2.923(2) 163 (3-x, 2-y, 1-z) 
N20-H···O8 3.032(2) 170 (2-x, 1-y, 1-z) 
C2-H···O9 2.727(2) 100 (x, y, z) 
C5-H···O19 3.172(2) 122 (1+x, -1+y, z) 
C14-H···O10 3.094(2) 137 (-x, 1/2+y, 1/2-z) 
C16-H···O8 3.236(2) 126 (x, y, z) 
C17-H···O8 3.253(2) 139 (2-x, 1-y, 1-z) 
 
When combined, the synthons described above form three hydrogen bonding patterns. The first 
occurs between the amide groups of two isonicotinamide cations and is described by the graph 
set designator N1 = R2
2(8), and is shown in Figure 5.54. The second pattern is a larger ring, 
N2 = R4
2(16), comprising two acipimox anions and two isonicotinamide cations and is presented 
in Figure 5.55. This pattern is assembled from the hydrogen bonds N15-H···O9 and C16-H···O8. 
These two patterns are each located at centres of inversion. The final pattern (Figure 5.56) is that 
found in the asymmetric unit. It is described by the graph set designator N1 = R2
2(7). 
 
Figure 5.54: Hydrogen bonding pattern, N1 = 𝑅2
2(8), occurring in ACPISO 




Figure 5.55: Hydrogen bonding pattern, N2 = 𝑅4
2(16), occurring in ACPISO 
 
Figure 5.56: Hydrogen bonding pattern, N3 = 𝑅2
2(7), occurring in ACPISO 
  








2(7). The repeating unit of this pattern is shown in Figure 5.57. The layers then 
stack along the a-axis in distinct columns. The columns are related by a two-fold screw axis such 
that the layers in adjacent columns are inclined at 50.7°. These columns are shown in Figure 5.58 
and their inclination is shown in Figure 5.59. 
 
Figure 5.57: Layer formed from combined hydrogen bonding patterns N1, N2 and N3 in ACPISO 
 
Figure 5.58: Packing of ACPISO viewed along [0 1 0] highlighting the columns in alternating 
colours 




Figure 5.59: Packing of ACPISO viewed along [0 0 1] illustrating the inclination of the columns 
As mentioned above, three of the C-H···O hydrogen bonds present in this structure are involved 
in stabilising the packing. Two of the listed interactions, C5-H···O19‡ (‡: 1+x, -1+y, z) and 
C17-H···O8‡ (‡: 2-x, 1-y, 1-z), occur within columns stabilising the columns and layers. The 
remaining hydrogen bond, C14-H···O10‡ (‡:-x, 1/2+y, 1/2-z), stabilises the interaction between 
the adjacent columns.  




The bulk material obtained during production of ACPISO was subjected to PXRD analysis. This 
trace was compared with that calculated from the refined crystal structure. There are slight 
differences in the locations of the peaks, which result from the temperatures at which the bulk 
PXRD data (room temperature) and the single crystal structure data [173(2) K] were collected. 
Upon cooling the unit cell contracts and/or expands, which in turn causes the slight differences 
in the angular positions of the peaks. 
 
Figure 5.60: The PXRD trace for the bulk sample (blue) and the computed PXRD pattern based on 
the single crystal X-ray structure of ACPISO (orange) 
  




The crystal structure of ACPISO showed the position of the proton on the pyridyl nitrogen of the 
isonicotinamide component. Furthermore, no proton was found on the acipimox carboxylate 
moiety. As a proton transfer had taken place during formation, ACPISO was designated a salt. 
Infrared spectroscopy was performed to investigate if the spectrum of ACPISO supported this 
designation and as a rapid identification method for ACPISO. The methods for these experiments 
are outlined above for previous multi-component crystalline systems. 
The infrared spectrum of ACPISO (Figure 5.61) shows two signals characteristic of a carboxylate 
anion, the first was seen at 1582 cm-1 and the second at 1345 cm-1, representing a C-O stretch. 
The presence of these peaks indicate that a proton transfer from acipimox has taken place. This 
supports the designation of ACPISO as a salt. 
To identify a new phase the spectrum of ACPISO was compared with those of the starting 
materials. The O-H signal, 3554 cm-1 in the acipimox spectrum, is absent in that of ACPISO. The 
carboxylic acid carbonyl peak was also observed in the acipimox spectrum (1701 cm-1), but is 
absent in the product spectrum. The positions of the amide carbonyl signals in the 
isonicotinamide spectrum (1620 cm-1) and product spectrum (1699 cm-1) aid in distinguishing 
these spectra. The differences presented here allow one to establish unequivocally the formation 
of a new phase. 
The signals used in determination of proton transfer and differentiating between the product and 
starting material spectra are characteristic of ACPISO. The broad absorption region from 
2919 cm-1 to 3418 cm-1 representing the hydrogen bonded amine moieties, is a further feature 
distinctive of this multi-component crystalline system. Therefore, using these signals one can use 
FTIR as a rapid identification technique for ACPISO. 




Figure 5.61: FTIR spectra for ACPISO (blue), acipimox (orange) and isonicotinamide (grey) 
  




The multi-component crystalline system formed between acipimox and tranexamic acid will be 
referred to as ACPTRA. 
SAMPLE PREPARATION 
The system was prepared in three ways. The first was dry grinding where acipimox (10 mg, 
0.065 mmol) was weighed out and placed in an agate mortar. An equimolar quantity of 
tranexamic acid (10 mg, 0.065 mmol) was added and the compounds were ground together using 
an agate pestle for 15 minutes. The second method used to produce ACPTRA was liquid-assisted 
grinding. In this method the same procedure as dry grinding was used with the dropwise addition 
of butan-1-ol. 
The third method employed was co-precipitation, where 10 mg of acipimox (0.065 mmol) was 
weighed into a clean vial. The acipimox was then dissolved in 3 cm3 butan-1-ol and an equimolar 
amount of tranexamic acid (10 mg, 0.065 mg) was added to this solution. The resulting mixture 
was stirred at 50 ℃ for 3 hours and then filtered through a 0.45 μm nylon filter into a clean vial. 
This was then left to stand on the benchtop until needle-shaped crystals were observed. The 
precipitate formed before filtration was determined to be a powdered form of the desired 
product. Single crystals were required for the analyses performed below. 
STOICHIOMETRY 
The stoichiometric ratio of ACPTRA was determined via 1H-NMR spectroscopy. Crystals resulting 
from co-precipitation were dissolved in DMSO-d6 and subjected to 1H-NMR spectroscopy. The 
relative integration of the acipimox methyl moiety, set as the reference integral, and the C-H21a,b 
protons of tranexamic acid were used to determine a stoichiometric ratio of 1:1. The proton 
labelling of acipimox and tranexamic acid are shown in Figure 5.62 while the integration values 
are presented in Table 5.19 and the spectrum in Figure 5.63. The signals for the protons C-H2 and 
C-H5 overlap, therefore their integration was considered together. 
 
Figure 5.62: Proton labelling of acipimox (left) and tranexamic acid (right) 
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Table 5.19: Integrals and assignment of component protons for stoichiometric determination 
Proton δ (ppm) 
Integration Experimental/ 
Theoretical Experimental Theoretical 
Acipimox 
C-H11a,b,c 2.37 3.00‡ 3.00 1 
C-H2 + C-H5 8.49, 8.55 2.08 2.00 1.04 ≈ 1 
Tranexamic Acid 
C-H21a,b 2.70 1.98 2.00 0.99 ≈ 1 
‡ Reference integral 
 
Figure 5.63: 1H-NMR spectrum of ACPTRA in DMSO-d6 used to determine the stoichiometric ratio 
  




The absence of thermal events in the initial stages of the thermal analysis of ACPTRA indicates 
that no solvent molecules are present in the sample. One major thermal event occurs from 
214.0 ± 1.3 ℃ (n = 2) in the TGA trace (Figure 5.64). This is interpreted as the initial stages of 
decomposition. This event is followed by a slow continuous mass loss resulting from the 
continued decomposition of ACPTRA. The DSC trace (Figure 5.64) shows only one endotherm at 
241.5 ± 0.2 ℃ (n = 2) corresponding to the simultaneous melting and decomposition of the 
multi-component crystalline system. The hot stage micrographs in Figure 5.65 at 247 ℃ show the 
melting and decomposition of the sample, corroborating the interpretation of the TGA and DSC 
profiles. The decomposed product can be seen in the HSM micrograph at 260 ℃. 
 
Figure 5.64: Representative TGA (blue) and DSC (orange) traces for ACPTRA 
 
Figure 5.65: Hot stage micrographs showing ACPTRA crystals at various stages of heating  
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CRYSTAL STRUCTURE ANALYSIS 
DATA COLLECTION AND SPACE GROUP DETERMINATION 
A Bruker KAPPA APEX DUO II diffractometer was used to collect the single crystal intensity data 
at 173 ± 2 K. The crystal system was determined using the computer program LAYER.2 The 
triclinic crystal system was determined from the observed Laue symmetry1. Centrosymmetry 
of the crystal was deduced from the value of |E2-1| = 1.034 for the intensity data (program 
XPREP3) and hence the space group P1 was assigned.  
STRUCTURE SOLUTION AND REFINEMENT 
Data reduction and unit cell refinement were performed using the program SAINT.10 The intensity 
data were corrected for absorption by the multi-scan technique employed in the program 
SADABS.11 The atomic co-ordinates were located by direct methods using SHELXS.5 Once the 
atoms were placed in their presumed positions SHELXL5,6 was used to refine the structure. All 
non-hydrogen atoms were initially refined isotropically and subsequently refined anisotropically. 
Tranexamic acid is known to exist as a zwitterion in its pure state and as an ammonium ion 
(-NH3)+ when present in a salt.13,14 Close inspection of the Fourier difference map revealed the 
proton on the tranexamic acid carboxyl group. The absence of a hydrogen atom on the carboxylate 
anion of acipimox confirmed the occurrence of a proton transfer during formation of the product. 
Further evidence of a proton transfer was provided by the similarities in the C-O bond lengths of 
the acipimox carboxylate group. The values are 1.243(1) Å and 1.249(1) Å, and are intermediate 
between single and double carbon-oxygen bonds. The location of the proton on the tranexamic 
acid carboxyl group provides unequivocal proof of a proton transfer, leading to the designation 
of ACPTRA as a salt. Once the remaining hydrogen atoms were located in the Fourier difference 
map they were placed in idealised positions using a riding model with Uiso values 1.2 to 1.5 times 
those of the parent atoms. The asymmetric unit of ACPTRA comprises one deprotonated acipimox 
molecule (i.e. an anion) and one protonated tranexamic acid molecule (i.e. a cation). The 
crystallographic data for this structure are presented in Table 5.20.  
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Table 5.20: Crystallographic data for the single crystal X-ray structure of ACPTRA 
Chemical Formula (C6H5N2O3)-·(C8H16NO2)+ 
Molar mass (g mol-1) 311.34 
Crystal System Triclinic 
Space Group P1 
Unit cell parameters  
a (Å) 6.9663(14) 
b (Å) 9.5250(19) 
c (Å) 12.154(2) 
α (°) 79.27(3) 
β (°) 84.99(3) 
γ (°) 70.49(3) 
Volume (Å3) 746.6(3) 
Z 2 
Densitycalcd. (g cm-3) 1.385 
μ [MoKα] (mm-1) 0.106 
F (000) 332 
Temperature (K) 173(2) 
Crystal size (mm) 0.08⨯0.13⨯0.41 
Range scanned θ (°) 1.7 – 28.4 
Index ranges h: -9, 9; k; -12, 12; l: -16, 16 
ϕ and ω scan angle (°) 0.50 
Total number of frames 2835 
Dx (mm) 47.24 
Total number of reflections 13 715 
Number of independent reflections 3 701 
Number of reflections with I > 2σ(I) 3 382 
Rint 0.027 
R1 [I > 2σ(I)] 0.0367 
wR2 0.1041 
S 1.032 
Number of parameters 202 
Number of reflections omitted 10 
Parameters a, b  
in w = 1/[σ2(FO2)+(aP)2+(bP)] 
a: 0.0580, b: 0.769 
(δ/σ)mean <0.001 
Δρ excursions (e Å-3) -0.26, 0.33 




The asymmetric unit of ACPTRA, shown in Figure 5.66, comprises one acipimox anion and one 
tranexamic acid cation. During the formation of this product a proton transfer from the carboxylic 
acid moiety of acipimox to the carboxylate group of tranexamic acid occurs. There are several 
hydrogen bonding interactions between the ions that will be expanded upon in the Hydrogen 
Bonding section. 
 
Figure 5.66: The asymmetric unit of the salt ACPTRA with numbering scheme of acipimox (left) 
and tranexamic acid (right). Thermal ellipsoids are drawn at the 50 % probability level 
HYDROGEN BONDING 
There are four hydrogen bonding synthons present in the organic salt ACPTRA. All the hydrogen 
bonds involve acipimox anions and the tranexamic acid counterions. The first involves the 
tranexamic acid carboxylic acid and the acipimox carboxylate anion (Figure 5.67a.). The second 
interaction links the ammonium cation of tranexamic acid to the pyrazine oxide group of 
acipimox, seen in Figure 5.67b. The third synthon, in Figure 5.67c., is an interaction of the 
carboxylate anion of acipimox and the ammonium cation of tranexamic acid. The final hydrogen 
bond, Figure 5.67d., is an interaction of the ammonium cation of tranexamic acid with the 
aromatic nitrogen of acipimox. The hydrogen bonding parameters are presented in Table 5.21. 




Figure 5.67: Hydrogen bonding synthons present in ACPTRA 
Table 5.21: Hydrogen bonding parameters in ACPTRA 
D-H···A D···A (Å) Angle (°) Symmetry Operator 
O20-H···O9 2.639(1) 176 (x, y, z) 
N22-H···O8 2.738(1) 163 (1-x, 2-y, -z) 
N22-H···N6 3.063(1) 142 (1+x, y, -1+z) 
N22-H···O10 2.797(1) 158 (2-x, 1-y, -z) 
C2-H···O19 3.312(2) 151 (x, y, z) 
C14-H···O10 3.481(2) 150 (1-x, 1-y, -z) 
C21-H···O19 3.422(2) 173 (2-x, 1-y, -z) 
 
Each acipimox anion is hydrogen bonded to four tranexamic acid counterions (Figure 5.68a.) 
through the four hydrogen bonds above. Each of the tranexamic acid cations is hydrogen bonded 
to four acipimox anions through the same four hydrogen bonds (Figure 5.68b.). 




Figure 5.68: Stereo diagrams highlighting the a. four tranexamic acid cations hydrogen bonding to 
a single acipimox anion and b. four acipimox anions bonding to a single tranexamic acid 
counterion  
These hydrogen bonds between acipimox and tranexamic acid form four hydrogen bonding 
patterns. Each of the patterns is described by a graph-set designator as a hydrogen bonded ring. 
Each of these rings comprises two acipimox anions and two acipimox cations.  
The first of these patterns, N1 = R4
4(26), involves two acipimox anions and two tranexamic acid 
cations. The latter are linked through the carboxylate anions of two acipimox counterions. The 
carboxylate group of each acipimox anion acts as an acceptor of hydrogen atoms from a carboxylic 
acid and ammonium cation of the respective tranexamic acid ions. The hydrogen bonding pattern, 
N1, is located at a centre of inversion and is shown in Figure 5.69. 




Figure 5.69: Hydrogen bonding pattern N1 = 𝑅4
4(26) in ACPTRA 
The second ring pattern comprises two acipimox anions linked through the ammonium cations 
of two tranexamic acid counterions. The ammonium cation hydrogen bonds with the pyrazine 
oxide and aromatic nitrogen groups of inversion-related acipimox anions. The ring is described 
by the graph-set designator N2 = R4
4(16) and is located at a centre of inversion, shown in 
Figure 5.70. 
 
Figure 5.70: Two views of the hydrogen bonding pattern N2 = 𝑅4
4(16) in ACPTRA 
The hydrogen bonding pattern N3 = R4
4(14) is similar to N2 as it too comprises two acipimox 
anions linked through the ammonium cations of two tranexamic acid cations. The ammonium ion 
of each tranexamic acid cation acts as hydrogen bond donors to the aromatic nitrogen and the 
carboxylate anion of the two acipimox ions. This hydrogen bonding pattern can be seen in 
Figure 5.71, where it is also shown that it lies at a centre of inversion. 




Figure 5.71: Hydrogen bonding pattern N3 = 𝑅4
4(14) in ACPTRA 
The final hydrogen bonding pattern N4 = R4
4(32) is the largest, involving two acipimox anions and 
two tranexamic acid counterions. The carboxylate group of each acipimox anion acts as a 
hydrogen bond acceptor to the carboxylic acid group of a tranexamic acid cation. The ammonium 
cation of each tranexamic acid ion is hydrogen bonded to the pyrazine oxide of an acipimox anion. 
The pattern is located at a centre of inversion and is shown in Figure 5.72. 
 
Figure 5.72: Hydrogen bonding pattern N4 = 𝑅4
4(32) in ACPTRA 





4(32). Each of the patterns described above is adjacent to a 
neighbouring hydrogen bonding ring. The overall network is illustrated in the stereo diagram in 
Figure 5.73. 
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Two of the C-H···O hydrogen bonds listed in Table 5.21 above serve to stabilise the interaction 
between the networks. The C2-H···O19‡ (‡: x, y, z) and C14-H···O10‡ (‡: 1-x, 1-y, -z) H-bonds are 
interactions between acipimox anions and tranexamic acid counterions, while the C21-H···O19‡ 
(‡: 2-x, 1-y, -z) interaction involves two tranexamic acid cations. 
 
Figure 5.73: Stereo diagram showing the hydrogen bonding network present in ACPTRA 
CRYSTAL PACKING 
The hydrogen bonding network propagates along the c-axis forming layers. The layers are 
hydrogen bonded to subsequent layers along the b-axis. The hydrogen bonding pattern N1 is 
responsible for linking these layers. The layers and hydrogen bonding can be seen in Figure 5.74a. 
A consequence of this packing pattern is that the acipimox anions form columns which stack along 
the a-axis. The tranexamic acid cations are arranged in columns stacking along the b-axis. The 
acipimox anion and tranexamic acid cation columns can be seen in Figure 5.74b., where the 
hydrogen atoms have been omitted for clarity. 
The packing of the structure is further stabilised by two non-classical hydrogen bonds in the 
structure. The hydrogen bond C14-H···O10‡ (‡: 1-x, 1-y, -z) occurs within the layers stabilising 
this arrangement. The hydrogen bond C21-H···O19‡ (‡: 2-x, 1-y, -z) links the layers, stabilising 
their packing. The overall structure is further stabilised by π-π stacking, which is expanded upon 
below. 




Figure 5.74: Packing of the salt ACPTRA highlighting a. the layers of the network N, linked through 
the hydrogen bonding pattern N1 with alternating layers in blue and green and b. the columns of 
acipimox anions (green) and tranexamic acid cations (blue) with hydrogen atoms omitted for 
clarity 
The π-π stacking takes place between the aromatic rings of inversion-related acipimox anions in 
the columns along the a-axis. There are two such interactions, the first having a 
centroid-to-centroid distance of 3.581(1) Å with the centroids offset by approximately 1.4 Å. The 
acipimox aromatic rings in the second π-π stacking interaction have centroids that are offset by 
a small distance of approximately 0.9 Å. The centroid-to-centroid distance is 3.636(1) Å. The 
least-squares planes of the acipimox aromatic anion rings in each of these interactions are parallel 
because the respective ring-pairs are both inversion-related. The relevant data for the π-π 
stacking in ACPTRA are presented in Table 5.22. 
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Cg(A)···Cg(A) 3.581(1) (-x, 1-y, 1-z) 
Cg(A)···Cg(A) 3.636(1) (1-x, 1-y, 1-z) 
Cg refers to the centroid of a ring and the symmetry operator in column 3 refers to the second Cg listed in column 1 
Ring A: C1-C2-N3-C4-C5-N6 
  




The data for the PXRD trace were collected at room temperature, while the data for the single 
crystal structure were collected at 173(2) K. The PXRD patterns of the bulk sample of ACPTRA 
and the pattern calculated from refined single crystal data show good agreement, with slight 
differences in the angular positions of the peaks. This indicates that the single crystal of ACPTRA 
is representative of the bulk material. The slight differences in peak locations are due to the 
anisotropic contraction of the unit cell upon cooling for the single crystal structure data collection. 
 
Figure 5.75: The PXRD trace for the bulk sample (blue) and the computed PXRD pattern based on 
the single crystal X-ray structure of ACPTRA (orange) 
  




The designation of ACPTRA as a salt was established from the position of a proton on the 
carboxylic acid group of tranexamic acid. This was observed from the refined single crystal 
structure. Infrared spectroscopy was performed to investigate whether the spectrum of ACPTRA 
supported this designation. FTIR was also investigated for its use as a rapid identification method 
for the product. These investigations were performed as for previous structures. 
From the infrared spectrum (Figure 5.76) of ACPTRA the presence of both a carboxylic acid and 
carboxylate anion were observed. The signals at 1705 cm-1 and 1268 cm-1 are characteristic of a 
carboxylic acid carbonyl group and C-O stretching respectively. The signals for the carboxylate 
anion can be seen at 1579 cm-1 and 1369 cm-1. As pure tranexamic acid exists as a zwitterion13 
and acipimox possesses a carboxylic acid group, it is not possible to confirm the presence of a 
proton transfer from infrared spectroscopy alone. 
To investigate the use of FTIR as a rapid method for identifying ACPTRA, first the formation of a 
new phase was investigated. This was done by comparison of the ACPTRA spectrum with the 
spectra of the starting materials. Differences were observed in the carbonyl absorbance peaks at 
1705 cm-1 and 1701 cm-1 in the ACPTRA and acipimox spectra respectively. The signals of the 
carboxylate anion functional groups in the ACPTRA and tranexamic acid signals showed variation 
in their positions. The carboxylate signals were observed at 1579 cm-1 and 1369 cm-1 in the 
ACPTRA spectrum and at 1531 cm-1 and 1379 cm-1 in the tranexamic acid spectrum. An O-H group 
signal, present in the acipimox spectrum (3554 cm-1), overlaps with the broad region from 
3241 cm-1 to 2404 cm-1 in the ACPTRA spectrum. This broad absorption is indicative of hydrogen 
bonded amine and hydroxyl groups. The peaks used in an attempt to confirm a proton transfer 
would serve to identify ACPTRA. 




Figure 5.76: FTIR spectra for ACPTRA (blue), acipimox (orange) and tranexamic acid (grey)  




The hydrated multi-component crystalline system of acipimox and tranexamic acid will be 
referred to as ACPTRA-W. 
SAMPLE PREPARATION 
This system was prepared via co-precipitation. Acipimox (10 mg, 0.065 mmol) was weighed out 
and dissolved in 3 cm3 butan-1-ol. An equimolar quantity of tranexamic acid (10 mg, 0.065 mmol) 
was added to the solution. The resulting mixture was stirred for 2 – 3 hours at 50 ℃, at which 
point a few drops of Milli-Q water were added to the resulting solution. The solution was then 
filtered through a 0.45 μM nylon filter into a clean vial. The vial was then left to stand on the 
benchtop for several days until plate-shaped crystals were observed. 
STOICHIOMETRY 
1H-NMR spectroscopy was used to determine the stoichiometry of ACPTRA-W. Several crystals 
obtained from co-precipitation were dissolved in DMSO-d6 and 1H-NMR spectroscopy was 
performed on the sample. The relative integration of the acipimox methyl group, set as the 
reference integral, and the tranexamic acid C-H21 proton peaks were used to determine a 1:1 
stoichiometric ratio. The proton labelling schemes of acipimox and tranexamic acid are shown in 
Figure 5.77, while the integration values are presented in Table 5.23. The spectrum is shown in 
Figure 5.78. 
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Table 5.23: Integrals and assignment of component protons for stoichiometric determination 
Proton δ (ppm) 
Integration Experimental/ 
Theoretical Experimental Theoretical 
Acipimox 
C-H11a,b,c 2.36 3.00‡ 3.00 1 
C-H2 8.47 1.05 1.00 1.05 ≈ 1 
C-H5 8.53 1.05 1.00 1.05 ≈ 1 
Tranexamic Acid 
C-H21a,b 2.70 2.04 2.00 1.02 ≈ 1 
‡ Reference integral 
 
Figure 5.78: 1H-NMR spectrum of ACPTRA-W in DMSO-d6 used to determine the stoichiometric 
ratio 
  




The TGA trace for ACPTRA-W (Figure 5.79) shows a mass loss of 4.5 ± 0.1 % (n = 2) beginning at 
76.7 ± 0.6 ℃. This mass loss corresponds to the loss of a single water molecule (calculated 5.5 %). 
The discrepancy between the measured and calculated values was greater than usually observed. 
Further reference to this point is made in the section entitled Structure Solution and Refinement. 
A large mass loss of 53.6 ± 2.8 % occurs from 209.6 ± 0.8 ℃ to 266.0 ± 2.7 ℃ corresponding to 
the beginning stages of decomposition of the crystalline system. The mass then continues to 
decrease as the decomposition continues. The DSC trace shows two endotherms relating to each 
of the mass losses, the first relating to the loss of water and then at 239.9 ± 1.0 ℃ (n = 2) 
corresponding to simultaneous melting and decomposition of the product. The HSM micrographs 
(Figure 5.80) at 110 ℃ and 247 ℃ show the loss of the water and the simultaneous melting and 
decomposition respectively. The image at 282 ℃ shows the decomposed product. 
 
Figure 5.79: Representative TGA (blue) and DSC (orange) traces for ACPTRA-W 
 




Figure 5.80: Hot stage micrographs showing ACPTRA-W crystals at various stages of heating 
The removal of water from the structure through heating gives rise to the anhydrous salt ACPTRA. 
The dehydrated product was subjected to PXRD analysis to confirm the formation of the 
anhydrous salt. The conversion from the hydrated ACPTRA-W salt to the anhydrous 
multi-component crystalline system was not pursued in detail.  
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CRYSTAL STRUCTURE ANALYSIS 
DATA COLLECTION AND SPACE GROUP DETERMINATION 
The single crystal intensity data were collected at 173 ± 2 K on a Nonius KappaCCD 
diffractometer. The computer program LAYER2 was used to determine the crystal system and 
space group of ACPTRA-W. The Laue symmetry of1 indicated that the crystal system was 
triclinic. The program XPREP3 was used to determine the space group, where an |E2-1| value of 
1.017 indicated centrosymmetry. The only remaining choice of space group was thus P1. 
STRUCTURE SOLUTION AND REFINEMENT 
Data reduction and unit cell refinement were performed using the software program DENZO.4 
The atomic co-ordinates were located by SHELXS5 employing direct methods. Once the atoms 
were placed in their presumed positions the program SHELXL5,6 was used to refine the structure 
isotropically. The non-hydrogen atoms were subsequently refined anisotropically. Careful 
inspection of the Fourier difference map revealed the position of a hydrogen atom located on the 
carboxylic acid group of the tranexamic acid cation. The carboxylate moiety of the acipimox anion 
lacked the presence of the hydrogen atom. The transfer of the hydrogen atom led to the 
designation of ACPAPYR-W as a salt. This designation was further supported by the C-O bond 
lengths of the acipimox carboxylate anion. These bond distances were found to be of intermediate 
distance between single and double carbon-oxygen bond lengths and are equal within 
experimental error with values of 1.250(2) Å and 1.257(2) Å. The hydrogen atoms of the water 
molecule were similarly located. After locating the hydrogen atoms in the Fourier difference map, 
they were placed in idealised positions using a riding model and refined isotropically with 
thermal parameters 1.2 to 1.5 times those of the parent atoms. 
Due to the discrepancies in the TGA experimental and calculated values for water content, special 
consideration was given to the oxygen atom of the water molecule in the crystal structure. The 
oxygen atom of the water molecule was assigned a s.o.f. of 0.81 based on the experimental TGA 
value. This resulted in an unrealistic Uiso value of 0.0202(4) Å2 compared to the average Uiso value 
of 0.033(3) Å2 for hydrogen-bonded oxygen atoms. When the s.o.f. of the water oxygen atom was 
set to unity, the Uiso value converged to a physically more reasonable value of 0.0327(3) Å2, and 
hence the final model accounted for a full water molecule in the asymmetric unit. It was therefore 
assumed that the water content had been underestimated in the TGA analysis, possibly due to 
prior loss of water during sample manipulation. 
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Table 5.24: Crystallographic data for the single crystal X-ray structure of ACPTRA-W 
Chemical Formula (C6H5N2O3)-·(C8H16NO2)+·H2O 
Molar mass (g mol-1) 329.35 
Crystal System Triclinic 
Space Group P1 
Unit cell parameters  
a (Å) 6.6123(13) 
b (Å) 8.4195(17) 
c (Å) 15.016(3) 
α (°) 93.36(3) 
β (°) 102.63(3) 
γ (°) 101.14(3) 
Volume (Å3) 795.9(3) 
Z 2 
Densitycalcd. (g cm-3) 1.374 
μ [MoKα] (mm-1) 0.108 
F (000) 352 
Temperature (K) 173(2) 
Crystal size (mm) 0.11⨯0.23⨯0.47 
Range scanned θ (°) 3.0 – 27.5 
Index ranges h: -8, 8; k; -10, 10; l: -19, 19 
ϕ and ω scan angle (°) 0.5 
Dx (mm) 45 
Total number of reflections 6 735 
Number of independent reflections 3 612 
Number of reflections with I > 2σ(I) 2 697 
Rint 0.032 
R1 [I > 2σ(I)] 0.0382 
wR2 0.1062 
S 1.034 
Number of parameters 214 
Number of reflections omitted 6 
Parameters a, b  
in w = 1/[σ2(FO2)+(aP)2+(bP)] 
a: 0.0493, b: 0.2055 
(δ/σ)mean <0.001 
Δρ excursions (e Å-3) -0.31, 0.24 
  




The asymmetric unit of the hydrated salt ACPTRA-W (Figure 5.81) comprises one acipimox anion, 
one tranexamic acid cation and one water molecule. A proton transfer from the carboxylic acid 
group of acipimox to the carboxylate group of tranexamic acid occurs during synthesis of this 
crystalline system resulting in salt formation. Both the acipimox anion and the tranexamic acid 
cation are hydrogen bonded to the water molecule in the asymmetric unit. There are further 
interactions among the components of this hydrate, which are expanded upon in the Hydrogen 
Bonding section below. 
 
Figure 5.81: The asymmetric unit of ACPTRA-W with the numbering scheme of acipimox (left) and 
tranexamic acid (right). Thermal ellipsoids are drawn at the 50 % probability level 
HYDROGEN BONDING 
In the multi-component crystalline system ACPTRA-W there are six hydrogen bonding synthons. 
Three of these involve the water molecule. The first of these is a hydrogen bond between the 
water molecule and the pyrazine oxide moiety of acipimox (Figure 5.82a.), while the second is 
that between the water molecule and a carboxylate oxygen atom of the acipimox anion 
(Figure 5.82b.). The third hydrogen bond involving the water molecule is that linking it to the 
carboxylic acid group of the tranexamic acid cation (Figure 5.82c.). The water molecule acts as 
the donor in the first two hydrogen bonds, while in the third the oxygen of the water molecule is 
the acceptor. 




Figure 5.82: Hydrogen bonds in ACPTRA-W involving the water molecule with a. the pyrazine oxide 
of the acipimox anion, b. a carboxylate oxygen atom of the acipimox anion and c. the carboxylic 
acid group of the tranexamic acid cation. 
The remaining three hydrogen bonding synthons involve the tranexamic cation. The first two 
occur between the ammonium cation of tranexamic acid and two acipimox anions related by 
translation along the a-axis, both interacting through their carboxylate groups. These hydrogen 
bonds can be seen in Figure 5.83a. The final hydrogen bonding synthon involves two ammonium 
cations of tranexamic acid, whereby each of the ammonium groups hydrogen bonds to the 
carbonyl oxygen of its inversion-related counterpart. In this homosynthon dimer the two 
moieties hydrogen bond in a head-to-tail manner. This can be seen in Figure 5.83b. The 
parameters of these hydrogen bonds are presented in Table 5.25. 
 
Figure 5.83: Hydrogen bonding interactions between the tranexamic acid cation and a. 
carboxylate oxygen atoms of two acipimox counterions and b. an inversion-related tranexamic 
acid cation 
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Table 5.25: Hydrogen bonding parameters in ACPTRA-W 
D-H···A D···A (Å) Angle (°) Symmetry Operator 
O20-H···O23 2.597(2) 176 (x, y, z) 
N22-H···O19 2.851(2) 144 (-1-x, -y, 1-z) 
N22-H···O8 2.894(2) 153 (-1+x, y, 1+z) 
N22-H···N6 2.958(2) 124 (-1+x, y, 1+z) 
N22-H···O9 2.782(2) 161 (x, y, 1+z) 
O23-H···O8 2.731(2) 174 (-x, -y, -z) 
O23-H···O10 2.739(2) 169 (x, y, z) 
C16-H···O23 3.431(2) 159 (-x, -y, 1-z) 
C21-H···O10 3.344(2) 141 (-x, 1-y, 1-z) 
When combined, these synthons form four hydrogen bonding patterns. The first, N1, has graph-
set descriptor R4
4(18). The hydrogen bonds in N1 involve two acipimox anions linked through two 
water molecules. The water molecules act as hydrogen bond donors, while the carboxylate anions 
and pyrazine oxide groups on the acipimox ions act as acceptors. This hydrogen bonding pattern 
is located on a centre of inversion (Figure 5.84). 
 
Figure 5.84: Two views of the hydrogen bonding pattern N1 = 𝑅4
4(18) in ACPTRA-W 
The second hydrogen bonding pattern (Figure 5.85) occurs between one tranexamic cation and 
one acipimox anion. It has the form N2 = R1
2(5), where a hydrogen atom of the ammonium group 
of the tranexamic acid cation forms a bifurcated hydrogen bond with the acipimox anion. The 
ammonium group acts as the donor with the pyrazine nitrogen and a carboxylate oxygen of the 
acipimox anion being acceptors. 




Figure 5.85: Hydrogen bonding pattern N2 = 𝑅1
2(5) in ACPTRA-W 
The third pattern comprises two tranexamic acid cations, one acipimox anion and one water 
molecule. The tranexamic acid cations hydrogen bond through the ammonium group on the first 
cation and the carbonyl oxygen on the second. The pattern has the graph-set descriptor 
N3 = R4
3(10) where the ammonium cation of the first tranexamic acid cation hydrogen bonds with 
the carboxylate anion of the acipimox counterion while the water molecule links the acipimox 
carboxylate anion to the second tranexamic acid carboxylic acid group (Figure 5.86). 
 
Figure 5.86: Hydrogen bonding pattern N3 = 𝑅4
3(10) in ACPTRA-W 
The final hydrogen bonding pattern comprises two tranexamic cations in a head-to-tail 
arrangement. The ammonium cation groups act as hydrogen bond donors on each tranexamic 
acid molecule interacting with the carbonyl oxygens of its inversion-related counterpart. This 
final pattern has the graph-set descriptor N4 = R2
2(18) and is shown in Figure 5.87. The pattern 
N4 is located on an inversion centre. 




Figure 5.87: Hydrogen bonding pattern N4 = 𝑅2
2(18) in ACPTRA-W 
The hydrogen bond C16-H···O23‡ (‡: -x, -y, 1-z) stabilises the position of the water molecule in 
each of these patterns. 
The four hydrogen bonding patterns combine to form a large repeating network, shown in 




2(18) and can be seen 
in the stereo diagram (Figure 5.88). 
 
 











The repeating network N forms infinite sheets, which stack along the b-axis creating layers 
(Figure 5.89a. and Figure 5.89b.). They are arranged such that the acipimox anions in adjacent 
layers are positioned one above another, which can be clearly seen in Figure 5.89c. This pattern 
is stabilised by a π-π interaction between the aromatic rings of acipimox within the layers. The 
least-squares planes of the acipimox anion aromatic rings are parallel in the interaction, being 
related by inversion. The centroids of the aromatic rings are offset by approximately 1.5 Å. 
Relevant data for the π-π interaction are presented in Table 5.26. The C21-H···O10‡ (‡: -x, 1-y, 1-z) 
hydrogen bond links the adjacent layers and aids in stabilising the structure. 
Table 5.26: π-π interaction parameters in ACPTRA-W 




Cg(A)···Cg(A) 3.883(1) (1-x, 1-y, -z) 
Cg refers to the centroid of a ring and the symmetry operator in column 3 refers to the second Cg listed in column 1 
Ring A: C1-C2-N3-C4-C5-N6 
 




Figure 5.89: Packing diagrams of ACPTRA-W viewed along [1 0 0], a. showing the packing of the 
networks, b. highlighting the layers formed (indicated by alternating colours), c. showing the 
stacking of acipimox (blue), tranexamic acid (green) moieties and the water molecules (red)  




The PXRD experimental data were recorded at room temperature and compared with the trace 
calculated from the refined single crystal structure of ACPTRA-W. There exists a 1:1 
correspondence between the angular positions of the peaks in the calculated and experimental 
traces but there are discrepancies between the intensities of corresponding peaks. This is 
attributed to preferred orientation of the crystallites of the sample, which is a result of the 
pronounced plate-like morphology of the crystals (Figure 5.80) persisting in the sample ground 
for PXRD analysis. 
 
Figure 5.90: The PXRD trace for the bulk sample (blue) and the computed PXRD pattern based on 
the single crystal X-ray structure of ACPTRA-W (orange) 
 
  




The refined single crystal X-ray structure of ACPTRA-W showed the position of the carboxylic 
acid proton on the tranexamic acid cation. No hydrogen atom was present on the carboxylate 
anion of the acipimox counterion. As a proton transfer had occurred, ACPTRA-W was designated 
a salt. Infrared spectroscopy was performed to determine whether the FTIR spectrum of 
ACPTRA-W supported this designation. As previously, FTIR was investigated as a rapid 
identification method for the product. 
The infrared spectrum of ACPTRA-W (Figure 5.91) shows two signals characteristic of a 
carboxylate anion at 1568 cm-1 and 1374 cm-1. A peak corresponding to the carbonyl carboxylic 
acid group at 1704 cm-1 was also observed in the spectrum. In its pure form, the co-former 
tranexamic acid exists as a zwitterion,13 therefore it is not possible to conclusively assign these 
signals in the infrared spectrum of ACPTRA-W to either acipimox or tranexamic acid. One cannot 
therefore determine the presence of a proton transfer from FTIR alone. 
A second purpose of using FTIR was to investigate this technique as a possible means of rapid 
identification of ACPTRA-W in future batches. The presence of the peaks presented above can be 
used for this purpose. Two distinct peaks at 3230 cm-1 and 2936 cm-1 were observed. However, 
due the broad absorption band from 3550 cm-1 to 2672 cm-1 the distinct peaks could not be 
unambiguously assigned. The comparison of the salt spectrum with the spectra of the starting 
materials was used to confirm the formation of a new phase. The peak corresponding to the 
hydroxyl group in the acipimox spectrum (3554 cm-1) is not visible in that of ACPTRA-W. In the 
product spectrum, the broad absorption band (3550 cm-1 to 2672 cm-1) obscures easy 
identification of a hydroxyl functional group signal. The slight differences in the carbonyl group 
peak in the two spectra can serve as an additional diagnostic difference. The carboxylate anion 
absorption peaks in the tranexamic acid spectrum (1531 cm-1 and 1379 cm-1) differ from those in 
the ACPTRA-W spectrum. The differences between the salt spectrum and the spectra of the 
starting materials allow one to unequivocally establish the formation of the new product and its 
identity. 




Figure 5.91: FTIR spectra for ACPTRA-W (blue), acipimox (orange) and tranexamic acid (grey)  




The crystalline system arising from the components acipimox, urea and acetonitrile shall be 
referred to as ACPUREA. 
SAMPLE PREPARATION 
The ACPUREA product was prepared in two ways. The first relied on mechanochemical action 
while the second was production via co-precipitation. 
Liquid-assisted grinding required equimolar amounts of acipimox (10 mg, 0.065 mmol) and urea 
(4 mg, 0.065 mmol) to be weighed out. The compounds were combined in an agate mortar and 
ground together for 20 minutes using an agate pestle. During manipulation acetonitrile was 
added in a dropwise fashion. 
When producing ACPUREA via co-precipitation 10 mg (0.065 mmol) acipimox was weighed into 
a vial. The acipimox was dissolved in 2.5 cm3 acetonitrile and an equimolar amount of urea (4 mg, 
0.065 mmol) was added to the vial and this mixture stirred at 40 ℃ for 2 hours. The resulting 
solution was then filtered into a clean vial through a 0.45 μm nylon filter and left on the benchtop 
to slowly evaporate. Over the course of 7 – 8 hours small block-shaped crystals appeared in the 
solution. 
STOICHIOMETRY 
The stoichiometric ratio of ACPUREA was determined via 1H-NMR spectroscopy. Crystals 
produced by co-precipitation were dissolved in DMSO-d6. The sample was then subjected to 
proton NMR spectroscopy. The relative integration of the acipimox methyl functional group (set 
as the reference integral) and the amine protons of urea were used to determine the 
stoichiometric ratio as 1:1. Due to the volatile nature of acetonitrile the product partially 
desolvated during manipulation and therefore the stoichiometry with respect to this component 
could not be determined through 1H-NMR spectroscopy. The proton labelling diagrams are shown 
in Figure 5.92. The integration values are shown in Table 5.27 and the spectrum is presented in 
Figure 5.93. 




Figure 5.92: Proton labelling of acipimox (left) and urea (right) 
Table 5.27: Integrals and assignment of component protons for stoichiometric determination 
Proton δ (ppm) 
Integration Experimental/ 
Theoretical Experimental Theoretical 
Acipimox 
C-H11a,b,c 2.42 3.00‡ 3.00 1 
C-H2 8.69 1.02 1.00 1.02 ≈ 1 
C-H5 8.76 1.02 1.00 1.02 ≈ 1 
Urea 
N-H14a,b + N-H15a,b 5.43 3.82 4 0.96 ≈ 1 
‡ Reference integral 
 
Figure 5.93: 1H-NMR spectrum of ACPUREA in DMSO-d6 used to determine the stoichiometric ratio  




The TGA profile (Figure 5.94) shows a mass loss between 49.9 ± 2.1 ℃ and 92.1 ± 0.1 ℃ (n = 2) 
of 15.2 ± 0.2 % corresponding to the loss of one acetonitrile molecule from the solvated system 
(calculated = 16.1 %). The DSC trace displays a corresponding endotherm. The TGA trace then 
shows a two stage mass loss, beginning at 147.4 ± 1.7 ℃ where the first mass loss of 20.5 ± 0.9 % 
corresponds to the loss of one urea molecule (calculated = 23.5 %). This is immediately followed 
by the decomposition of the remaining acipimox component. In the DSC trace endotherms 
corresponding to melting immediately followed by decomposition are visible over the same 
range. The HSM micrograph (Figure 5.95) at 75 ℃ shows bubbling, indicative of solvent loss. The 
micrograph at 180 ℃ shows the beginning stages of decomposition and the final micrograph at 
250 ℃ shows the sample in the final stages of decomposition.  
 
Figure 5.94: Representative TGA (blue) and DSC (orange) traces for ACPUREA 
 
 




Figure 5.95: Hot stage micrographs showing the ACPUREA multi-component crystalline system at 
various stages of heating 
Based on all the above data, a 1:1:1 stoichiometry for the APIco-formeracetonitrile system was 
predicted but the states of ionization (or otherwise) of the API and co-former remained to be 
determined. 
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CRYSTAL STRUCTURE ANALYSIS 
DATA COLLECTION AND SPACE GROUP DETERMINATION 
The single crystal intensity data were collected at 173 ± 2 K using a Bruker KAPPA APEX DUO II 
diffractometer. The computer program LAYER2 was used to determine the crystal system, the 
Laue symmetry1 indicating triclinic symmetry. The |E2-1| value of 1.035 calculated by program 
XPREP3 signified that the structure is centrosymmetric, so the correct choice for the space group 
was P1. 
STRUCTURE SOLUTION AND REFINEMENT 
The computer program SAINT10 was used to perform the data reduction and unit cell refinement. 
The absorption corrections were executed by the computer program SADABS11 employing the 
multi-scan method. The atomic co-ordinates were located by direct methods using SHELXS,5. 
After placing the atoms in their presumed positions the structure was refined using the program 
SHELXL.5,6 The non-hydrogen atoms were initially refined isotropically and later refined 
anisotropically. The designation of the product as a salt or co-crystal relied on careful 
examination of the position of the carboxylic acid hydrogen atom. The hydrogen atom in question, 
revealed in the difference Fourier map, was observed on the carboxylic acid moiety of acipimox. 
This was supported by the C-O bond lengths of the carboxylic acid group having values of 
1.210(2) Å and 1.316(2), which are indicative of a carboxylic acid moiety with a double and single 
C-O bond, respectively. The acipimox and urea components were thus shown to be in their neutral 
states. The asymmetric unit of the solvate ACPUREA contains one acipimox molecule, one urea 
molecule and one acetonitrile molecule. The product ACPUREA was therefore designated a 
solvated co-crystal. After the remaining hydrogen atoms were located in the difference Fourier 
map, they were placed in idealised positions using a riding model. The Uiso values of these 
hydrogen atoms were 1.2 to 1.5 times those of the parent atoms. The crystallographic data are 
available in Table 5.28. 
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Table 5.28: Crystallographic data for the single crystal X-ray structure of ACPUREA 
Chemical Formula (C6H6N2O3)·(CH4N2O)·(C2H3N) 
Molar mass (g mol-1) 255.24 
Crystal System Triclinic 
Space Group P1 
Unit cell parameters  
a (Å) 7.4990(9) 
b (Å) 9.4124(12) 
c (Å) 9.8814(12) 
α (°) 64.714(3) 
β (°) 70.679(3) 
γ (°) 85.476(3) 
Volume (Å3) 593.53(13) 
Z 2 
Densitycalcd. (g cm-3) 1.428 
μ [MoKα] (mm-1) 0.114 
F (000) 268 
Temperature (K) 173(2) 
Crystal size (mm) 0.14⨯0.26⨯0.27 
Range scanned θ (°) 2.4 – 28.2 
Index ranges h: -9, 7; k; -12, 10; l: -13, 11 
ϕ and ω scan angle (°) 0.5 
Dx (mm) 37.50 
Total number of reflections 8 285 
Number of independent reflections 2 866 
Number of reflections with I > 2σ(I) 2 200 
Rint 0.025 
R1 [I > 2σ(I)] 0.0419 
wR2 0.1155 
S 1.067 
Number of parameters 166 
Number of reflections omitted 5 
Parameters a, b  
in w = 1/[σ2(FO2)+(aP)2+(bP)] 
a: 0.0539, b: 0.1666 
(δ/σ)mean <0.001 
Δρ excursions (e Å-3) -0.28, 0.40 
  




The asymmetric unit of the solvate ACPUREA consists of one acipimox molecule, one urea 
molecule and one acetonitrile molecule. The asymmetric unit is shown in Figure 5.96. The 
acipimox and urea components interact through several hydrogen bonds as expanded upon 
below. 
 
Figure 5.96: The asymmetric unit of ACPUREA with numbering schemes. Thermal ellipsoids are 
drawn at the 50 % probability level 
HYDROGEN BONDING 
There are four hydrogen bonding synthons present in the co-crystal ACPUREA. The classical 
hydrogen bonds involve acipimox and urea. Acetonitrile is only involved in non-classical 
hydrogen bonding. The first, shown in Figure 5.97a., is the hydrogen bonding synthon linking the 
carboxylic acid group of acipimox and the amide group of urea. The second is a hydrogen bond of 
the ‘bifurcated acceptor’ type, in which both of the H atoms of one amine group of the urea 
molecule are donated to a common acceptor atom, namely the carbonyl oxygen of acipimox. This 
hydrogen bond is shown in Figure 5.97b. The third involves a hydrogen atom of the same amine 
as in the second interaction and the aromatic nitrogen of acipimox acting as the acceptor 
(Figure 5.97c.). The final hydrogen bond, Figure 5.97d., involves the pyrazine oxide group of 
acipimox as the acceptor and the second amine of urea as the donor. 
Acetonitrile does not participate in classical hydrogen bonding. However, two hydrogen bonds of 
the form C-H···A occur between acipimox and acetonitrile. The first, C5-H···N16‡ (‡: -x, 1-y, 1-z), 
has one of the aromatic hydrogens of acipimox interacting with the nitrogen group of acetonitrile. 
The second, C18-H···O10‡ (‡: -x, 2-y, -z), links the methyl group of acetonitrile and the pyrazine 
oxide of acipimox.  
The final non-classical hydrogen bond, C2-H···O13‡ (‡: -x, 2-y, -z), occurs between acipimox and 
urea, specifically between an aromatic hydrogen of acipimox and the oxygen atom of urea. The 
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hydrogen bonding parameters and symmetry operators of all the hydrogen bonds present in this 
structure can be found in Table 5.29. 
 
 
Figure 5.97: Hydrogen bonds present in ACPUREA 
Table 5.29: Hydrogen bonding parameters for ACPUREA 
D-H···A D···A (Å) Angle (°) Symmetry Operator 
O9-H···O13 2.551(2) 171 (x, y, z) 
N14-H···O8 2.931(2) 153 (x, y, z) 
N14-HA···O8 2.886(2) 104 (-x, 1-y, 1-z) 
N14-HB···O8 2.886(2) 100 (-x, 1-y, 1-z) 
N14-H···N6 3.100(2) 156 (-x, 1-y, 1-z) 
N15-H···O10 2.912(2) 162 (-x, 2-y, -z) 
C2-H···O13 3.300(2) 162 (-x, 2-y, -z) 
C5-H···N16 3.404(3) 168 (-x, 1-y, 1-z) 
C18-H···O10 3.295(2) 170 (-x, 2-y, -z) 
Five hydrogen bonding patterns are formed from these hydrogen bonds. The first, N1 = R2
2(8), is 
the hydrogen bonding synthon formed between an amide and a carboxylic acid.12 This synthon is 
shown in Figure 5.98. The second pattern is shown in Figure 5.99 and has the designator 




2(14) with two acipimox molecules and two urea molecules participating in the hydrogen 
bonding. This pattern is located at a centre of inversion. The third pattern also involves two 
acipimox molecules and two urea molecules. In this pattern, N3 = R4
2(8), the carbonyl oxygens of 
the acipimox molecules act as acceptors for two independent amine donors of the urea molecules. 
This pattern is located at a centre of inversion and can be seen in Figure 5.100. The fourth 
hydrogen bonding pattern, N4 = R2
2(8), involves one acipimox molecule and one urea molecule 
(Figure 5.101). The final pattern (Figure 5.102) includes an acipimox molecule and a urea 
molecule and can be described by the graph set N3 = R1
2(5). 
 
Figure 5.98: Hydrogen bonding pattern N1 = 𝑅2
2(8) in ACPUREA 
 
Figure 5.99: Hydrogen bonding pattern N2 = R4
2(14)  in ACPUREA 




Figure 5.100: Hydrogen bonding pattern N3 = 𝑅4
2(8) in ACPUREA 
 
Figure 5.101: Hydrogen bonding pattern N4 = 𝑅2
2(8) in ACPUREA 
 
Figure 5.102: Hydrogen bonding pattern N5 = 𝑅1
2(5) in ACPUREA 
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2(8) and  𝑅1
2(5) concatenate to form an 





2(5), This network forms a ribbon with 
which acetonitrile only interacts through weak interactions as described above. The ribbon can 
be seen in Figure 5.103. 
 
Figure 5.103: Ribbon created through the concatenation of the hydrogen bonding patterns to form 











The structure of ACPUREA packs in repeating ribbons comprising the repeating network 
described above. These ribbons (Figure 5.104a.) are separated by acetonitrile molecules in the 
interstitial spaces created as the ribbons propagate horizontally. The ribbons and acetonitrile 
molecules form layers (Figure 5.104b.) as they pack; however, no interactions were found 
between the ribbons. No non-classical hydrogen bonds, nor π-π stacking interactions were found 
between layers in this structure. Therefore, the packing of the structure is stabilised by only van 
der Waals interactions.  
 
Figure 5.104: Diagram illustrating a. the ribbons of acipimox and urea (blue) with acetonitrile 
(green) between ribbons and b. the ribbons packed in layers of alternating colours  
  




The refined crystal structure of ACPUREA showed the position of the carboxylic acid proton on 
the acipimox molecule. The lack of proton transfer allowed the designation of ACPUREA as a 
co-crystal. Infrared spectroscopy was performed to determine whether the spectrum of 
ACPUREA supported the designation as co-crystal. The use of infrared spectroscopy as a rapid 
identification method of this crystalline system was also investigated.  
The infrared spectrum of ACPUREA (Figure 5.105) shows a characteristic signal of a carboxylic 
acid carbonyl peak at 1738 cm-1. A second characteristic peak of carboxylic acids can be seen at 
1271 cm-1, arising from C-O stretching. The presence of these peaks indicates that no proton 
transfer took place from the carboxylic acid of acipimox during formation of ACPUREA. This 
supports the designation of this crystalline phase as a co-crystal. 
Several differences were observed between the spectra of the starting materials and the spectrum 
of ACPUREA. The hydroxyl signal in the acipimox spectrum (3554 cm-1) is seen at 3451 cm-1 in 
the spectrum of ACPUREA. A further difference is the position of the carboxylic acid carbonyl 
signal at 1701 cm-1 in the acipimox spectrum and 1738 cm-1 in the ACPUREA spectrum. These 
differences allow one to establish unequivocally the formation of a new phase. A signal at 
3175 cm-1 in the product spectrum, corresponding to a hydrogen bonded amine, was observed. 
The signals presented here, along with those used in investigation of a proton transfer, are 
characteristic of ACPUREA and can be used to rapidly identify the co-crystal. Therefore, FTIR can 
be used to rapidly determine the formation of a new phase and identify ACPUREA. 
Due to its volatile nature, acetonitrile was not observed in the ACPUREA spectrum as the 
co-crystal desolvated during sample manipulation. 




Figure 5.105: FTIR spectra for ACPUREA (blue), acipimox (orange) and urea (grey) 
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EQUILIBRIUM SOLUBILITY STUDIES 
Solubility studies were performed on ACPABEN, ACPAPYR, ACPBEN, ACPISO, ACPTRA and 
ACPUREA. Attempts were made to produce the two hydrated structures in sufficient quantities, 
but several issues resulting from scaling up the procedure arose. Therefore, it was not possible to 
obtain enough sample of ACPAPYR-W and ACPTRA-W, and the solubility studies of these two 
multi-component systems were therefore not pursued. 
SAMPLE PREPARATION 
A stock solution of water containing DMSO (99:1 H2O:DMSO, v/v) was prepared and 1 cm3 
measured into a polytop vial. An excess of the multi-component system was added to the solution 
and stirred at 500 rpm and a temperature of 25 ± 1 ℃ for 24 hours. The solutions were then 
centrifuged at 15 000 rpm for 45 minutes. An aliquot of the supernatant was filtered and 300 μl 
of this filtered solution was diluted with an equal volume of D2O. The sample was then analysed 
via 1H-NMR spectroscopy. For each system the process was duplicated. The DMSO concentration 
was used as an internal standard against which the acipimox concentration could be determined. 
Water suppression, using the presaturation pulse program zgpr,15 was employed to improve the 
signal-to-noise ratio of the acipimox sample peaks. This was performed by a simple two-pulse 
experiment where the frequency of water was selectively saturated such that no signal was fully 
accumulated and a secondary pulse excited the desired resonances. As the DMSO peak was found 
at 2.71 ppm and the acipimox methyl peak at approximately 2.50 ppm these were sufficiently 
removed from the H2O peak to be unaffected by the presaturation pulse. The relative integration 
of the DMSO peak and the acipimox methyl peak was used to determine the equilibrium 
concentration of acipimox in each sample. A sample of acipimox was prepared and analysed in 
the same manner to determine its intrinsic solubility. The NMR spectra, with integration values, 
can be found in Appendix E. 
SOLUBILITY 
The concentration of acipimox was determined using the known concentration of DMSO (0.1408 
mol dm-3) as an internal standard.  
The equilibrium solubility of acipimox in a 1% DMSO aqueous solution at 24 hours was calculated 
in the following manner. If the concentration of acipimox and DMSO were equal, the methyl peak 
of acipimox would integrate for 3.00 protons while the methyl signals from DMSO would integrate 
for 6.00 protons. The ratio of the experimental integration to three protons was used to determine 
the actual concentration of acipimox. The experimental integration of this peak was found to be 
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0.1408 = 0.2249 mol dm-3 (224.9 mM). 
The equilibrium concentrations of acipimox in the multi-component system solutions are 
presented in Table 5.30. The values were calculated by employing the same procedure as 
described above. 
Table 5.30: Equilibrium solubility of acipimox in multi-component system solutions 
Multi-component system Acipimox concentration (mM) Solubility ratio‡ 
ACPABEN (co-crystal) 70.7 ± 6.5 0.31 
ACPAPYR (salt) 622.2 ± 31.9 2.77 
ACPBEN (co-crystal) 85.9 ± 4.4 0.38 
ACPISO (salt) 231.9 ± 10.1 1.03 
ACPTRA (salt) 330.9 ± 2.1 1.45 
ACPUREA (co-crystal) 273.6 ± 4.5 1.22 
‡ Defined as (solubility of salt or co-crystal)/(solubility of acipimox) at 25 C, where denominator = 224.9 mM 
From the values in Table 5.30 it is clear that the equilibrium solubility was not increased in all 
cases. The final acipimox concentration was decreased by the presence of 4-aminobenzamide and 
benzamide. Each of these decreased the apparent solubility of acipimox to approximately one 
third the intrinsic solubility value. This may be due to precipitation of the co-crystals over time, 
or to the co-crystals themselves having relatively poor solubility. 
The presence of isonicotinamide in the structure did not change the concentration of acipimox at 
equilibrium. Tranexamic acid and urea showed slight solubility enhancement of 1.45 and 1.22 
respectively. Only ACPAPYR showed a significant increase to the apparent equilibrium solubility 
of acipimox. This multi-component system showed an apparent increase in acipimox solubility of 
2.77-fold. 
  




Eight multi-component crystalline systems were presented. These comprised acipimox and each 
of the following co-formers: 4-aminobenzamide, 4-aminopyridine, benzamide, isonicotinamide, 
tranexamic acid and urea. Five of the multi-component crystalline systems were organic salts, 
whereby a proton transfer from the carboxylic acid of acipimox to the co-former occurred during 
synthesis. In the cases of ACPAPYR and ACPAPYR-W (common co-former 4-aminopyridine) and 
ACPISO (co-former isonicotinamide) the acceptor of the proton transfer was the co-former 
pyridyl nitrogen atom. Instead, in the cases of ACPTRA and ACPTRA-W the acceptor was the 
carboxylate functional group of the co-former tranexamic acid. The remaining three systems, 
ACPABEN, ACPBEN and ACPUREA (containing the respective coformers 4-aminobenzamide, 
benzamide and urea) are co-crystals. 
Four of the eight systems were solvated. Three of the systems were hydrated. The salt 
ACPAPYR-W contains two water molecules per acipimox/4-aminopyridine unit, ACPBEN is a 
hemihydrated structure, while ACPTRA-W contains one water molecule per 
acipimox/tranexamic acid unit. The solvate ACPUREA contains one acetonitrile molecule per 
co-crystal unit. 
THERMAL ANALYSIS 
The antihyperlypidemic agent acipimox has a melting point of 199.7 ℃ and melting is followed 
immediately by decomposition. The multi-component crystalline systems produced with 
acipimox displayed the same behaviour upon heating.  
The melting points of the multi-component crystalline systems were investigated by obtaining 
several DSC traces, using the peak temperatures, to determine the average melting points and 
standard deviations. 
Several of the multi-component crystalline systems raised the melting and decomposition 
temperature of acipimox. The greatest increase in melting point was seen with the systems 
ACPAPYR and ACPAPYR-W which have melting and decomposition temperatures of 
246.2 ± 0.9 ℃ and 249.2 ± 0.1 ℃ respectively. The systems with tranexamic acid have melting and 
decomposition temperatures greater than that of acipimox, occurring at 241.5 ± 0.2 ℃ for 
ACPTRA and 239.9 ± 1.0 ℃ for ACPTRA-W. Upon heating, the systems ACPAPYR-W and 
ACPTRA-W dehydrated, converting to the unsolvated species ACPAPYR and ACPTRA 
respectively. Therefore, the thermal behaviour of the hydrates was identical to that of the 
unsolvated salts after dehydration. The multi-component crystalline system ACPISO has a 
marginally higher melting point and decomposition temperature than the API of 210.8 ± 0.5 ℃. 
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The co-crystal ACPABEN was found to have a melting point of 201.1 ± 0.1 ℃. The melting point of 
this co-crystal is only a small increase over that of the untreated API. 
Two of the co-crystals showed lower melting and decomposition temperatures relative to 
untreated acipimox. The co-crystal ACPBEN melted at 133.9 ± 1.3 ℃ and began to decompose 
immediately thereafter. In the co-crystal ACPUREA, system began decomposing at 147.4 ± 1.7 ℃ 
initially losing the urea component. Once the urea was lost, the remaining component was lost 
immediately thereafter. 
In 2009, Schultheiss and Newman performed a survey of 50 co-crystalline samples and found that 
51 % had melting points between those of the components. Of the systems studied, 39% had 
melting points lower than either of the component melting points, while 6 % had higher melting 
points than either component melting point and 4 % had a melting point equal to that of one of 
the components.16 From the data presented in Table 5.31 it was found that four of the acipimox 
multi-component crystals have melting points between those of the co-former and acipimox 
(ACPBEN, ACPTRA-W, ACPTRA and ACPUREA). The remaining systems (ACPABEN, ACPAPYR, 
ACPAPYR-W and ACPISO) all have melting points higher than both those of acipimox and the 
respective co-former. 
Table 5.31: Melting points of multi-component crystal systems and their co-formers 
Multi-component system Melting Point Co-former Melting Point17 
ACPABEN (co-crystal) 201.1(1) 183 
ACPAPYR (salt) 246(1) 159.0(5) 
ACPAPYR-W (salt) 249.2(1) 159.0(5) 
ACPBEN (co-crystal) 134(1) 128(1) 
ACPISO (salt) 210.8(5) 156.0(5) 
ACPTRA-W (salt) 239(1) 249(4) 
ACPTRA (salt) 241.5(2) 249(4) 
ACPUREA (co-crystal) 147(2) 132.4(5) 
In the second column the values in parentheses represent e.s.d.s calculated from multiple DSC runs 
In the third column the values in parentheses represent the uncertainties calculated as combined expanded uncertainties 
(level of confidence 95 %). No uncertainty value was reported for 4-aminobenzamide. 
A search of the literature shows numerous examples of correlations between the melting points 
of the co-former and those of co-crystals and salts for a given API.16,18–20 The melting points of the 
acipimox multi-component crystalline systems and their co-formers are shown in graphical form 
in Figure 5.106. The general trend is that the co-formers with high melting points tend to produce 
multi-component crystalline systems with high melting points. Two systems, ACPAPYR and 
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ACPAPYR-W, are outliers raising the melting point further than expected relative to untreated 
acipimox. 
It is worth noting that the systems which displayed higher melting points than that of pure 
acipimox are all salts (except ACPABEN with a melting point higher by less than two degrees). 
This is most likely due to the fact that the interactions between charged species are generally 
stronger than those between neutral species. It is however difficult to draw conclusions regarding 
the melting point from the intermolecular interactions alone. Many factors affect melting points, 
including, but not limited to intermolecular forces, molecular motion in crystals and molecular 
arrangement. The introduction of numerous components further complicates one’s ability to 
draw conclusions as each component has its own properties which can affect the 
environment.16,21 
 
Figure 5.106: Melting point data for acipimox multi-component crystals (blue) and their respective 
co-formers (orange) 
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CRYSTAL STRUCTURE ANALYSIS 
Five of the multi-component crystalline systems obtained were found to belong to the space 
group P1. The remaining three, ACPAPYR-W, ACPBEN and ACPISO crystallise in the space groups 
P21/c, C2/c and P21/c respectively. 
The occurrence of a proton transfer from the carboxylic acid group of acipimox to an appropriate 
acceptor was observed in five of the eight structures. This was established by careful location of 
hydrogen atoms in difference Fourier syntheses before assigning idealised geometries. Proton 
transfers were found to have occurred in ACPAPYR, ACPAPYR-W, ACPISO, ACPTRA-W and 
ACPTRA. The conformational similarities in the acipimox moieties in the salts and the co-crystals 
will be treated separately. In the five salts the conformation of the acipimox species is essentially 
identical, as shown in the overlay of the acipimox anions in Figure 5.107. The structure ACPAPYR 
contains two independent acipimox anions, designated by the suffixes A and B. 
In the salts mentioned above, acipimox anions are approximately planar. The magnitude of the 
torsion angles N6-C1-C7-O8 and N6-C1-C7-O9 for the carboxylate anions are presented in 
Table 5.32 to illustrate the similarities. As these structures are all centrosymmetric, only the 
magnitude of this torsion angle is presented. The absolute values of the torsion angle 
N6-C1-C7-O8 show it is in a syn-periplanar conformation with little variation in the rotation of 
the carboxylate moiety during intermolecular interactions. The torsion angle N6-C1-C7-O9 is 
anti-periplanar in each of the co-crystal structures with similarly little variation. 
 
 
Figure 5.107: Overlay of acipimox molecules from ACPAPYR(A), ACPAPYR(B), ACPAPYR-W, 
ACPISO, ACPTRA and ACPTRA-W 
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Table 5.32: The magnitude of the torsion angles N6-C1-C7-O8 and N6-C1-C7-O9  
Structure 




ACPAPYR(A) 2.1(2) 178.2(2) 
ACPAPYR(B) 6.1(2) 173.9(1) 
ACPAPYR-W 16.5(2) 164.1(1) 
ACPISO 3.2(2) 176.4(1) 
ACPTRA-W 19.1(2) 160.8(1) 
ACPTRA 16.1(1) 163.2(1) 
The conformations of the acipimox molecules in the co-crystals are very similar to those of the 
salts. The overlay of the acipimox molecules from ACPABEN, ACPBEN and ACPUREA illustrates 
the similarities among the conformations of these molecules. (Figure 5.108). As indicated above, 
these crystal structures are centrosymmetric, therefore only the magnitude of the torsion angle 
is presented in Table 5.33. The planarity of the molecules can be seen from the absolute values of 
the anti-periplanar torsion angle N6-C1-C7-O8 for ACPABEN and ACPBEN and the syn-periplanar 
conformation of this torsion angle for ACPUREA. The torsion angle N6-C1-C7-O9 is syn-periplanar 
in the ACPABEN and ACPBEN structures, but is anti-periplanar for the ACPUREA structure. The 
carboxylic acid group is rotated approximately 180° in ACPUREA relative to ACPABEN and 
ACPBEN. 
 
Figure 5.108: Overlay of acipimox molecules from ACPABEN, ACPBEN and ACPUREA 
Table 5.33: The magnitude of the torsion angles N6-C1-C7-O8 and N6-C1-C7-O9 
Structure 




ACPABEN 176.1(1) 3.0(2) 
ACPBEN 174.0(1) 4.8(2) 
ACPUREA 9.2(2) 171.3(1) 
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The carboxylate anions show a greater deviation from planarity than the carboxylic acid groups. 
The greatest deviation (19.1(2)°) is seen for the salt ACPTRA-W in the torsion angle N6-C1-C7-O8. 
In comparison the greatest deviation for the co-crystals of the carboxylic acid group is 9.2(2)° for 
ACPUREA in the torsion angle N6-C1-C7-O8. 
HYDROGEN BONDING 
There are a total of eight different types of hydrogen bonding synthons (Figure 5.109) present in 
the eight multi-component crystals. The most common of these is the hydrogen bond between 
the acipimox pyrazine oxide and an amine group (Figure 5.109a.), occurring in five of the 
structures. This hydrogen bond can be found in ACPABEN, ACPAPYR, ACPAPYR-W, ACPTRA and 
ACPUREA. The common carboxylic acid-to-amide synthon (Figure 5.109b.) is found in four of the 
systems (ACPABEN, ACPBEN, ACPISO and ACPUREA). The amine interaction with the carboxylate 
ion (Figure 5.109c.) occurs in ACPAPYR-W, ACPISO, ACPTRA-W and ACPTRA. The bifurcated 
hydrogen between an amine group and the aromatic nitrogen and carboxylate anion of acipimox, 
shown in Figure 5.109d., is found in ACPAPYR-W, ACPAPYR and ACPTRA-W. The hydrogen bond 
formed between an amine and the aromatic nitrogen of acipimox, shown in Figure 5.109e., is 
present in three of the multi-component crystals (ACPBEN, ACPTRA and ACPUREA). The 
carboxylate anion-pyridyl motif (Figure 5.109f.) is found in the structures ACPAPYR and ACPISO. 
Two of the hydrogen bonding motifs occur only once. The first, shown in Figure 5.109g., is the 
hydrogen bond between the carboxylic acid of tranexamic acid and the carboxylate moiety of 
acipimox in ACPTRA. The second occurs between an amine group on urea and the carbonyl group 
of the acipimox carboxylic acid in ACPUREA (Figure 5.109h.). 
 
Figure 5.109: Hydrogen bonding motifs present in the multi-component crystal structures formed 
with acipimox 
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These hydrogen bonds interact within their respective crystalline systems to form a total of 
eighteen hydrogen bonding ring patterns. These are summarised in Table 5.34 below. The 
hydrogen bonding rings contain 5 to 34 atoms. These rings contain between 1 and 8 hydrogen 




2(5) each occur twice in the system ACPAPYR. While the pairs of these patterns have identical 
connectivity, they are crystallographically independent. 






2(5) ACPAPYR, ACPAPYR, ACPAPYR-W, ACPTRA-W, ACPUREA 5 
𝑅2
2(8) ACPABEN, ACPBEN, ACPISO, ACPUREA 4 
𝑅2
2(7) ACPAPYR, ACPAPYR, ACPISO 3 
𝑅6
5(28) ACPAPYR, ACPAPYR 2 
𝑅4
4(18) ACPAPYR-W, ACPTRA-W 2 
𝑅4
4(22) ACPISO, ACPUREA 2 
𝑅6
6(31) ACPAPYR-W 1 
𝑅6
6(22) ACPAPYR-W 1 
𝑅8
4(24) ACPAPYR-W 1 
𝑅8
8(34) ACPBEN 1 
𝑅4
2(16) ACPISO 1 
𝑅4
4(26) ACPTRA 1 
𝑅4
4(16) ACPTRA 1 
𝑅4
4(14) ACPTRA 1 
𝑅4
4(32) ACPTRA 1 
𝑅4
3(10) ACPTRA-W 1 
𝑅2
2(18) ACPTRA-W 1 
𝑅4
2(14) ACPUREA 1 
𝑅4
2(8) ACPUREA 1 
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HIRSHFELD SURFACE ANALYSIS 
Hirshfeld surface analysis was used to investigate the similarities and differences of the 
intermolecular interactions in the multi-component crystalline systems presented here. The 3D 
Hirshfeld surface and corresponding 2D fingerprint is unique for any crystal structure. This 
method can be used to gain further insight into intermolecular interactions by colour coding long 
and short contact distances. The fingerprint plot provides a method for quantitatively 
summarising the nature of the intermolecular interactions.22–25 In the discussion that follows, 
since the structure of ACPAPYR contains two crystallographically independent acipimox anions, 
where appropriate these have been treated individually, while retaining the designations A and 
B, as in their crystal structure. 
The fingerprint plots of the Hirshfeld surfaces of the acipimox moiety in each of the 
multi-component crystals is shown in Figure 5.110. The overall shapes of the fingerprint plots 
show the similarities and differences in intermolecular interactions present among the various 
structures. The most noticeable similarity is the presence of a lower sharp feature in each of the 
plots. This feature corresponds to the hydrogen bond acceptor (where di > de) of the O···H 
interactions present in each of the acipimox multi-component crystalline systems. The other 
sharp feature present in the plots for ACPABEN, ACPBEN and ACPUREA corresponds to the 
presence of an O···H interaction where acipimox is the donor (di < de). It is expected to be present 
only in these systems since they contain the carboxylic acid –OH group acting as a hydrogen bond 
donor. 




Figure 5.110: Two-dimensional fingerprint plots for the Hirshfeld surfaces of the acipimox moieties 
The relative contact contribution for the acipimox moiety in each multi-component crystalline 
system is shown in Figure 5.111. These values take into account the reciprocal contacts and 
therefore count the contribution of the acipimox moiety acting as both a donor and an acceptor 
in each interaction. The relative contributions of the intermolecular close contacts to the 
Hirshfeld surface of acipimox support the interpretation of the fingerprint plots above. It is clear 
that the main contributing interaction in each of the crystalline systems is an interaction between 
oxygen and hydrogen, which contributes over a third to each Hirshfeld surface. Although the 
structure ACPTRA-W is hydrated, the O···H contribution is less significant than that in the 
anhydrous structure, ACPTRA. This is due to the anhydrous structure engaging in significantly 
more interactions involving O···H directly between acipimox and tranexamic acid ions. 
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While N···H interactions are present in each of the structures, the relative contributions to the 
Hirshfeld surfaces are significantly less than the O···H contribution. This is because relatively few 
intermolecular interactions take place between nitrogen and hydrogen atoms. The only such 
interactions occur when the aromatic nitrogen of acipimox acts as an acceptor atom. All other 
hydrogen bonding interactions with nitrogen take the form N-H···A, and as such do not contribute 
to the Hirshfeld surface.  
The lack of intensity in the fingerprint plots in the region di = de ≈ 1.8 Å indicates that π-π stacking, 
while present, does not contribute significantly to the overall interactions of these structures. 
Slightly higher intensity is seen in the Hirshfeld fingerprint plots of ACPABEN, ACPAPYR-W, 
ACPBEN, ACPTRA and ACPTRA-W in the region di = de ≈ 1.8 Å. This is expected since π-π stacking 
was directly observed in their crystal structures. The statistical analysis of the Hirshfeld surfaces 
also shows minimal contribution from C···C interactions. 
 
Figure 5.111: Relative contributions to the Hirshfeld surface for the close intermolecular contacts 
for acipimox moieties in the multi-component crystalline systems 
The Hirshfeld surfaces and 2D fingerprint plots were also calculated for the asymmetric unit of 
each of the structures. The overall shapes of the fingerprint plots (Figure 5.112) are very similar, 
indicating similar interactions at the Hirshfeld surfaces of the multi-component crystalline 
systems. The main differences between plots arise due to the H···H interactions, which are shown 
by the central feature. The sharp features at the lower di and de values represent the reciprocal 
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O···H interactions at the surfaces, as in the acipimox plots above. The ACPUREA fingerprint plot 
shows two additional sharp features in the same region. The outer features correspond to the 
N···H interactions while the inner represent the O···H interactions at the surface. 
 
Figure 5.112: Two-dimensional fingerprint plots for the Hirshfeld surfaces of the asymmetric units 
of the multi-component crystalline systems 
The contact contributions to the Hirshfeld surfaces for the asymmetric units, represented in 
Figure 5.113, show that the main interactions are of the type H···H, as opposed to O···H above. 
This is due to the fact that many of the O···H interactions occur directly between acipimox and the 
co-former within the asymmetric unit. This decreases the relative contribution of O···H 
interactions to the Hirshfeld surface of the asymmetric unit. While the relative contribution has 
decreased, the O···H interaction is still a significant contributor to the Hirshfeld surface. The N···H 
contribution to the surfaces, while greater than for acipimox alone, is a minor interaction. As with 
the decrease of the O···H surface contribution, this is due to the fact that the majority of N···H 
interactions take place directly between acipimox and the co-former within the repeating unit. 




Figure 5.113: Relative contributions to the Hirshfeld surface for the close intermolecular contacts 
associated with the asymmetric units of the multi-component crystalline systems 
CRYSTAL PACKING 
The eight crystal structures display some common packing features. All of them form layers that 
stack during crystal packing. The structure ACPABEN forms infinite ribbons of the network 
C(15)𝑅2
2(8). These ribbons then pack along the b-axis in layers. 
The dihydrate of acipimox with 4-aminopyridine forms stepped layers of a repeated hydrogen 
bonding network. These networks are then connected through a 𝑅6
6(22) pattern involving the 
water molecules. The salt ACPAPYR forms layers of interconnected hydrogen bonding patterns. 
Two of these networks are formed by two independent crystallographic units with identical 




The hemihydrate ACPBEN is another structure which forms stepped layers that are 
interconnected through a water molecule. This water molecule is located on a two-fold rotation 
axis. These stepped layers are interdigitated. 
Acipimox and isonicotinamide react to produce an organic salt that forms layers of ribbons which 
stack into columns along the a-axis. The stacking pattern is such that ribbons in neighbouring 
columns are inclined to one another at an angle of 50.7°.  
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The salt ACPTRA packs in layers of an extended hydrogen bonding network. If the acipimox and 
tranexamic acid ions are viewed independently they stack in columns along the a-axis and b-axis 
respectively. 
The hydrated form of the acipimox and tranexamic acid salt, ACPTRA-W, has a large repeating 
hydrogen bonding network which forms sheets. These sheets pack into layers along the b-axis.  
The final structure, ACPUREA, forms ribbons of repeating hydrogen bonding patterns. 
Acetonitrile molecules are found in the spaces between these ribbons interacting through C-H···O 
and C-H···N hydrogen bonds. The ribbons then pack in sheets that stack to form layers. 
The crystal packing of these structures is stabilised through various interactions. The aromatic 
nature of acipimox and many of the co-formers means that π-π stacking is present in ACPABEN, 
ACPAPYR-W, ACPBEN, ACPTRA-W and ACPTRA. The structures ACPABEN, ACPAPYR, ACPBEN, 
ACPISO, ACPTRA-W and ACPTRA are further stabilised by C-H···O hydrogen bonding. In the case 
of ACPUREA, the only interactions stabilising the packing arrangement are van der Waals forces, 
which are present in all crystal structures. 
INFRARED SPECTROSCOPY 
Infrared spectroscopy was employed to determine whether the spectra of the multi-component 
crystalline systems supported their designations as salts or co-crystals. The presence of carbonyl 
carboxylic acid signals in the regions of 1700 cm-1 and 1200 cm-1 indicated the presence of a 
carboxylic acid group (-COOH) in the structure. In the cases of ACPABEN, ACPBEN and ACPUREA, 
the presence of these absorption peaks in the spectra supported the designation of these systems 
as co-crystals. The presence of carboxylate anion peaks in the spectra in the region of 1500 cm-1 
to 1650 cm-1 and the area around 1300 cm-1 indicated the presence of a carboxylate anion 
(-COO)-. For ACPAPYR-W, ACPAPYR and ACPISO the presence of these signals in their spectra 
supported their designation as salts. The multi-component systems containing tranexamic acid 
contained both carboxylic acid and carboxylate anion signals. From the crystal structures, the 
tranexamic acid molecules are protonated and the acipimox molecules deprotonated at their 
respective carboxylic acid moieties. However, pure tranexamic acid is a zwitterion, having a 
carboxylate group, while acipimox has a carboxylic acid moiety. Therefore, it was not possible to 
use infrared spectroscopy to confirm the presence of a proton transfer in ACPTRA-W and 
ACPTRA. 
Infrared spectroscopy was further explored as a method of rapid identification of the crystalline 
systems. By close inspection of the spectra, observing characteristic signals in each case, it was 
possible to identify the salts and co-crystals. Comparisons were made with the API and co-former 
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spectra to determine whether FTIR could be used to establish the formation of new phases. The 
differences in the profiles of the starting material spectra and the crystalline system spectra were 
clear and unambiguous. Furthermore, the differences in peak positions of functional groups 
common to both the starting materials and the product were clear. These differences allowed one 
to unequivocally establish the formation of new phases. 
The use of infrared spectroscopy to distinguish salts and co-crystals was successful in most cases 
and its utility for rapid identification of the multi-component crystalline systems was clearly 
demonstrated. With the use of an ATR-FTIR spectrometer, spectra can be recorded in a matter of 
minutes allowing one to rapidly determine the presence of a known salt or co-crystal, or by 
comparison, the presence of a new phase. 
EQUILIBRIUM SOLUBILITY 
The formation of multi-component crystalline systems with acipimox was found to successfully 
modify the equilibrium solubility of the API in water containing 1% DMSO (1:99 DMSO:H2O, v/v). 
Acipimox was found to have an equilibrium solubility of 224.9 mM in this medium at 25 C. As 
salts and co-crystals have differing solubility behaviour, these systems will be discussed 
separately.  
Three co-crystals were prepared, namely ACPABEN, ACPBEN and ACPUREA, and their 
equilibrium solubilities were measured. From this experiment it was determined that these 
co-crystals had apparent acipimox concentrations of 70.7 ± 6.5 mM, 85.9 ± 4.4 mM and 
273.6 ± 4.5 respectively. These results showed that the co-formers 4-aminobenzamide and 
benzamide decreased the apparent solubility of acipimox. A decrease in the apparent API 
solubility when forming a co-crystal has been reported in the literature.26–28 The researchers 
Good and N. Rodríguez-Hornedo26 reported 25 co-crystal systems containing the APIs caffeine, 
carbamazepine or theophylline with various co-formers, eight of which displayed reduced 
solubility relative to their untreated API. Of the 25 co-crystal solubility experiments they 
presented, only ten were performed in water, and two of the results showed decreases in 
apparent drug solubility. The two systems, caffeine/salicylic acid and theophylline/salicylic acid 
displayed solubility ratios [defined as: (solubility of salt or co-crystal/solubility of API)] of 0.3 and 
0.4 respectively. This is a similar decrease as those observed with ACPABEN (0.31) and ACPBEN 
(0.38), at 25 ℃, in the present study. Reddy et al.27 prepared five multi-component crystalline 
systems with gabapentin, all of which displayed lower solubilities than that of the untreated API. 
The study on multi-component crystals with the API pentoxifylline28 in one case showed that the 
apparent concentration of the API was only 0.004 times its intrinsic solubility under the same 
experimental conditions. 
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In the present study, the co-crystal prepared with urea showed a slight increase (1.22-fold) in 
apparent acipimox solubility. It is has been proposed that the changes in apparent co-crystal 
solubility correlate with the solubilities of the co-former.26 With the three co-crystals presented 
in this study we see a similar trend. With increasing co-former solubility 
(4-aminobenzamide < benzamide < urea)29 we see increasing apparent solubility of acipimox 
(ACPABEN < ACPBEN <ACPUREA). 
The preparation of salts of poorly soluble APIs is the most common, and generally considered the 
most effective, procedure for increasing solubility,30 this is however not always the case. As seen 
by the work of Reddy et al.27 in some cases the conversion to a molecular salt does not necessarily 
improve (or may even decrease) the apparent solubility of the API. In the case of ACPISO the 
apparent solubility of acipimox was determined to be 231.9 ± 10.1 mM. This value is equal to the 
intrinsic solubility of acipimox within experimental error. A possible explanation for this is that 
upon dissolving the salt, the components dissociate in solution and acipimox recrystallises as the 
pure API.30,31 The remaining two salts increased the apparent solubility of acipimox. The salt of 
acipimox and tranexamic acid has an apparent API solubility of 330.9 ± 2.1 mM, which is an 
apparent increase of 1.45-fold. The salt ACPAPYR showed a greater increase in the solubility of 
acipimox, namely 622.2 ± 31.9 mM, corresponding to a 2.77-fold increase. The increase displayed 
by ACPAPYR is comparable with that for the carbamazepine/saccharine co-crystal presented by 
Good and N. Rodríguez-Hornedo.26 The values of the apparent solubility of acipimox in the salts 
do not display a trend with respect to the solubilities of the co-formers 
(4-aminopyridine < isonicotinamide < tranexamic acid).29 
The relationship between the melting point of a multi-component crystalline system and 
solubility is complicated and problematic.30 This assessment was borne out by the data from 
experiments performed in the present study. When seen as a group there is no clear correlation 
between melting point and solubility. However, if the salts are treated in isolation there is a trend 
whereby with increasing melting point we observe increasing apparent solubility 
(ACPISO < ACPTRA < ACPAPYR). While a trend is observed, the relationship is weak with nearly 
doubling of the apparent acipimox solubility (330.9 ± 2.1 mM to 622.2 ± 31.9 mM) from ACPTRA 
to ACPAPYR, but only an increase of 5 ℃ in melting point (241.5 ± 0.2 ℃ to 246.2 ± 0.9 ℃). While 
it is generally expected for melting points and solubility to be inversely related, solvent-solute 
interactions can be the determining factor in the solubility of a product, particularly in water.26 It 
is possible that hydrogen bonding interactions between the ACPAPYR and water aid in 
solubilising the salt, overcoming the lattice energy of the crystalline substance. The existence of 
the hydrated salt ACPAPYR-W with two water molecules per acipimox/4-aminopyridine unit 
would indicate that the formation of hydrogen bonding interactions between water and the salt 
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are favourable. The co-crystals do not exhibit any trend relating their melting point to their 
equilibrium solubility. 
CONCLUSION 
The data presented show that acipimox can form multi-component crystalline systems with six 
GRAS co-formers, producing eight fully characterised products. Of the eight multi-component 
crystalline systems presented here, six were produced using mechanochemical methods. Liquid-
assisted grinding was shown to be more effective than dry grinding, producing five of the six 
systems. Mechanochemical production of salts and co-crystals is advantageous as these methods 
do not require large volumes of organic solvents and therefore have less of an environmental 
impact than the alternatives. Furthermore, mechanochemical production of multi-component 
crystalline systems is generally easily scalable. Finally, obtaining the product is rapid when 
compared to co-precipitation, the mechanochemical methods typically produce the product 
within 20 minutes, while co-precipitation can take several days to yield the desired result. This 
clearly demonstrates the value of these methods. 
The thermal melting and decomposition temperatures of acipimox were exceeded by those of all 
but two of these systems. The products ACPAPYR, ACPAPYR-W, ACPTRA and ACPTRA-W began 
to decompose at temperatures over 40 ℃ greater than the decomposition temperature of 
acipimox alone. A trend was seen between the melting points of the co-formers and the melting 
points of the multi-component crystalline systems. It was also observed that the salts formed with 
acipimox had higher melting points than the co-crystals. 
Infrared spectroscopy was shown to be a useful rapid method for identifying the salts and 
co-crystals presented. 
The apparent equilibrium solubility of acipimox was found to have been increased by three of the 
co-formers, namely 4-aminopyridine, tranexamic acid and urea. These increased the solubility by 
factors of 2.77, 1.47 and 1.22 respectively. However, the remaining co-formers either did not 
affect, or decreased, the solubility of acipimox. No apparent trend was observed correlating the 
melting points of the systems and their aqueous solubility; however, if the salts are regarded in 
isolation a weak trend is observed between the two properties. 
  




1 Acipimox only to be used as additional or alternative treatment to reduce high triglyceride 
levels, European Medicines Agency, 
http://www.ema.europa.eu/ema/index.jsp%3Fcurl%3Dpages/medicines/human/referr
als/Nicotinic_acid/human_referral_prac_000020.jsp%26mid%3DWC0b01ac05805c516f 
(accessed July 2016) 
2 L. J. Barbour, J. Appl. Crystallogr., 1999, 32, 351–352. 
3 XPREP, Data Preparation and Reciprocal Space Exploration, Version 5.1, © Bruker 
Analytical X-ray Systems, 1997. 
4 Z. Otwinowski and W. Minor, in Methods in Enzymology, eds. C. J. Carter and R. Sweet, 
Academic Press, 1997, pp. 307–326. 
5 G. M. Sheldrick, Acta Cryst., 2008, A64, 112–122. 
6 G. M. Sheldrick, Acta Cryst., 2015, C71, 3–8. 
7 L. Loots and L. J. Barbour, in The Importance of Pi-Interactions in Crystal Engineering, eds. 
E. R. T. Tiekink and J. Zukerman-Schpector, John Wiley & Sons, Chichester, UK, 2012, Ch. 4 
pp. 109–124. 
8 Program cell_now, Bruker AXS Inc., Madison, WI, USA, 2008. 
9 G. M. Sheldrick, Program TWINABS, University of Göttingen, Germany, 2001. 
10 Program SAINT, Version 7.60a, Bruker AXS Inc., Madison, WI, USA, 2006. 
11 G. M. Sheldrick, Program SADABS, Version 2.05, University of Göttingen, Germany, 2007. 
12 G. R. Desiraju, Angew. Chem. Int. Ed. (English), 1995, 34, 2311–2327. 
13 P. Groth, Acta Chem. Scand., 1968, 22, 143–158. 
14 S. Kadoya, F. Hanazaki, Y. Iitaka, Acta Cryst., 1966, 21, 38–49. 
15 Program TopSpin, Version 3.2, Bruker BioSpin GmbH, 2014. 
16 N. Schultheiss and A. Newman, Cryst. Growth Des., 2009, 9, 2950–2967. 
17 W. M. Haynes, Ed., CRC Handbook of Chemistry and Physics, CRC Press/Taylor and Francis, 
Boca Raton, FL, 96th edn., 2016. 
18 P. Vishweshwar, A. Nangia and V. M. Lynch, Cryst. Growth Des., 2003, 3, 783–790. 
Chapter 5 – Acipimox 
 
 270 
19 A. D. Bond, Chem. Commun., 2003, 250–251. 
20 M. K. Stanton and A. Bak, Cryst. Growth Des., 2008, 8, 3856–3862. 
21 A. R. Katritzky, R. Jain, A. Lomaka, R. Petrukhin, U. Maran and M. Karelson, Cryst. Growth 
Des., 2001, 1, 261–265. 
22 M. A. Spackman and D. Jayatilaka, CrystEngComm, 2009, 11, 19–32. 
23 M. A. Spackman and J. J. McKinnon, CrystEngComm, 2002, 4, 378–392. 
24 J. J. McKinnon, M. A. Spackman and A. S. Mitchell, Acta Cryst., 2004, B60, 627–668. 
25 J. J. McKinnon, D. Jayatilaka and M. A. Spackman, Chem. Commun., 2007, 3814. 
26 D. J. Good and N. Rodríguez-Hornedo, Cryst. Growth Des., 2009, 9, 2252–2264. 
27 L. Sreenivas Reddy, S. J. Bethune, J. W. Kampf and N. Rodríguez-Hornedo, Cryst. Growth Des., 
2009, 9, 378–385. 
28 D. Stepanovs, M. Jure, L. N. Kuleshova, D. W. M. Hofmann and A. Mishnev, Cryst. Growth Des., 
2015, 15, 3652–3660. 
29 D. S. Wishart, C. Knox, A. C. Guo, S. Shrivastava, M. Hassanali, P. Stothard, Z. Chang and J. 
Woolsey, Nucleic Acids Res., 2006, 34, D668–72. 
30 D. P. Elder, R. Holm and H. L. de Diego, Int. J. Pharm., 2013, 453, 88–100. 
31 M. J. Bowker and P. H. Stahl, in The Practice of Medicinal Chemistry, 2008, pp. 747–766. 
 
 
Chapter 6 – Concluding Remarks 
 
 271 
CHAPTER 6 –  CONCLUDING REMARKS 
 
  




The bioactive molecules selected for study in this thesis were successfully derivatised using 
cyclodextrins and GRAS co-formers. 
CYCLODEXTRIN INCLUSION 
Cyclodextrin inclusion complexes with DCB and fenthion showed markedly improved thermal 
stability and aqueous solubility, fulfilling the aim of improving the physicochemical properties 
limiting the use of these pesticides. 
From the results presented in Chapter 3 and Chapter 4 we can conclude that the thermal 
stabilities of the pesticides DCB and fenthion are increased significantly by cyclodextrin inclusion. 
The loss of the pesticides from their respective CD complexes at elevated temperatures further 
indicates that the volatility of the pesticides is decreased upon complex formation. The increase 
in thermal stability and decrease in volatility show the potential for producing solid formulations 
that are safer for handling and transport. Furthermore, the reduction in volatility reduces the risk 
of exposure through inhalation when handling these toxic substances. 
The increases in apparent solubility of DCB with β-CD and HPBCD were not as large as expected; 
however, the observed changes may provide a sufficient increase in bioavailability to warrant an 
aqueous CD formulation for plant growth regulation. The large increases in apparent fenthion 
solubility effected by HPBCD and RAMEB show promise for an aqueous formulation, eliminating 
the need for organic solvents, such as xylene or gasoline, which are currently in use. The 
solubilisation of fenthion by CDs may provide a further application in facilitating soil 
decontamination.  
The formation of the solid-state inclusion complexes BCDFEN, TMAFEN and TMBFEN 
transformed fenthion into a solid material that can be easily transported and handled. This 
minimises the hazards currently associated with transporting and applying the volatile and toxic 
liquid. 
From the data obtained in this study the cyclodextrins recommended for the formation of stable 
inclusion complexes with DCB and fenthion having improved stability and solubility over the 
untreated pesticides are DIMEB and TRIMEA respectively. The inclusion complexes DMBDCB and 
TMAFEN show the greatest improvement in thermal stability relative to their untreated guest 
molecules. However, owing to the high cost of the host compounds phase solubility experiments 
were not performed with these host molecules. In the case of fenthion, RAMEB may serve as an 
alternative to TRIMEA if a solid inclusion complex can be obtained. The RAMEB/fenthion system 
showed markedly improved solubility and as this commercially available host is often used as an 
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alternative to the methylated cyclodextrin hosts it may show similar improvements to the 
thermal stability of fenthion, as seen with TRIMEA. An alternative to DIMEB would be 
recommended for inclusion of DCB owing, once again, to the high cost of the selectively 
methylated cyclodextrins. While phase solubility studies provided erratic results for the 
RAMEB/DCB system, a dissolution profile may provide the required solubility information to 
support this choice in future. 
MULTI-COMPONENT CRYSTALLINE SYSTEMS 
The work described in Chapter 5 has shown that one can tailor the solubility of a product using 
the formation of salts and co-crystals. The modification of the apparent solubility of acipimox in 
the multi-component crystalline systems may provide a guide to rapid or slow-release 
formulation, depending on the desired application. The co-crystals ACPABEN and ACPBEN 
showed decreased aqueous solubility and could potentially be used in the manufacture of a slow-
release dosage of acipimox. If a product with raised aqueous solubility were desired, the salt 
ACPAPYR showed the greatest increase in solubility. The greatest increase in the melting point 
relative to untreated acipimox was also observed with this salt. Therefore, if a thermally stable, 
water soluble formulation of acipimox is desired the recommended co-former is 
4-aminopyridine. The salt ACPAPYR has the added advantage of being easily produced by both 
dry grinding and liquid-assisted grinding. 
The co-formers investigated in this study were chosen on the basis of their potential hydrogen 
bonding interactions. The statistics of the hydrogen bonding motifs presented above show that 
the most common hydrogen bonding interaction between acipimox and the six co-formers was 
that between the pyrazine oxide of acipimox and an amine group of a co-former. From the 
frequency of occurrence of the hydrogen bonding motifs, one can infer that when choosing a 
suitable co-former for reaction with acipimox, those with an amine or amide moiety are most 
suitable. The proton transfer from the carboxylic acid of acipimox to a pyridyl nitrogen atom is 
observed in all structures where the co-former contains a pyridine ring. These interactions 










For the cyclodextrin inclusion complexes, studies such as relative humidity stability and long-
term thermal stability determination would provide useful information for potential 
formulations. Investigations into the bioavailability changes imparted by the inclusion complexes 
could serve as a guide to the justification for pursuing these systems for industrial application. 
Comparative studies of the kinetics of hydrolysis or photolysis of the untreated and cyclodextrin-
encapsulated pesticides could be performed to determine the efficacy of complexation in 
enhancing their chemical stability. Studies on the environmental impact of the cyclodextrin 
inclusion complexes with DCB and fenthion compared to the untreated pesticides would provide 
valuable information for possible implementation and regulation of such formulations. 
Dissolution rate studies and bioavailability studies would be of importance moving forward with 
acipimox multi-component crystalline systems. Detailed study of the thermally-induced 
transition from the hydrated salts ACPAPYR-W and ACPTRA-W to their anhydrous counterparts 
(ACPAPYR and ACPTRA) was not pursued here and may provide further insight into the 
properties of these structures. The procedures for the regulation and intellectual property 
protection of salts and co-crystals are distinct from those for unsolvated species. Thus, 
investigation of such systems is of importance to researchers synthesising multi-component 
crystalline systems with APIs. The occurrence of the solvated salts and co-crystals with acipimox 
(ACPAPYR-W, ACPBEN, ACPTRA-W and ACPUREA) indicates that more solvated 
multi-component crystalline systems may exist with this API.  
By investigating more co-formers with acipimox, the modification of the physicochemical 
properties could be tailored to the desired purpose. With the synthons presented in this thesis as 
a starting point one could limit the vast library of co-formers to likely candidates. As acipimox is 
prescribed as an additional treatment, co-crystallisation with a second antihyperlipidemic agent, 
based on the above synthons, may provide a dual dose formulation, assuming dosage differences 










The work presented here shows the value and applicability of supramolecular derivatisation to 
the beneficiation of bioactive compounds. 
Each of the derivatised systems showed altered physicochemical properties when compared with 
the untreated bioactive compound. The structural, thermal and solubility data presented in this 
work will provide important perspective on any potential future developments towards practical 
applications of the supramolecular systems obtained here. The ability to control the 
physicochemical properties of medicinal, agrochemical and other functional molecules without 
altering their inherent biological activities is of fundamental importance for the many and varied 








The appendices have been attached as a zip archive file (Appendices.zip) organised as follows: 
 
Appendix A: Crystallographic data files of the refined single crystal structures are presented. The 
.cif and .lis files are included and labelled according to the code name designated for each system.  
 
Appendix B: The 1H-NMR spectra, with integration values, used for stoichiometric ratio 
determinations are presented as PDF files. The files are labelled according to the designated code 
name of each system. 
 
Appendix C: The geometric parameters and hydrogen bonding parameters for the structure 
BCDFEN are presented in a PDF file. 
 
Appendix D: A list of the co-formers attempted for the formation of salts and co-crystals with 
acipimox. 
 
Appendix E: The 1H-NMR spectra and integration values for the solubility experiments of the 
multi-component crystalline systems formed with acipimox are available in PDF format. The files 
are labelled according to the code name designated for each system. 
